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Summary 
Antimicrobials are unique drugs in that they target ―infectious‖ or ―transferable‖ 
diseases.  There is considerable evidence linking increasing antimicrobial use with 
increasing resistance.  Resistant bacteria do not know the boundaries, either between 
countries or within a society between hospital and primary care.  Inappropriate 
prescribing of antimicrobials in hospitals therefore has consequences for whole 
communities and problems may spread both nationally and internationally.  The 
gathering of reliable measurements of antibiotic use in hospitals employing standardised 
methods is essential to building an evidence base and highlighting inconsistencies at 
national and international levels. 
In this study, after data processing, validating and record linkage, a method for 
electronic conversion of drug supply data to the ATC/DDD classification and for 
longitudinal analysis was established for Tayside and then for a set of European 
hospitals.  Time series analysis and interrupted time series analysis were described and 
used for longitudinal surveillance and interventional study of antimicrobial use.  This 
thesis explores issues concerning the evolution and management of hospital 
antimicrobial use using a wide range of methods.  A series of drug utilisation research 
studies were implemented as the basis of research methods that, in combination of 
previously described methods, provided novel studies.   
No single measure can currently capture all of the aspects of hospital antibiotic use.  
However, a combination of detailed, point prevalence data from individual patients with 
longitudinal analysis of total consumption can provide meaningful data for comparison 
between hospitals and for analysis of the relationship between use and outcome.  
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Additionally, there is a need to apply standard processes and novel methods to produce 
more meaningful surveillances.   
Longitudinal and point prevalence surveillances together with an explanation of 
variations in hospital characteristics are used to produce a set of coherent measurements 
of hospital antimicrobial use.  
Administrative data for longitudinal surveys requires continuous quality control.  
Whereas drug utilisation researchers and clinicians should target a set of indicators for 
interventional studies, large studies at national or international level need central data 
processing by country to identify targets for evaluation and for interventional studies.  
Support from experts in other fields is needed to address any shortcomings that may be 
experienced during continuous antibiotic drug utilisation monitoring at national and 
international levels.  
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CHAPTER ONE:  LITERATURE REVIEW ON 
MEASUREMENT OF ANTIBIOTIC USE IN HOSPITALS 
1.1.  Drug Utilisation Research 
Drug utilisation research has expanded from simple quantification of drug use by 
different providers or users of healthcare to include social, economic and qualitative 
methods with a more generalised public health focus.
1
  Drug utilisation was defined by 
the World Health Organisation (WHO) as ―marketing, distribution, prescribing and use 
of drugs in society with special concern on the resulting medical, social and economic 
consequences‖.  In this and other definitions of drug utilisation, the non-pharmacologic 
(socio-anthropological, behavioural, and economic) factors influencing drug utilisation 
are explicitly or implicitly recognised.
2
  
However the definition by WHO goes beyond the process aspects of drug utilisation. 
Rather, it explores the movement of drugs along other therapeutic drug chains and 
includes consideration of the outcomes of drug use.  According to this definition, 
studies of drug utilisation include not only studies of medical and non-medical aspects 
influencing drug utilisation, but also the effects of drug utilisation at all levels.  Studies 
of how drug utilisation relates to the effects of drug use, beneficial or adverse, are 
usually labelled analytical pharmacoepidemiology research because they apply the 
classical epidemiological methods for observational or interventional studies of disease 
aetiology.
2
  Drug utilisation research and pharmacoepidemiology have developed along 
parallel lines, but may now be regarded as interrelated and part of a continuum of 
interests and methodologies. As stated by Lunde and Baskaas, the general objectives of 
drug utilisation studies are: ―problem identification and problem analysis in relation to 
importance, causes, and consequences; establishment of weighted basis on problem 
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solution; and assessment of the effects of the action taken‖.3  Drug utilisation may be 
quantitative or qualitative.  The objectives of quantitative drug utilisation studies are to 
quantify the past and present trends in drug use at various levels whether national, local 
of reported adverse drug reactions, to monitor use of specific therapeutic classes and to 
evaluate interventions.  Qualitative studies, on the other hand, assess knowledge, skills 
attitudes or behaviours of prescribers or users of antimicrobials.
2
  
In the United States drug utilisation programs are commonly called Drug Use 
Evaluation (DUE) and they are part of quality assurance activities required by Medicare 
regulations, the Joint Commission and Accreditation of Health Care Organizations 
(JCAHO).  In Europe, most drug utilisation programs have taken the form of a 
therapeutic audit performed at various levels (such as patient, prescriber, hospital, 
county, and national levels) assessing not only clinical consequences but also social and 
economic consequences.
2
  A widely adopted measure of drug utilisation is the number 
of drugs that account for 90% of total drug use or DU 90% and the percentage of these 
drugs that adhered to guidelines. 
4
  Besides being an indicator of the quality of drug use 
, the DU90%, is a powerful alert and driving force for change.
5
 
Measurement of utilisation is an essential component in building the evidence for 
evaluating health care (Figure 1.1)  
Figure 1.1:  Building evidence for evaluating health care 
6
 
 
 
 
 
 
Literature Review 3 
 
Clinical research using Randomised Clinical Trials (RCTs) and other methods 
establishes the efficacy, safety and overall effectiveness of drugs and other interventions 
at the individual patient level.  Health care utilisation studies derived from 
administrative and clinical databases establish actual clinical practice profiles and this 
evidence is used to inform and improve clinical guidelines. 
6
 Utilisation studies provide 
essential additional evidence about effectiveness because in addition to efficacy or 
safety they measure reach, adoption, implementation and maintenance (RE-AIM). The 
RE-AIM framework for evidence about effectiveness was originally applied to health 
promotion interventions. 
7
 However, the same criteria can be applied to quality 
improvement (Table 1.1). 
Table 1.1:  RE-AIM criteria for evaluating the impact of an intervention in real 
life. 
7, 8
 The RE-AIM model proposes that intervention impact = reach x efficacy, 
filtered through the organisational dimensions of adoption, implementation and 
maintenance. 
Reach What proportion of the target population actually get the 
intervention? 
Efficacy What is the success rate if implemented as in protocol? 
Adoption What proportion of target hospitals/practices/clinicians adopt it? 
Implementation To what extent is the intervention implemented as intended/per 
protocol? 
Maintenance To what extent is the program sustained over time? 
 
According to the RE-AIM model clinical effectiveness at the individual patient level is 
not the only dimension that matters if you are deciding whether to use an intervention in 
a population, because an intervention can be effective in a trial, but ineffective in real-
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life implementation.  An example of this in pharmaceutical research is the use of COX-
2 non-steroidal anti-inflammatory drugs.
8
  To quote Guthrie and Wyke: “According to 
trials which compared them to older NSAIDs, they have fewer gastric adverse effects, so 
their introduction was expected to reduce hospital admissions with gastro-intestinal 
(GI) bleeding because they would be used to substitute for existing NSAID use. Instead, 
the introduction of „safer‟ COX-2 inhibitors in Canada was associated with increased 
hospital admissions for GI bleeding, because rather than substituting for NSAID 
prescription, much COX-2 prescription was to patients who would not otherwise have 
received an NSAID.  Implementation therefore served to increase the number of patients 
exposed to drugs with GI toxicity.” 8 
1.2      Why is the Evaluation of Antimicrobial Use in Hospitals 
Important? 
The aim of this section is to review the evidence about consequences of antimicrobial 
prescribing such as resistance, its relationship with antimicrobial use, patient safety, and 
attributable costs.  Problem areas, deficiencies or controversies relating to the existing 
knowledge of the topic are identified. 
1.2.1  Antibiotics, Past and Present 
The development and use of antimicrobial agents was one of the most important 
measures leading to the control of bacterial disease in the 20
th
 century.  Further to 
improvements in better health and nutrition in general, antibiotics have saved countless 
lives and transformed the practice of medicine since the first flowering of antimicrobial 
chemotherapy in the 1930s and 40s.  Antimicrobial resistance became a challenge 
shortly after penicillin gained extensive use in the 1940s, when it was introduced for the 
treatment of severe staphylococcal infections.  In 1947 physicians observed the first 
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case of clinical resistance and the optimism generated by the dawn of the antimicrobial 
era
 
was quenched by the emergence of penicillin-resistant
 
Staphylococcus aureus. By 
1952 75% of Staph aureus isolates in hospitals were resistant to penicillin.
9-11
  
Antimicrobial resistance has become one of the biggest public health issues to be faced 
at the beginning of the new millennium, with the emergence of a ‗post-antibiotic‘ era 
threatening current and future medical advances.
12, 13
  Moreover, 70 years after 
introducing antibiotics, mortality as a result of infectious diseases represents one-fifth of 
global deaths resulting in more than 11 million deaths annually.  Respiratory infections 
are the leading killer, causing nearly four million deaths annually.
14
  We are 
increasingly faced with pathogens for which no effective antimicrobials exist and 
consequently there is a rise in treatment failure rate.  Furthermore, fewer antimicrobial 
agents are under development.  In the past, pharmaceutical industry research efforts 
always provided clinicians with new and effective alternative agents.
13
  Now it may take 
10 years to develop a new antimicrobial.  Figure 1.2 shows the innovation gap in 
antibiotic discovery.  Between 1962 and 2000, no major classes of antibiotics were 
introduced.
15
  In the developed world, clinicians and scientists are concerned about the 
slow process of introducing new antibiotics.  The Pharmaceutical Industry is mainly 
concerned with investing time developing drugs to combat chronic diseases rather than 
drugs such as antibiotics where, with the exception of tuberculosis, the duration of 
therapy may last only 5 to 7 days.
16, 17
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Figure 1.2: The History of Antibiotic Innovation
15
 
  
1.2.2  Inappropriate Use of Antimicrobials 
The World Health Organisation (WHO) estimated that antibiotics account for 15 to 30% 
of drug expenditures, the largest share of any single drug group.
18, 19
  Nevertheless, 
about half of antibiotic usage in the developed world (and perhaps more in the 
developing countries) is inappropriate.
20
  WHO defines the appropriate use of 
antibiotics as "the cost-effective use of antimicrobials, which maximises clinical 
therapeutic effect while minimising both drug-related toxicity and the development of 
antimicrobial resistance".
21
  Globally, there is an extensive overuse of antimicrobials, 
e.g. use based on incorrect medical indications as well as misuse by using the wrong 
agent, administration route and dosage or treatment duration.
22, 23
 In England general 
practitioners (GPs, or family doctors) prescribe 270 million antibiotic Defined Daily 
Doses (DDD) each year.  This equates to enough antimicrobials to treat each man, 
woman and child in England for five days a year.
24
  
Between 25% and 50% of hospitalised patients receive antimicrobials, which in turn, 
account for one-third of the pharmacy budgets of most inpatient facilities and are the 
leading drug classes causing adverse drug effects with regard to the risk of collateral 
damage to patient.  Furthermore, surveys suggest that these agents are inappropriately 
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or incorrectly used in 22% to 65% of those treated.
25, 26
  Antimicrobials are the largest 
single group of drugs used in UK hospitals and control of expenditure on them must 
form a major part of any attempts at pharmaceutical budgeting.
27
  As a result attempts to 
control antimicrobial prescribing in hospitals have examined both acquisition costs and 
quality of use.  However, control of antibiotic use in hospitals is arguably more 
important for preventing proliferation of multiply resistant organisms than control of 
community consumption.
27, 28
 
Wrong dose, duration and indication 
Traditionally, standard antimicrobial regimens for common infections, such as acute 
Upper Respiratory Tract Infections (URTI), have been administered for duration of 7 to 
10 days.
29
 There is new accumulating evidence that for single pathogen infections, such 
as those causing URTI 
30
, Community Acquired Pneumonia (CAP)
31, 32
, otitis media, 
sinusitis, tonsillopharingitis
29
, cystitis
33
, and Ventilator Associated Pneumonia (VAP) 
34
 
shortened courses of therapy may be as or more effective than conventional regimens of 
longer duration. 
35-37
  Stuart Levy, President of the Alliance for the Prudent Use of 
Antimicrobials said:"The number of bacteria resistant to many different antimicrobials 
has increased, in many cases, tenfold or more.  Even new drugs that have been 
approved are confronting resistance, fortunately in small amounts, but we have to be 
careful how they're used.  If used for extended periods of time, they too risk becoming 
ineffective early on." 
38
 Finally, underuse, through lack of access to effective 
antimicrobials may also play an important a role in driving resistance as overuse.
21
   
Societal barriers 
Inappropriate use of antimicrobials is not limited to primary and secondary care or 
prescribing habits.  It is also a societal issue because of public attitudes and beliefs, for 
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example in their perception of antimicrobials as magic bullets, combined with failure of 
some governments to regulate antimicrobial sales without prescriptions.  In 2001, a 
large questionnaire study (5,379 subjects) in nine countries indicated that antimicrobials 
could be obtained without prescription in all countries.
39
 Recent surveys indicates 
obtaining antimicrobials without prescription ranges from 100% of community 
pharmacies in Athens,
40
 85% in Malta
41
 , 80% in Catalonia 
42
 to 4.8% in UK.
43
  
1.2.3.   Mechanisms of association between antimicrobial use and resistance 
Many bacterial genes responsible for resistance were found in nature before
 
the 
introduction of antimicrobials.  Extensive use of antimicrobial
 
agents benefits the 
resistant strains or species by eliminating
 
more susceptible competitors.
9
  
Antimicrobials affect both pathogens and normal flora.  The normal flora of the skin 
and mucous membranes has important protective properties, but it may also serve as a 
reservoir for resistance.  All antimicrobials can be selected for resistance.  However, in 
general, broad-spectrum antimicrobials are more likely to lead to super infections with 
resistant bacteria than narrow–spectrum antimicrobials because they have an increased 
potential to interfere with the normal flora.  One micro-organism may select resistance 
to one or more other antimicrobials, because resistance may be genetically linked (co-
selection).  Therefore, there is an established but complex relationship between 
consumption of antimicrobials and the prevalence of drug resistant bacteria.
44-48
   
The selection of drug‐resistant organisms and the unwanted development and 
colonisation of multidrug‐resistant organisms; namely, collateral damage is a term used 
to refer to the ecologically adverse effects of antimicrobial therapy.  The risk of 
collateral damage induced by different antimicrobial classes can be assessed by a 
variety of epidemiologic studies.  Cephalosporin use has been linked to subsequent 
infection with vancomycin‐resistant enterococci, extended‐spectrum β‐lactamase–
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producing Klebsiella pneumonia, β‐lactam–resistant Acinetobacter species, and 
Clostridium difficile. Quinolone use has been linked to infections with 
Methicillin‐Resistant Staphylococcus Aureus (MRSA) and with increasing Quinolone 
resistance in gram‐negative bacilli, such as Pseudomonas aeruginosa.  Neither 
third‐generation Cephalosporins nor Quinolones appear suitable for sustained use in 
hospitals as ―workhorse‖ antimicrobial therapies.49  Data that links information about 
prescribing and resistance at the population level is subject to ecological bias, which is 
likely to underestimate the impact of antimicrobial use.
50
  There is relatively little 
information about attributable risk in hospitals because of the scarcity of data about 
prescribing to individual patients and the difficulty of separating the impact of 
prescribing from transmission.
51
  The best evidence about absolute risk comes from 
prospective studies that compare patients who do and do not receive antimicrobials. 
52
 
Mathematical models of the relationship between antimicrobial consumption in human 
communities and the frequency of resistance suggest that the impact of reduction in 
prescribing may be critically dependent on the fitness cost of resistance to bacteria.
13, 53, 
54
   Evidence suggests that antimicrobial resistance is more likely to be encouraged by 
prolonged courses of low dose treatment rather than by shorter courses at high dose.
55, 56
 
This theory is supported by mathematical modelling which indicates that the time scale 
for the emergence of resistance is shorter than the decay time following a decline in 
antimicrobial consumption and so, as a consequence, the therapeutic goal should be to 
maximise patient outcome whilst minimising the potential for the selection and spread 
of resistance.  It has been suggested that the best way to achieve this is through the use 
of agents that elicit rapid eradication of the bacterial population including emerging 
resistant mutants from the site of infection.
57
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1.2.4  Surveillance of antimicrobial resistance 
The European SENTRY Antimicrobial Surveillance Programme analysed the 
prevalence of resistance to Aminoglycosides in 20 European hospitals in 1998 and 
reported considerable intra-country variations in the prevalence of resistance 
phenotypes, Aminoglycoside resistance rates were generally higher in Italy, Portugal, 
Spain, Greece, France, the UK, and Poland than in Austria, Belgium, Germany, the 
Netherlands, and Switzerland.  Compared with the 1987-88 data of the European Study 
Group on Antimicrobial Resistance, Gentamicin resistance has increased up to 5% in 
some gram-negative bacteria species.  Furthermore, a greater than 10% increase in 
resistance to Gentamicin has been seen in Staphylococcus aureus during previous 
decade.  The reason for this observation was unclear, although changes in antimicrobial 
prescribing patterns resulted in increased selective pressure from Gentamicin may have 
contributed. 
58
  
In the UK, resistance to the Aminoglycosides, Penicillins and Ceftazidime was 
significantly higher in 1993 than 1982.
59
  The use of βeta-lactams and Macrolides in 
1997 and the proportion of resistant isolates of Streptococcus pneumonia to these drugs 
in 1998 and 1999 were higher in the UK than in Sweden, Netherlands, and Germany 
and Finland.
60
  In Scotland in 2001, the proportion of all Staphylococcus aureus isolates 
due to MRSA was similar to 2000 (40%).  During the same period there appeared to be 
a general increase in the level of resistance to most antimicrobials amongst E.coli 
isolates.
61
 The European Antimicrobial Resistance Surveillance Scheme (EARSS) 
collects routinely generated antimicrobial susceptibility data from 33 European 
countries.
62
  Collective data from community and hospital from 2008 compared with 
year 2005 show some significant decreases in resistance of Strep pneumoniae and Staph 
aureus balanced by alarming increase in resistance of E coli and K pneumonia.  
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Although multiple resistance of these pathogens to third generation Cephalosporins, 
Fluoroquinolones and Aminoglycosides is still low (1%) in some countries, resistance 
to Fluoroquinolones is increasing rapidly and is now >5% in all participating European 
countries.
52
 
63
    
1.2.5   Evidence linking bacterial resistance with antimicrobial use  
Several studies document the effect of change in prescribing on antimicrobial resistance 
rates. In Japan between 1974 and 1975, a high frequency of
 
Erythromycin resistance 
(61.8%) was detected among group
 
A streptococcal isolates.  The consumption of 
Macrolides had risen dramatically from 1970 to 1977 and had decreased again by 1984.  
Between 1981 and 1982,
 
rates of resistance had decreased to about 22%, and after
 
1983 
they remained at between 1 to 3 percent.
9
  A seven-year survey (1980-1986) in France 
showed significant correlation between an increase in antimicrobial use and a decrease 
in antimicrobial susceptibility, especially for third generation Cephalosporins.
64
 In 
Greece an 80% reduction in Quinolone use was associated with a significant decrease in 
resistance amongst gram-negative bacilli.
65
  In the Netherlands increased resistance of 
pneumococci to Erythromycin followed an increase in the use of Macrolides with a time 
lag of 2 to 3 years.
66
  In Finland, after a nationwide significant reduction of 57% use of 
Macrolides in 1992 compared with 1991 and steady low use until 1997, the frequency 
of Erythromycin resistance among group A streptococcus isolates significantly changed 
from 16.5% in 1992 to 8.6% in 1996.
67
  Surveillance of AMR using the European 
Antimicrobial Resistance Surveillance System (EARSS) and antibacterial sales data 
from 11 European countries showed a linear relationship between the use of βeta-lactam 
antimicrobials and Macrolides in 1997 and the proportion of Penicillin-Nonsusceptible 
Streptococcus pneumonia (PNSP) in 1998-1999.
68
  This association between 
antimicrobial use and resistances is also seen on a larger scale, as the frequency of 
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resistant bacteria is considerably higher in countries with high antimicrobial 
consumption.  If total outpatient antimicrobial
 
consumption in different countries is 
correlated with the rate
 
of penicillin-resistant Streptococcus pneumonia (PRSP)
 
, then a 
direct correlation is seen (Spearman coefficient
 
r = 0.75; P < 0.001) (Figure 1.2).
69
 
Figure 1.3:  Correlation between penicillin-resistant (non-susceptible) 
pneumococci and outpatient antibiotic use (with 95% confidence intervals) 
69
 
 
 
 
 
 
 
 
 
 
 
  
Studies in primary care with patient level data show that prior Trimethoprim use is 
associated with increased risk of infection with E.coli resistant either to Trimethoprim 
or to other antibacterials  within 0-12 months. 
50, 70-72
  Studies of the incidence of 
colonisation with drug resistant bacteria provide particularly convincing evidence of a 
time sequence consistent with the selection of drug-resistant bacteria through exposure 
to antimicrobials. 
71
 The departmental consumption of Cephalosporins and Amikacin in 
six autonomous departments of medicine in a Dutch hospital in the year before was 
associated with a measurable and statistically significant increase in the probability of 
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infection caused by a resistant pathogen.
51
 There is further evidence that spread of 
antimicrobial resistance in hospitals and in community is driven by increased use of 
antimicrobials.
73-75
    
However, it does not follow that reversal of resistance will follow decrease use.
76
 A 
recent prospective interventional study in Sweden found despite 85% reduction in use 
of Trimethoprim containing antibacterials, 2 years after the intervention there was a 
marginal but significant increase in resistant E.coli isolates both in primary care and in 
hospital. The authors reported that no change in trimethoprim resistance occurred after a 
large reduction in trimethoprim use.
77
 A UK study provided evidence that despite huge 
decrease in human sulphonamide use during 1991-1999, Sulphamethoxazole resistant E 
coli isolates remained equally high in 1999 versus 1991.  Resistance to six of eight other 
antimicrobial agents tested was significantly more frequent (P<0.05) in sulphonamide-
resistant than sulphonamide-susceptible isolates in both 1991 and 1999.
78
  There are two 
likely explanations for these results. First sulphamethoxazole and trimethoprim 
resistance is linked to other mechanisms of resistance so other antibacterials will exert 
selective pressure for this gene to be conserved.
76, 77
 Second sulphamethoxazole and 
trimethoprim resistance have been well established for decades and are not associated 
with much fitness cost for the bacteria.
77
 In contrast, quinolone resistance in E coli has 
emerged relatively recently and is associated with considerable fitness cost.
79
 
Consequently, national restriction of ciprofloxacin in Israel was associated with rapid 
decrease in resistance in E coli, which returned to previous levels after the restriction 
was lifted.
80
 
In conclusion, there is considerable evidence linking increasing antimicrobial use with 
increasing resistance.  Although it does not follow that reducing use will result in 
reversal of resistance, this is more likely to occur in hospitals than in the community 
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and can occur in the community provided that acquisition of resistance is still associated 
with some fitness cost for the bacteria. 
1.2.6   Special concerns about hospital antimicrobial use 
Antimicrobial resistant pathogens are increasingly common causes of health care 
associated infections (HAI) and are resulting in prolonged hospital stays, increased 
antimicrobial use, increased morbidity and mortality, greater direct and indirect costs, 
and greater opportunities for the spread of infection to other individuals.
26, 81
  Much 
antimicrobial prescribing is likely to be of limited therapeutic value and there is some 
evidence that lower rates of antimicrobial prescribing may also lead to lower rates of 
antimicrobial resistance.
82
  About nine patients in every 100 admitted to hospital in 
Scotland acquire an infection during their hospital stay.
83
  In 20 teaching and non-
teaching hospitals in the UK, types of MRSA had an 11% increase rate in two 
consecutive years starting from 1996.
60
  Several studies have observed increased 
mortality in VAP caused by multiply resistant bacteria compared with other bacterial 
pathogens, which they have attributed to a higher risk of initial inappropriate 
antimicrobial therapy in these patients.
84-88
 However, Schwaber and Carmelli have 
questioned the reliability of the measurement of appropriateness in these studies. 
89
 
Zervos et al. in a 10 year survey (1991-2000) on use of and resistance to 
Fluoroquinolones in 10 US hospitals found that increase in resistance was associated 
with increased use and the changes were hospital specific.
90
 In a London hospital, the 
increase
 
and decline in the frequency of Erythromycin resistance among
 
Staphylococcus 
aureus isolates, from 18 percent to 3
 
percent, correlated with the hospital's policy on
 
the 
use of Erythromycin.  In a burns treatment unit in which topical Gentamicin
 
had been in 
use since 1964, only 9 percent of Pseudomonas aeruginosa were
 
susceptible in 1969.  In 
late 1969, the use of topical Gentamicin was discontinued,
 
and by the following year 
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only 5 percent of Pseudomonas aeruginosa isolates
 
were resistant to Gentamicin.
9
  On 
the other hand, a comparison of antimicrobial use and resistance between two hospitals 
in Sweden and Lithuania concluded that a high antimicrobial pressure in a single 
hospital per se does not necessarily promote resistance and other factors that must be 
considered and are subject to further study include the total antimicrobial pressure in the 
community, adherence to guidelines for doses and duration of antimicrobial treatment 
and spread of resistant clones and other issues related to good infection practices.
81
 
1.2.7   Cost of antimicrobial resistance and health care associated infection (HAI)   
The annual cost associated with antimicrobial resistance in the United States was 
estimated to be between USD 100 million to 30 billion in 1989 and USD 157 million to 
47 billion in 1999.
91
 The wide range of costs is likely resulted from implementation of 
direct or indirect costs and uncertainties with cost analysis in general.  In United states, 
HAI per 1000 patient days increased by 36% between 1975 and 1995.  Furthermore, it 
has been estimated that there are approximately 88,000 deaths attributed to HAI 
annually, ranking it as the fifth leading cause of death in acute care hospitals.
92
  These 
trends suggest that many challenges still exist in the prevention and control of HAI in 
the health care setting.  The total annual hospital-related financial burden of HAI in the 
United States was estimated to exceed USD 4.5 billion in 1992, USD 6.5 billion in 2004 
and Euro 9 billion in Europe.
93, 94
   
A multicentre study in the United States showed that MRSA infections caused a 10% 
higher mortality rate and a USD 3,500 per patient cost increase compared with 
Methicillin Susceptible Staphylococcus aureus (MSSA).  The same data for 
Vancomycin Resistant Enterococci (VRE) infections indicated a 39% higher mortality 
rate and USD 100,000 per patient increase compared with Vancomycin Susceptible 
Enterococci (VSE) infections.
91
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In a systematic review of economic analyses of health care-associated infections on 
publications from 2001-2004, attributable costs were USD 25,546 for surgical site 
infections (8 studies),  USD 36,441 for blood stream infections (9 studies), USD 9,969 
for ventilator-associated pneumonia (2 studies) and USD 1,006 for urinary tract 
infections. 
93
 
In the UK, the cost of containing an MRSA outbreak in a single hospital was estimated 
at over GBP 400,000.
58
  Hospital-acquired infections were estimated to cost the NHS in 
England GBP 986.36 million annually.
95
   In 2001, hospitals across Scotland needed 
243,000 more bed-days to clear their waiting lists completely. At the same time it was 
estimated that over twice as many bed days (517,000) were occupied because of HAI 
and that eliminating HAI would free up 1,420 beds in acute services.  The annual cost 
of the additional 9.2 days length of hospitalisation due to HAI was estimated to be £183 
million per annum in Scotland  in 2005/2006.
96, 97
  
On the other hand, there are concerns about the reliability of methods in estimation of 
economic burden of HAI.  Differences in methods used to estimate costs, which has 
been a chronic problem found in economic evaluations, contributes to the wide range of 
costs reported.  Furthermore, in many publications the costs include estimates of 
hospital costs only, not costs to the broader health care sector or to society.  High 
estimates of costs, designed to push decision makers into action, may do more harm 
than good in the struggle to attract funding for infection control.  Expectations among 
policy makers might be raised, and then they are disappointed when the reduction in the 
number of HAIs does not yield the anticipated cost saving.
93, 98
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1.2.8   National and International recommendations 
The problem of antimicrobial resistance crosses boundaries and requires concerted 
action against a global problem.  Thus the ―Copenhagen Recommendations‖ were 
released after the European Union conference on The Microbial Threat in Copenhagen, 
1998.
44
  This conference identified the lack of information about, and the lack of 
surveillance of, resistance and the importance of bridging this gap in knowledge and 
monitoring.  Although the information generated about antimicrobial usage and key 
infection control practices provide the basis for development of codes of good practice, 
the availability of antimicrobial consumption data to the public health authorities and 
scientists is very limited.  Accordingly the Copenhagen Recommendations focused on 
data collection, including;  
 Data on antimicrobial resistance over time or prevalence. 
 Consumption data over time or prevalence. 
 Correlation between consumption and resistance. 
Consumption data should be used to develop therapeutic guidelines appropriate to local 
need, and to form the platform on which educational and other interventions can be 
built.  These data are important triggers for action and investigation and consequently, 
more coherent and well-funded research initiatives are needed.
44
  Recommendations 
were re-emphasised by the 2001 report, ―Acting on the Council of the European Union 
Recommendations on the Prudent Use of Antimicrobial Agents in Human Medicine‖.99 
The Pan-European recommendations resulted in funding for research projects.   
Antimicrobial Resistance: Prevention And Control (ARPAC) was a research project 
funded by the European Commission.
100
  This project was developed by four European 
Society of Clinical Microbiology and Infectious Diseases (ESCMID) study groups and 
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aimed to identify antimicrobial policies, prescription patterns and infection control 
policies associated with lower rates of antimicrobial resistant pathogens at the 
individual hospital level.  ARPAC had some shared aims with two other EC funded 
projects: the European Antimicrobial Resistance Surveillance System (EARSS) and 
European Surveillance of Antimicrobial Consumption (ESAC). The three project 
leaders have therefore agreed to work in close collaboration (sharing data and using the 
same methodology).
101
 
The European Union (EU) Council Recommendation on patient safety including the 
prevention and control of healthcare-associated infections were adopted by EU Health 
Ministers in June 2009 and listed a series of actions in this area.
102
 Ten years after 
Copenhagen conference and call for action it was claimed that Europe was showing the 
way on turning the tide of antimicrobial resistance.
103
  Nonetheless, in November 2009, 
EU and US, agreed to establish a transatlantic task force on urgent antimicrobial 
resistance issues focused on appropriate use of antimicrobials and prevention of health-
care.  This implies that the current situation on antimicrobial resistance, among all 
medical and health related topics, is a global challenge besides the financial crisis, 
climate change and war in Middle East.
104
  
In the UK, in 1998, the Standing Medical Advisory Committee published ―The Path of 
Least Resistance‖ to identify the main problems faced in reducing antimicrobial 
prescribing. The report pointed out that "…regimens of antimicrobial vary hugely from 
hospital to hospital often with no underlying rationale
105
. Following the House of Lords 
Select Committee on Science and Technology report in 1998, there was a national drive 
to reduce antimicrobial prescribing.  Nonetheless, the House of Lords reported that 
rather to their dismay, data on antimicrobial use in hospitals which had been 
unsatisfactory in 1998, were no better in 2001.
24, 106
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In 2002, the Scottish Executive Antimicrobial Resistance Steering Group was 
established to gain commitment to a co-ordinated, focused approach at the local, 
national and international levels for prudent antimicrobial use in humans and set the 
surveillance of antimicrobial use and resistance as one of the key elements.
107
  
1.2.9   Conclusion: the importance of evaluation of antibiotic use in hospitals 
Antimicrobials are unique amongst drugs in that they target ―infectious‖ or 
―transferable‖ diseases.  Resistant bacteria do not know the boundaries, either between 
countries or within a society between hospital and primary care.  Inappropriate 
prescribing of antimicrobials in hospitals therefore has consequences for the whole 
community that the hospital serves and problems may spread both nationally and 
internationally.  A few years ago it was thought that reversal of resistance could happen 
after a relatively short time of reducing antimicrobial use pressure but it is now clear 
that this is not necessarily true.  However, in the confined environment of hospitals 
prudent use of antimicrobials has the greatest potential for reversing collateral damage.  
Hospitals are a critical component of the antimicrobial resistance problem worldwide.  
The combination of vulnerable patients, intensive and prolonged antimicrobial use, and 
cross-infection have resulted in nosocomial infections with highly resistant bacterial 
pathogens.  Resistant hospital-acquired infections are expensive to control and difficult 
to eradicate.  Given the recent worldwide escalation in resistance, and the overwhelming 
clinical and economic effects of inappropriate usage of antimicrobials, the pragmatic 
and essential approach to the control of resistance is the control of antimicrobial use.  It 
follows that reliable measurement of antibiotic use in hospital with standardised 
methods will be essential to building the evidence base and highlighting inconsistencies 
at national and international levels (Figure 1.1, Table 1.1).  The next section identifies 
important gaps in the evidence about hospital antibiotic use. 
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1.3 Methods & Gaps in Hospital Antibiotic Use Measurement 
1.3.1  Introduction  
In this section methods applied to hospital antibiotic use measurement are reviewed.  
The aim is to identify gaps in the evidence and the need for additional valid, comparable 
and feasible methods.  Firstly, key elements of standard measure are described.  
Secondly, different methods in the study field are reviewed to identify those can be 
implemented and improved for this thesis.  
Different methods and measurements have been applied to Drug Utilisation Research 
(DUR) of antimicrobials in hospitals depending on the aims and availability of data.  
DUR studies have been carried out to identify the problems within institutions,
108-115
 to 
allow benchmarking between institutions,
81, 116-119
 to allow follow up and compliance 
with the guidelines,
120-124
 to assess appropriateness,
123, 125-127
 to estimate the costs of 
antibiotic therapy,
25, 111, 127, 128
 to evaluate changes over time,
28, 114, 129-132
 and to evaluate 
organisational changes.
122, 133
  Nonetheless, despite this extensive experience some gaps 
and shortcomings are not usually addressed.  
1.3.2  Quality criteria of outcome measure 
Whatever the aims of DUR studies are, and regardless of the size and number of 
hospitals included in the studies, the choice of outcome measure is a central issue.  
There are well established criteria for assessing the quality of an outcome measure that 
could be considered before choosing the measures and methods.
134-136
  
1 Discrimination: Reliability and Responsiveness - It indicates the related concepts of 
reliability (the degree to which a result obtained by a measure can be replicated) and 
sensitivity to change, which is also known as responsiveness.  All else being equal, 
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a measure that has poor reliability (because most variation in it is due to random 
error) will also be less responsive.  The study design determines whether the 
objective is to determine the stability of a measure (reliability) or its ability to 
respond to external change (responsiveness).  Reliability should be reported using 
both relative and absolute statistics because they provide different information and 
are subject to different biases depending on the study design and subjects.  
Responsiveness can also be reported using several methods.
134-136
 Discrimination is 
the degree to which a measure is good at differentiating high from low.  It has been 
argued in literature if the discrimination and reliability are the same or difference.
137
 
2 Validity - Is it valid for the purpose?  In simple terms, validity is the extent to which 
an instrument measures what is intended.  There are three types of validity to 
consider: content, criterion and construct.  Content validity or comprehensiveness is 
the extent to which the items in the scale adequately represent the domain being 
measured (e.g. how does the total cost of antibiotics represent all manifestations of 
the antibiotic use). Content validity is evaluated qualitatively through a combination 
of consensus expert opinion, interviews with patients and literature review.  
Criterion validity addresses the question of whether a measure agrees with 
(concurrent criterion validity) or predicts (predictive criterion validity) a ―gold-
standard‖ measure of the same and different attributes.  Construct validity refers to 
how well the instrument measures what is intended.  It is evaluated by analysing the 
relationship between the measure and other measures of the same and different 
attributes.  Accuracy of the data, data processing, satisfactory statistical method, and 
adequate sample size are key components of validity. 
134-136
  
3 Feasibility - Can the measure be applied easily, given the constraints of time, 
money, interpretability, acceptability to all users and ethics?
134-136
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1.3.3 Patient Specific Data and Measures 
The first audits on hospital antibiotic use were obtained from patient records within 
institutions or specialties. They were mainly focused on the evaluation of either a single 
or a group of antimicrobials prescribed for a given indication and sought to identify or 
evaluate the appropriateness of treatment at baseline and after an intervention, and to 
evaluate costs.
25, 109, 115, 132, 138-143
  These audits were successful in identifying the 
problem and contributed to quality indicators for hospital antimicrobial use. In some of 
these studies, computerised patient records were used, making the surveys more 
precise.
144-147
  Most of these studies reported that the interventions were cost saving. 
25, 
132, 138, 143, 144
 However, these studies do not provide enough detail about the cost of 
design and implementation of the intervention to allow other hospitals to estimate the 
cost of repeating the same intervention.
148
 
A limitation of the studies was that they extracted data from patient records.  Several 
studies have shown that information extraction was not complete 
149-151
.  Extracting data 
from patient records is subject to personal interpretations, even within one institution. 
This issue needs more investigation when the outcome is appropriateness of 
antimicrobial treatment. The level of agreement, even with clear criteria, also varies 
according to personal judgments.
152
 These studies are limited in reproducibility because 
they are mainly focused on addressing a specific problem of concern at a given time.  
Additionally, some studies were not repeated over time and cannot be applied to other 
institutions within the same country or at international level.  The same measures may 
not be available in other hospitals or in the same hospital at different times.   
When used for cost assessments, these studies have limited reproducibility if not 
adjusted for price changes over time and different pricing systems in other institutions 
within the same country and in other countries.  Also focusing on cost may exaggerate 
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the impact of new and expensive drugs and may mask important changes in patient 
exposure to cheaper and older drugs.  Introducing guidelines targeted at specific 
antimicrobials may shift the use to other agents and, therefore, monitoring of the 
broader group of antimicrobials is essential while assessing the outcomes.    
1.3.4 Point Prevalence Surveys 
Point Prevalence Survey (PPS), a single measurement at one point in time was 
introduced in the 1980s and since then, has become a widely used method to assess 
hospital antimicrobial use and hospital infection at the patient level 
150, 153
.  PPS is a 
feasible, inexpensive method that provides rapid results.  This kind of survey is usually 
carried out on a single day. Patient records are used to identify prescribed 
antimicrobials, dosages, indications, infection sites and diagnoses.  It is an easy method 
to allow understanding of the problem and, over time, highlights a number of areas for 
improvement and benchmarking within or between hospitals.  On the other hand, 
because this method allows rapid analysis, it is becoming a valuable tool for timely 
feedback to clinical groups and physicians.  Rapid feedback of PPS usually brings more 
organisational support for further surveys.   
In a few European countries, PPS is carried out on a regular basis once or twice a year.  
Computer based data collection and analysis can make PPS even easier and less time 
consuming.  A few studies proved that handheld computers are cost effective tools in 
survey studies. However, in the early stages they may encounter errors without any 
possibility of correcting them.
154-156
 
As mentioned above, these studies can have their limitations – such as data extraction 
and personal interpretations made by auditors from the patient records and data 
collection forms.  The survey team may include infectious disease specialists, 
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pharmacists, microbiologists, infection control nurses and epidemiologists. It is possible 
that each of these disciplines has different attitudes towards the importance and 
interpretation of specific data items. For example pharmacists are more likely to look 
for information related to the appropriateness of the prescribed antimicrobial whereas 
infectious diseases specialists may be more focused on the diagnosis of infection. 
Finally, in published studies it is usually unclear as to the amount of resources allocated 
to the process of agreeing what information will be asked for during the data collection 
phase.
148
  
PPS assessing antimicrobial treatment on a single day can reasonably represent the most 
common indications and the most commonly used antibacterials.  However, 
examination at single point in time may underestimate or overestimate the frequency of 
use of less common drugs.
157
 In a PPS in Tayside and Glasgow Health Boards, there 
were only a few prescriptions for antibiotics classed as Alert Antibiotics, antimicrobials 
included in most prescribing stewardship programmes.
158
  Although all PPS measure 
the prevalence of antibiotic therapy, studies often use different measures making 
comparison across studies and institutions difficult (Table 1.2). PubMed was searched 
for Point Prevalence Surveys in European countries either in single hospitals or 
multicentre and national surveys. Eighteen studies were identified
116, 117, 153, 158-172
 and 
the content of each study was compared with the annual point prevalence survey in 
Swedish hospitals co-ordinated by STRAMA (The Swedish Strategic Programme for 
Rational Use of Antimicrobial Agents and Surveillance of Resistance).
161
  None of the 
other studies contained all of the information collected by the STRAMA surveys 
(Erntell 2003 and 2004 in Table 1.2). Eight studies excluded surgical prophylaxis, four 
studies only included adults and four studies only included children (Table 1.2). These 
differences make it very difficult to compare results between studies and countries. 
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Table 1.2:  Published Point Prevalence Surveys from European countries  
Study Year Country Hospitals Surveys Population Patients Surgical 
prophylaxis 
Prevalence Site of 
infection 
Prescribed 
doses 
Route of 
administration Cook 153 1983 UK 1 1 All 921 Included 21% N N N 
Astagneau
159
  1999 France 23 1 Adults 6839 Excluded Not given Y N N 
Berild 
160
 2002 Norway 1 12 Adults 6588 Included 16.6% Y Y N 
Erntell 
161
 2003 Sweden 19 1 All 4178 Included 30.9% Y Y Y 
Erntell 
161
 2004 Sweden 18 1 All 3622 Included 31.9% Y Y Y 
Bugnon-Reber 
162
 2004 Switzerland 8 1 All 695 Included 25% N N N 
Ufer 
163
 2005 Croatia, 
Germany 
2 1 Children 600 Included 17.4% y N N 
Usluer 
164
 2005 Turkey 18 1 All 9471 Included 30.6% N N N 
Pujate 
165
 2005 Latvia 7 1 All 3150 Excluded 27% Y N N 
Vlahovic-Palcevsky 
116
 2006 
Croatia, 
Estonia, Latvia, 
Lithuania, 
Sweden 
5 1 All 4138 Included 24.8% Y N N 
Hajdu 
166
 2007 Russia 1 1 Children 472 Included 39.0% N N N 
Seaton 
158
 2007 UK 10 1 All 3826 Excluded 28.3% Y N Y 
Dumpis 
117
 2007 
Latvia, 
Lithuania, 
Sweden 
3 1 All 1611 Included 26.4% N N Y 
Willemsen 
167
 2007 Netherlands 1 6 All 4105 Excluded 22.9% N N N 
Ang 
168
 2008 UK 1 1 Children 359 Included 49.3% Y N N 
Degli Atti 
169
 2008 Italy 1 1 Children 412 Excluded 43.9% N N N 
Diminia 
170
 2009 Latvia 7-12 5 All 18,226 Excluded 26.9% N N Y 
de With 
171
 2009 Germany 1 1 Adults 941 Excluded 28% N Y Y 
O'Neill 
172
 2009 N. Ireland 1 1 All 529 Excluded 36.8% N N N 
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1.3.5 Aggregated data using pharmacy dispensing database 
While patient specific data for inpatients are still difficult to obtain on a continuous 
basis, pharmacy dispensing data are available monthly or quarterly in most hospitals. 
These data allow comparison over time and place and longitudinal surveillance of 
antimicrobial use.  This source has been widely used since the 1970s with different 
measures and different methods.  As a result of computerised data in hospitals in recent 
decades, this information has become easier to obtain. 
Quantitative measures in terms of grams can be meaningful for a single drug but cannot 
be used for aggregated use or to compare the use of different antimicrobials.  The 
number of dispensed packages has even lower value, even for measuring the use of a 
single drug.  The cost of antimicrobial use is often used as a measure of antibiotic use.  
This measure usually highlights expensive antimicrobials.  Furthermore, as mentioned 
above, costs should be adjusted for changes in prices over time, especially in 
longitudinal studies.  It is not a valid measure for international comparisons and even 
for local benchmarking in some countries.  Using dispensing information without 
converting the data to doses cannot provide meaningful data.  Pharmacy stock data, 
even if converted to doses, have some limitations.  Dispensing data may overestimate 
exposure as a result of drug wastage or expiration in ward stock, not accounting for 
returned drugs or inclusion of outpatient drug use associated with outpatient clinics or 
prescribing on discharge.  In some countries not all antimicrobials are always available 
from the hospital pharmacy and they may be supplied out of hospital.  In these countries 
pharmacy dispensing data underestimates the total use.  In some of the published DUR 
studies, differences in hospital characteristics are not mentioned or regarded.  Pharmacy 
information at patient level is becoming available in more hospitals but is still only 
available in a minority of hospitals in any European country.  When these data are not 
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available, pharmacy dispensing data is the most commonly available data in hospitals 
but should be interpreted with caution.   
The WHO Collaborating Centre for Drug Statistics Methodology was established in 
Oslo in 1982 to improve and manage the Anatomical Therapeutic Chemical 
classification (ATC) ATC/DDD system that had been recommended by the WHO 
Regional Office for Europe for international drug utilisation studies in 1981.  In the 
ATC classification system, the drugs are divided into different groups according to the 
organ or system on which they act and their chemical, pharmacological and therapeutic 
properties.
173
 The basic definition of the Defined Daily Dose (DDD) unit is: the 
assumed average maintenance dose per day for a drug used for its main indication in 
adults. The WHO Centre emphasises that ―the defined daily dose is a unit of 
measurement and does not necessarily reflect the recommended or prescribed daily 
dose. Doses for individual patients and patient groups will often differ from the DDD‖. 
1, 174
  In further publications the WHO Centre reviewed the studies using ATC/DDD.  
They found that in many studies, changes in ATC/DDD are not considered and the 
ATC/DDD version has not been referenced.  They also emphasised that the DDD is a 
technical unit of measurement.
175
 
The DDD is implemented to produce a quality indicator of antimicrobial use in 
hospitals or primary care is DU90%.  DU90% reflects bulk indices of antimicrobial 
utilisation.
4
   It is applied to hospital antimicrobial consumption for local, national and 
international comparisons and monitoring of antibiotic use and resistance, identifies 
impact of change programmes and adherence to guidelines.  DU90% can be used with 
routinely available data in any hospital derived from pharmacy stock data or prescribing 
at patient level.  
5, 118, 122, 176-180
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For normalised information about hospital drug use, the WHO Centre recommended 
occupied bed-days as a denominator since this information is available in many 
hospitals from hospital administrative data.
174
 Accordingly, the recommended measure 
is DDD/100 bed-days.  Since then this measure has been widely used in DURs of 
antimicrobials in hospitals, and recommended for use at national level in most countries 
and at international level.  The reasons are feasibility, reproducibility, discrimination, 
easily achieved organisational support, continuity and regularity, and, to some extent, 
relevance to usual practice.  DDD/100 bed-days are used for benchmarking, evaluation 
of changes over time and effectiveness of interventions.
175
 Nevertheless, the WHO 
Centre has observed discrepancies between studies due to the use of different 
ATC/DDD versions, comparing studies with different DDDs for one substance, and 
miscalculations.
181, 182
 
Other problems associated with the DDD measure are a result of misunderstandings in 
comparative studies.  In some benchmarking studies on the total use of antimicrobials, a 
decrease in use was interpreted as better practice without taking account of the variety 
of antimicrobials contributing to total use.  The proportion of ICU beds, presence of 
haematology specialties, paediatrics, and renal units can affect the level of use.  In some 
studies these basic hospital characteristics are not considered in the interpretation of the 
results.  
The Antibiotic Resistance, Prevention and Control (ARPAC) 2002-2004 was a 
European project that used antimicrobial use and resistance data from 170 hospitals in 
31 countries.
100
  The project introduced the Anti-Bacterial Consumption (ABC) 
calculator for systemic antibacterials, class J01 in ATC classification. ABC is an Excel 
sheet with a designed formula for calculating DDD/100 bed-days. The user should enter 
the total volume of each antibacterial used in grams together with the number of bed-
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days.  However, the ARPAC project revealed significant errors in the calculation of 
both numerator and denominator.  Assigning the correct ATC, dealing with trade 
names, and different coding systems in each hospital pharmacy are problems that can 
lead to miscalculations.  In one of the publications from this project
183
, the authors 
provide examples of miscalculations arising from incorrect entry of raw data. These 
clearly illustrate two fundamental problems.  First the resulting errors can be very large 
because of multiplication factors.  Second, even very extreme results were not identified 
as being implausible by the staff responsible for data entry.  Comparison across 
countries and hospitals therefore requires both careful training of local data collectors, 
and a central checking process. 
1.3.6   Longitudinal surveillance measures: numerators and denominators   
The literature is confusing because of the use of apparently similar but actually different 
numerators and denominators. For example, in 1998 a multi-centre study in the United 
States reported antibiotic use in Intensive Care Units as DDD.  However, the measure 
was actually the average Prescribed Daily Dose rather than the WHO DDD.  For 
example the ―DDD‖ for parenteral ampicillin in this study was 4g184 whereas the actual 
WHO DDD is 2g.
185
  In a recent study in 130 US hospitals, Days of Therapy 
(DOT)/1000 patient-days was introduced and compared with DDD/1000 patient days.  
The authors recommended using DOT/1000 patient-days instead of DDD/100 patients-
days.
186
 However, longitudinal measurement of days of therapy requires electronic 
access to patient specific prescribing data and this is not available in most European 
hospitals.  In two studies conducted in UK hospitals, authors introduced DDD per 
finished consultant episode (FCE) for antimicrobial use in hospital.
187, 188
  An FCE is a 
continuous period of time an admitted patient receive care under one consultant, or one 
consultation team, within one healthcare provider.  DDD/FCE was used as a measure to 
Literature Review 30 
 
evaluate an intervention indicator in one of the studies 
187
 and compared with DDD/100 
bed-days 
188
 in the second one.  The FCE data are available in England and Scotland 
and each Trust processes their data slightly differently therefore this denominator 
cannot be applied to international studies.  Additionally, because one patient can be 
under care by two or more consultation team at the same time data FCE may bias 
results.   
Most longitudinal studies of hospital antibiotic use have used DDD/bed-days or 
DDD/patient-days and have applied the WHO ATC/DDD classification.  However, 
recent studies have questioned the validity of only using bed days or patient days to 
adjust for clinical activity. In 2005, two longitudinal surveys in Dutch hospitals were 
performed to find and examine an additional measure to quantify antibiotic use in 
hospitals.  The authors concluded that DDD/100 bed-days overestimates antibiotic use 
compared with DDD/100 admissions because of a systematic reduction in mean length 
of hospital stay over the study period.  These studies made the point that while DUR 
researchers are looking for a more clinically meaningful numerator, a different 
denominator can change the trends over time and affect the whole interpretation of 
longitudinal and benchmarking surveys.  They authors suggested using both 
denominators to evaluate change in antibiotic use.
189, 190
  A limitation in both of the 
studies was the statistical analysis of trends, which used simple linear regression of 
aggregated annual data.  
An additional study in one German hospital reported similar results over 12-year 
longitudinal data, with systematic reduction in mean length of stay and widening gap 
between DDD/100 bed days compared with DDD/100 admissions. However, statistical 
analysis was limited to comparison of the average use in the first three years versus the 
last three years.
191
  Comparison of two denominators of clinical activity was also used 
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in two published study form Switzerland.
192, 193
 However, in these studies ―admissions‖ 
included transfers between clinical departments in the same hospital and was therefore 
likely to introduce similar biases to the Finished Consultant Episode used in England. 
Collectively these studies recommend use of both admissions and bed days as 
denominators for surveillance of antibiotic use but they do not provide a robust 
statistical method for analysis of trends over time either within or between hospitals.
189-
193
 
1.3.7   Conclusions: gaps in the evidence and methods used in this thesis to close 
the evidence gaps 
No single measure can currently capture all of the aspects of hospital antibiotic use.  
However, a combination of detailed, point prevalence data from individual patients with 
longitudinal analysis of total consumption could provide meaningful data for 
comparison between hospitals and for analysis of the relationship between use and 
outcome. This approach would also inform the development of electronic prescribing 
records for individual patients because it would define the minimum dataset that is 
required to support the initial prescription of an antibiotic, capture the outcome of 
prescribing and determine roles and responsibilities at each point in the care pathway.  
However, the evidence reviewed identified significant problems with standardisation of 
data collection, statistical analysis and interpretation that need to be addressed for both 
longitudinal surveillance of total antibiotic use and point prevalence of individual 
patient use.  
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Guides to chapter 2- 8 
In Chapter 2 I review the literature on methods for statistical analysis of time series and 
interrupted time series and identify those that could be applied to longitudinal 
surveillance of antibiotic use in hospitals. 
Chapter 4 is a brief overview of the ESAC (European Surveillance of Antibiotic 
Consumption) and the opportunities provided for collaboration on longitudinal and 
point prevalence surveys. 
The justification for chapters 3 and 5 to 8 of the thesis is summarised below in the form 
of the research questions posed and the contributions made to close the gaps in the 
evidence identified in Chapter 1. 
Chapter 3 
Interrupted time series analysis of an intervention to reduce unnecessary use of Alert 
Antibiotic in NHS Tayside 
Research Question 3.1 
 What is the impact of an Alert Antibiotic policy on the use of antibiotics 
reserved for second line treatment of resistant organisms? 
Research Question 3.2  
What is the cost of designing and implementing the policy and to what extent 
are these costs offset by savings in drug costs? 
Contribution 3.1  
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A method for electronic conversion of drug supply data to the ATC/DDD 
classification and for longitudinal analysis that can be applied to data from other 
hospitals 
Contribution 3.2  
A template for documentation of the cost of design and implementation of an 
intervention 
Contribution 3.3  
A method for standardisation of antibiotic cost data over a four year period 
Chapter 5 
ESAC longitudinal survey 1: analysis of total antibiotic use 
Research Question 5.1  
What is the change in hospital antibiotic use over the study period? 
Research Question.2   
What effect do different denominators (bed days or admissions) have on 
longitudinal analysis of hospital antibiotic use? 
Contribution 5.1.   
A method for standardising and processing data from multiple hospitals and 
different countries. 
Contribution 5.2.  
A plan for multivariable analysis of time series and comparison of the impact of 
different measures of clinical activity on hospital antibiotic use. 
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Chapter 6 
ESAC longitudinal survey 2: comparison of total, parenteral and broad-spectrum 
antibacterial usage 
Research Question 6.1  
Are the same time trends present in use of total antibiotics, parenteral antibiotics 
and antibiotics with high risk of collateral damage? 
Contribution 6.1  
Application of the method for multivariable analysis to comparison between 
trends for different antibiotics. 
Chapter 7 
ESAC point prevalence survey of antibacterial use 
Research Question 7.1  
Can the STRAMA methods be applied in other European countries? 
Research Question 7.2  
What is the PDD (Prescribed Daily Dose, the actual daily doses prescribed in 
each hospital) and how does this compare with the WHO DDD for antibiotics 
used in European hospital? 
Contribution 7.1  
Test of the feasibility of using a web based reporting system for collection of 
data from multiple countries. 
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Contribution 7.3  
A method for comparison of DDD with PDD data from multiple hospitals. 
Contribution 7.2  
Application of a statistical method for analysis of variance to ranking of 
hospitals for prevalence of antibiotic use. 
Contribution 7.3  
Identification of potential quality indicators for hospital antibiotic use. 
Chapter 8 
Research Question 8.1  
To what extent does variation in hospital characteristics explain variation in 
antibiotic use? 
Contribution 8.1  
Test of the feasibility of collection of data about hospital characteristics 
Contribution 8.2  
A plan for statistical, multivariable analysis of the association between hospital 
characteristics and antibiotic use as measured by point prevalence or total 
consumption.  
Chapter 9 
Review of potentials of this thesis in implementing new methods to improve indicators 
of hospital antimicrobial use. 
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Review the impacts of the studies on providing evidence of practice profile and to 
change programmes.   
State the overall weakness and limitations of thesis and suggestions for further research.  
Recommended further studies. 
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CHAPTER TWO:  Time Series and Interrupted Time Series 
Analyses 
2.1 Introduction 
A time series is a sequence of measurements that follow a non-random order.  Time 
series analysis is an application which was mainly conceptualised in economic studies, 
but is increasingly implemented in public health and bioscience.  A search of PubMed 
for the term ―time series analysis‖ in the titles or abstracts of English publications 
identifies 234 papers before 1990 and 1,501 from 1990 to 2010.   
Analysis of time series may have different goals including: to identify the pattern in a 
sequence of observations over time and the context of underlying process; to examine 
the impact of interventions; and to forecast the future pattern of events or to compare 
series with different kind of events. 
The application of time series analysis methods is multifaceted and varied in nature 
rather than a homogeneous set of statistical techniques.  In experimental designs, 
interrupted time series analysis (ITSA) refers to analysis of time series to estimate the 
outcomes of a change in policy or an intervention.  The application of ITSA in medical 
sciences is increasing.  A search of PubMed retrieves 14 papers before 1990, and 116 
papers from 1990 to 2010. 
This chapter provides an overview of time series concepts, analysis methods, and 
statistical approaches. Later in the chapter, interrupted time series analysis is described.  
These methods are used in chapters 3, 5, and 6 of this thesis. 
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2.2  Time Series Analysis                      
A time series is a sequence of data points, measured typically at successive times, 
spaced at uniform intervals.  Sometimes the observations are from a single case but 
more often they are aggregated from many cases.  One of the concepts that make 
possible the use of probability in time series is the assumption of stationarity.  The 
stationarity implies that the individual observations all have the same univariate 
distribution, in particular, same mean and variance which do not change over time.   
Under this assumption, we can use the replication over time in a time series to make 
inferences about the common mean, variance and other statistics.  When the series are 
not stationary they contain unit root.
194, 195
  Later in this chapter the methods for making 
a non-stationary series to stationary are described.   
Time series analysis comprises methods that attempt to understand such time series.  
Box and Jenkins
196
 introduced an approach to statistical analysis for time series that 
accounts for autocorrelated series where successive data points are correlated, with three 
steps 1) Identification2) Estimation and 3) Diagnosis.  
1) Identification 
In first step, identification, Autocorrelation Functions (ACFs) and Partial 
Autocorrelation Functions (PACs) are examined for presence of autocorrelation, trend 
and seasonality in the series.  ACF and PACF are explained in section 2.3.  In the 
identification step, the ACF and PACF are examined whether or not the series are 
stationary.  When series are found to be stationary, have the same mean and variance 
which do not change over time, then the plots are examined again to distinguish the 
Autoregressive (AR) and Moving Average (MA) in the series and if this is the case then 
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to identify the order of AR and MA, or the degree to which successive points are 
correlated.   AR and MA are more fully explained later.  
2) Estimation  
In the second step, estimation, the analyst uses a series of statistical modelling to 
estimate parameters of the particular model.  The order of autoregressive, moving 
average and their effects are tested against the null hypothesis of zero.  
3) Diagnosis  
In the third step, diagnosis, residuals are examined to determine if there are still patterns 
in the data that are not accounted for.  This includes examining of the residual from the 
model using ACF and PACF plots.  Residual scores are the difference between the 
predicted values by the model and the actual values.  Provided that all autocorrelations 
are captured by the model then the residuals plot should be consistent with a pure 
random process.  In time series analysis, power depends on the accuracy of the model.  
196
  In addition to other outputs of a fitted model there are two criteria to measure 
goodness-of –fit. The Akaike Information Criterion (AIC) is a measure of goodness of 
fit for an estimated model.  It is often used in model selection.  Smaller values of the 
AIC are preferred. For example, you can choose the length of a lag distribution by 
choosing the specification with the lowest value of the AIC.  The Schwarz Bayesian 
Criterion (SBC) is an alternative to the AIC that imposes a larger penalty for additional 
coefficients.  The ratio of AIC to SBC should be close to one.
195, 197
  An example of 
time series fitted model and output parameters is will be described in Chapter 3.  
When the best equation is identified through estimation and diagnosis steps and 
statistical tests that are described later in this chapter either on the model or on residuals, 
the formula can be used to predict or forecast and it is application of many time series 
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analyses in an economic arena.  However, in healthcare analyses, the goal is often to 
assess the impact of interventions, both naturally occurring and quasi-experimental. 
196, 
198
     
2.3  Autocorrelation 
Autocorrelation is likely to be present in time series.  When data are ordered in 
chronological order, the error in one period may be associated with the data in another 
time period or the next time point. In time series, autocorrelation means that errors or 
residuals of the fitted model are correlated with each other in particular lags.  
Autocorrelation may be positive or negative. The presence of autocorrelation violates 
the assumption in Ordinary Least Squares (OLS) of independence where the correlation 
between errors over time is zero.  One of the important tools for identifying the presence 
of autocorrelation is the correlogram. Usually two types of correlograms are examined 
to identify the presence of autocorrelation: 1) the Autocorrelation Function (ACF) and 
2) the Partial Autocorrelation Function (PACF).  ACF is a simple and unconditional 
correlation between a time series data point and its lags.
197
 
Visual examination of ACF and PACF plots are used to describe and identify the series 
and prediction of the model.  If an autocorrelation at some lag is significantly different 
from zero, the correlation is included in the model and if the condition applies to partial 
autocorrelation it will be included too. 
198
 
One factor that can cause autocorrelation is omitted variables.  If the omitted variable is 
correlated with previous observations, then this will lead to unavoidable correlation 
between consecutive error terms.  Autocorrelation can also occur due to 
misspecification of the model. Suppose that the Yt is connected to X2t with a quadratic 
relationship but we wrongly specify a linear relationship, then the error term will 
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increase or decrease with x2t, indicating autocorrelation.  A third factor is systematic 
error in measurement. In this case the series will contain a cumulated measurement 
errors causing autocorrelation. Presence of autocorrelation can be a combination of 
those factors.
195
 
2.3.1 Statistical tests for autocorrelation 
In addition to examining the ACF and PACF plots there are also a number of formal 
statistical tests to identify autocorrelation in the series.  
Box and Jenkins 
196
 presented Q statistics in their time series modelling. For a given lag 
length N, the null hypothesis is that no lags up to and Including N contain an AR and 
MA parameter which is significantly different from zero.  A limitation of Q statistics is 
that with high lag lengths N, or degrees of freedom, the power of this test to reject the 
null hypothesis is quite low.  In fact it is possible that the ACF plot shows a marked 
spike but the while the Q statistics is insignificant.
196
   Therefore, it is not a good idea to 
rely on Q test.   
Another test for presence of serial (first order) autocorrelation is the Durbin-Watson 
(DW) test (1950, 1951 and 1971).  Under the null hypothesis of no autocorrelation (P = 
0), DW is equal to or around 2.  A test statistic below 2 suggests positive 
autocorrelation (P > 0), while a test statistic above 2 suggests negative autocorrelation. 
There are two other critical values which allow a degree of uncertainty in testing the 
hypothesis; a smaller value DWL and a larger value DWH. Tables containing DWL and  
DWH for various sample sizes and number of repressors are contained in many  
econometrics text books. 
To test for positive autocorrelation, we do not reject the null of no autocorrelation if 
DW > DWH, and we reject the null in favour of the alternative hypothesis that p> 0 if 
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DW < DWL.  If DW lies between DWL and DWH, the test is inconclusive; in that case, 
alternative tests for autocorrelation should be considered.  
Although less common than positive autocorrelation, negative autocorrelation can also 
be detected using the Durbin-Watson statistic. If DW < (4 - DWH), the null hypothesis 
is not rejected. If DW > (4 - DWL), the null is rejected in favour of the alternative that 
p< 0. If (DWH -4) < DW < (DWL – 4), the test is inconclusive. 
199
  
The DW test has several drawbacks that make its use inappropriate in various cases. 
195
 
For instance, it may give inconclusive results, it is not possible to be used with a lagged 
dependent variable as an explanatory variable, and it cannot be used where there are 
higher than first order autocorrelation. 
This test is valid when:  
 The regression model includes a constant 
 Serial autocorrelation is assumed to be first order only , and  
 The equation does not include a lagged dependent variable as an explanatory 
variable.
195
 
The Lagrange multiplier test of Breusch (1978) and Godfrey (1978) and Durbin's (1970) 
alternative test are two tests for serial correlation that relax the requirement that the 
regressors be strictly exogenous (so that the model can contain lagged dependent 
variables as regressors), test for the possibility that the residuals follow an AR(p) or 
MA(p) process, so  there is no indeterminant region.  Both tests are based on fitting 
equation by OLS, collecting the residuals, then fitting the regression 
199
 .  
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2.3.2 Types of autocorrelation 
Two distinct types of autocorrelation are identified: 1) autoregressive process and 2) 
moving average process. 
In an autoregressive process, the ACF plot dampens out relatively quickly while the 
PACF plot has large spikes at lag points with near zero spikes at subsequent lags. The 
order of the autoregressive process, p, is defined by number of large spikes. For 
example an AR process of order 2 has two large spikes in PACF. Nonetheless, in 
practice ACF and PACF plots are not usually as clear as typical plots. 
In contrast a Moving Average (MA) process is identified by a PACF plot which 
dampens quickly or relatively quickly and an ACF plot with large spikes at lag order q. 
It is also important to consider the extent of autocorrelation provided by AR and MA 
models. In both processes the limits of autocorrelation must meet bounds within -1 and 
+1 limits. For AR process this limit is called bounds of stationary while for MA process 
it is called bounds of invertibility. 
199
 Bounds of invertibility and stationarity are 
described later in the chapter. 
Tables 2.1 summarises the different shapes in ACF and PACF plots and the most 
possible explanation for them for a times series consisting of 10 time points
198
 . The 
three values in the parenthesis are the orders of the nonseasonal autoregressive (AR) or 
P, differencing or d, and moving average (MA) or q operators, respectively. These are 
three components of ARIMA( Autoregressive Integrated Moving Average) and ARMA 
(Autoregressive Moving Average) methods are later described in this chapter. There are 
two common ACF patterns. There may be constant spikes  Table 2.1 (a), or there may 
be a ―damped sine wave‖ Table 2.1 (b), in which spikes oscillate first on one side and 
then on the other side of zero. 
198
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Table 2.1:  ACF and PACF for Common ARIMA Models.  Adapted from 
Tabachnick et al. 2000.
198
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2.3.3  Trend component and stationary 
In order to establish whether a given series contains autocorrelation, it is necessary to 
explore whether the series is stationary. This is an important concept in time series 
analysis. A time series is stationary if 
- It exhibits a reversion around a constant long-run mean; 
- It has a finite variance that is time invariant; and 
Time Series & Interrupted Time Series Analysis 46 
 
- It has a theoretical correlogram that diminishes as the lag length increases.195 
In other words the properties are stable over time.  
Series containing such unit roots are classified as difference stationary. Series with trend 
and without a unit root are classified as trend stationary and can be analysed using 
generalised regression methods.    
Stationary series vary around a constant mean level, either increasing or decreasing 
systematically over time with a constant variant.  Non-stationary series have systemic 
trends such as linear or quadratic.  A non stationary series that can be made stationary 
by differencing is called ―non-stationary in the homogenous sense‖. 198    
Figures 2.1.a and 2.1.b show examples of correlograms and  raw graph for non-
stationary series 1 and stationary series 2.  
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Figure 2.1.a:  Example of correlogram and raw data graph for a non-stationary 
series, Series01  
  
Figure 2.1.b:  Example of correlogram and raw data graph for a stationary series, 
Series02 
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There are two general approaches to achieve this: 1) differencing by subtracting the 
value of each data point from previous data point 2) de-trending the series using a 
regression approach.  The two relevant features in plot of a time series are the central 
tendency and dispersion. If the mean is changing, the trend is removed by differencing. 
After removing the trend the series are expected to be stationary with respect to central 
tendency.  If the variability is changing, the process may be made stationary by 
logarithmic transformation. If after transformation the variability does not improve, 
untransformed series are used in future analyses. 
200
 
The visual tests for whether a series is stationary are based on the correlogram. For a 
stationary series, the correlogram will die out quickly as the lag length increases, while 
in a non-stationary series the correlogram will not die out quickly. However this might 
be imprecise if confused with the examination of correlogram for autocorrelation. 
194
 
The best way is to use a formal statistical test for stationarity.   
2.3.4. Statistical tests for unit root 
Dickey- Fuller test  
The Dickey-Fuller 
201
 test for whether a time series is stationary is simply the normal  t-
test on coefficients of lagged dependent variable yt-1.  This test does not have a 
conventional t distribution and so we must use critical values which were originally 
calculated by Dickey and Fuller. A limitation of this test is when a series contains a 
major break such as change in level or slope.  Another limitation is that when the null 
hypothesis of a unit root is rejected it does not necessarily mean that the error term is a 
result of a white noise, and it may be affected by autocorrelation.
195
  Enders showed that 
the Dickey-Fuller test has limited power and suggested adopting a more liberal alpha 
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(e.g. P<0.1 rather than than P<0.05) in order to avoid differencing in the series which 
are not in fact difference stationary in nature. 
197
 
Augmented Dickey-Fuller test (ADF) 
Since the error term is unlikely to be the white noise, Dickey and Fuller extended their 
test procedure suggesting an augmented version of the test which includes extra lag 
terms of the dependent variable in order to eliminate autocorrelation.  The lag length of 
those extra terms is either determined by the Akaike Information Criterion (AIC) or 
Schwartz Bayesian Criterion (SBC), or more usually by the lag length necessary to 
whiten the residuals.
195
 The Augmented Dickey-Fuller test (ADF) includes extra lag 
terms of dependent variable in regression to eliminate autocorrelation in detecting white 
noise.    
The Phillips-Perron Test (PP) 
While the ADF test corrects for higher order of serial autocorrelation, the Philips-Perron  
(PP) test makes a modification that takes into account the less restrictive nature of the  
error process. Philips and Perron 202 further developed the ADF test. 
The distribution theory supporting the Dickey-Fuller tests is based on the assumption 
that the error terms are statistically independent and have a constant variance. So, when 
using the ADF methodology we have to make sure that the error terms are uncorrelated 
and that they really have a constant variance.  Phillips and Perron (1998) developed a 
generalization of the ADF test procedure that requires less restrictive assumptions.  
While the ADF test corrects for higher order series correlation by adding lagged 
differenced terms, the PP test make a correction to the t statistics of the coefficient   
from AR(1) regression to account for the serial correlation in   .  So, the PP statistics 
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are modifications to the ADF test that take into account the less restrictive nature of the 
error process.  The asymptomatic distribution of the PP t test statistics is the same as the 
ADF t statistics and therefore the Mackinnon (1991) critical values are still applicable.  
As with the ADF test, the PP test can be performed with the inclusion of a constant, a 
constant and linear trend, or neither in the test regression. 
195
   
The Box-Jenkins approach is a series of re-estimating and diagnosis to capture the best 
possible ACF and PACF of the residuals.  This approach is conceptualised as (p, d, q) 
where p represents the order of AR and q the order of MA (if present) and d the 
differencing order.  This approach is called ARIMA (p, d,q) or Autoregressive 
Integrated Moving Average.  The autoregressive element, p, is persisting effect of 
preceding scores.  The integrated element, d, represents trend in time points, and 
moving average element, q, is the persisting effect of preceding random shocks. When 
the value of p, d, or q is zero, the element is not needed in the model.  The set of more 
general ARMA (Autoregressive Moving Average) elements that utilises the AR and 
MA but can use different approaches to achieve a non-stationary in differencing the 
model. 
199
 
2.3.5 Autoregressive Process 
The autoregressive component is the memory of the process for preceding observation.  
Most time series consist of elements that are serially dependent on the consecutive 
element or coefficients called an autoregressive process, memory of elements.  In this 
process a coefficient or a set of coefficients describe the consecutive elements. In other 
words each component is made up of a random error component and a linear 
combination of prior observations. One approach to autocorrelation is the autoregressive 
process.
203
  Autoregressive process of order P for a stationary time series Y is theorised 
in the following equation
203
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Yt =C+ ΦYt-1+ ΦY t-p+...+ΦpY t-p + at   (2.1)  
In which the value of Y in a given time has constant C, a random shock or error 
component of at and the components of Y values at previous lag with P order.  
Therefore a first order autoregressive process would be: 
Yt = C+ ΦYt-1+at   (1.8)  (2.2) 
It implies that the value of Y at a given time t is dependent on a random component 
defined by the parameter Φ.  If the definite value of coefficient Φ is greater or equal to 
one, there is a random walk and the series is not stationary. 
196
  
For an autoregressive order of two the coefficients Φ1 and Φ2 must meet the following 
condition: Φ1   Φ2 <1.  These are called bounds of stationary for an autoregressive 
parameter(s). 
198
 
2.3.6  Moving Average Process 
The moving average component is the memory of the process for the preceding random 
shock.  In order to eliminate noise of individual observations, in time series analysis we 
can average a number of observations around time t to get the measure of central 
tendency.  Moving average cancels positive and negative shocks, so taking an average 
should normally reduce any idiosyncratic noise in the series.  
199
 
If Xt denotes the level of our series at time t, the moving average Mt is defined as
198
  
   
 
      
                (2.3)        
where L denotes the number of lagged terms to include in the average and F denotes the 
number of leading terms to include. The number of lagged terms depends on the 
periodicity of data. Commonly the number of terms chosen to include in a moving 
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average is the number of time periods in a year. For quarterly data four terms are used, 
and for monthly data twelve terms are used. Nonetheless a four-period moving average 
cannot smooth out fluctuations that occur over an entire year. On the other hand, a 
twelve-period moving average is based on data that span an entire year, resulting in an 
average that is not influenced by seasonal factors.  This doesn‘t mean that analyses 
should only use monthly data.  In fact, if we want to make the seasonal fluctuations 
visible, we can use three or four-monthly data to do this.  The number of available 
observations is also important, so with a low number of data points we tend to use lower 
MA process to avoid having too few data points in final analysis.
197
 
When q is 1, there is a relationship between the current time point and the random shock 
at lag 1.  It is also possible that each element in the series is dependent on past error 
terms which cannot be accounted in autoregressive process.  In other words the each 
time point is made up of a random error component (random shock) and a linear 
combination of prior error components (random shocks). 
195, 197
 
The MA process equation can be inverted (rewritten) to AR process, a duality between 
MA and AR.
196
 This can happen when the MA parameters follows a process called 
invertibility; otherwise the series are not stationary. If q is the order of moving average 
process:  
Yt =C+ θ1Yt-1+ ...+ θqY t-q     (2.4)     
Therefore for a first order MA process would be:  
Yt = C+ θYt-1     (2.5)  
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For a first order moving average process the coefficients, θ, must be between -1 and 1 
and for second order it must meet the following condition θ1   θ2 < 1. These are called 
bounds of invertibility.
198
  
2.3.7  Seasonality in time series 
The nature of time series has a function of periodicity.  The outcome of interest may 
vary on a seasonal basis. Monthly data with a seasonal component exhibit seasonal 
effects at lag 12 while quarterly data show the seasonality at lag 4.  When time series 
contain seasonality the ACF and PACF show significant spikes at multiples of lags 
equal to periodicity.  For example in monthly series with seasonal variation the ACF 
plot shows spikes at lags 12, 24, 36 that die out slowly. When a series does not contain a 
seasonal unit root, the magnitude of the autoregressive parameters decrease 
approximately exponentially.  There are various approaches to detect and test for 
seasonality, and to include seasonality in time series.  Detection and inclusion of a 
seasonal component are implemented in time series analysis methods with ARIMA, 
ARMA, and dynamic regression of time series because seasonality induces 
autoregressive and moving average process.  Here, seasonal component and two 
methods of adjusting for seasonality are briefly described.
199
 
Two basic components of time series are trend and seasonality.  The seasonal 
component could interact with trend components either in a multiplicative or in an 
additive way. 
2.3.8 Time domain approach for seasonality 
For a time domain approach, used in additive seasonality 
199
, we can apply deterministic 
seasonal dummies or adopt a stochastic approach to estimate seasonal autocorrelation 
terms.   Seasonal variations can be easily examined by the use of dummy variables in 
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regression. In a stochastic seasonal approach the autocorrelated error terms at a given 
seasonal lag are incorporated in the model. 
195, 199
 
2.3.9 Seasonal decomposition 
When seasonal component exists, seasonal decomposition is way of decomposing a 
series into its components; trend and seasonality in either an additive or multiplicative 
interaction.   This method can therefore remove the seasonality component, and is 
suitable for when the analyst is interested in trend or wants to forecast. 
204
  The method 
is particularly useful when the seasonal component is multiplicative and the study is an 
interrupted time series analysis.  In this case, the decomposition based approach can be 
used to remove seasonality before the intervention analysis.  Adjusting for seasonality 
by seasonal decomposition approach method is built-in in statistical packages.  
2.3.10 Multivariate Time Series 
Multivariate time series is analysis of the relationship between two or more time series.  
Other terms are also used as cross-correlation function, transfer function models, 
models with input series, and dynamic regression.
205
  
2.4  Other statistical concerns in time series analysis 
194, 195
 
2.4.1 Collinearity  
Collinearity arises when a predictor variable is highly correlated with another predictor 
variable.  The presence of collinearity may bias the regression estimates, variance 
estimates and the test statistics and the test statistics and P values. An approach to test 
the collinearity is regressing predictor variables with one another, which is called a 
tolerance test.   
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2.4.2 Outliers 
Outliers are very common in inconsistent time series.  They can greatly affect the 
results, and should be dealt with. Checking the original data, deleting outliers and 
replacing the observations with imputed values, and using dummy variables are several 
measures to deal with outliers. There is no single best way to deal with outliers and so 
in the series these kind of time points should be labelled as outliers.
198
  An outlier time 
point may indicate an important change such as an intervention, in which case it should 
be modelled by an interrupted time series design. 
2.4.3 Nonlinear trend 
It is possible that while the data do not contain a unit root, the nature of the trend is not 
linear, for example increasing or decreasing in a quadratic character.  In this case 
applying a linear trend term to the model will be misleading.  One approach is applying 
polynomial terms where appropriate. 
2.4.4 Model Selection Criteria
195, 198
 
The random shock that happens in the series is assumed to be independent and normally 
distributed.  Contingencies among errors over time are a part of model identification 
and estimation. If the model is powerful then all serial contingencies are removed so 
that the final model is left with random distribution of errors. This should be reflected 
by the residual error having mean zero and homogeneity of variance. When the 
residuals are not normally distributed, then square root, logarithmic, or inverse 
transformations are appropriate measures.  In the final model there should be no 
remaining autocorrelations at various lags.
205
   
Statistical packages report R-Squared, adjusted R-squared that help in this stage.  Two 
other important outputs are AIC (Akiake‘s Information Criterion) and SBC (Schwarz‘s 
Time Series & Interrupted Time Series Analysis 56 
 
Bayesian Criterion). Ideally, we select the model that minimises these statistics, as 
compared to alternative specifications.
195
  
In summary, in analysis of time series the following steps are suggested: 
1- Check for normality of data 
2- Examination of time plots, ACF and PACF 
3- Establish whether the series are stationary 
4- Check and account for autocorrelation, and seasonal adjustments 
5- Fit the model  
6- Examine the residuals, and other tests for model comparison.  
7- Test the plausibility of alternative models and asses the relevant test results and 
outputs.  
2.5 Interrupted Time Series Analysis (ITSA) 
Analysis of a time series with an intervention (an interrupted time series) examines a 
time series before and after the intervention.  This method is the strongest quasi-
experimental design to evaluate longitudinal effects of such time delimited 
interventions.
206
 Interrupted time series analysis design is widely used to evaluate the 
effects of one or more events or intervention retrospectively or prospectively. Statistical 
methods are piecewise or segmented regression, and ARIMA and ARMA based models. 
The statistical tests, precautions, and procedure are mainly the same as time series 
analysis. Segmented regression analysis is appropriate for studying the impact of 
interventions that constitute a natural experiment (eg where researchers examine the 
effect of a policy change) or quasi-experiment (eg where researchers themselves create 
an intervention). It requires data on continuous or counted outcome measures, 
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summarised at regular, evenly spaced intervals.
206
 These designs are also suitable when 
a randomised control trial is not feasible.  
The effects produced by interventions differ in both the onset (abrupt or gradual) and 
duration (permanent or temporary).  In quasi-experiment designs it is more likely that 
the intervention lasts for a long time. Because there are two levels of duration and two 
levels of onset, there are four possible combinations of effects, but gradual onset, 
temporary effects occur rarely and require curve fitting.
198
 
Segmented regression analysis of interrupted time series allows the assessment, in 
statistical term, of how much an intervention changed an outcome of interest, 
immediately and over time; instantly or with delay; transiently or long term; and 
whether factors other than the intervention could explain the change.  The choice of the 
beginning and end of each segment depends on the beginning and end of the 
intervention, with the possible addition of some pre-specified lag time to allow the 
intervention to take effect. 
206
  Segmented regression analysis uses least squares 
estimation of parameters.  This method is appropriate when the response variable has a 
linear trend over a certain range of independent variable (time), followed by another 
linear trend over a succeeding range.
207
 
Campbell and Stanley
208
  identified eight patterns of time series data that may result 
from a change as shown in figure 2.2. Series H exhibits a polynomial pattern.  Series B 
represents a temporary effect.  From the remaining models A, C, D, E, F and G can be 
handled by segmented regression while case H would require a polynomial or other type 
of regression model, as a linear trend is not appropriate. 
207
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Figure 2.2:   Patterns of time series interrupted with an intervention adopted 
from Gillings et al.
207
   
  
 
 
 
 
 
 
 
 
Outcomes of an intervention, using ARIMA, ARMA or segmented regression, are 
expressed by three measures; change in level and change in slope after the intervention 
and the intervention effect size if nothing had happened.  This is fitted in models using 
dummies for each change or intervention point.  
The graphical illustration of interrupted time series with segmented regression is 
presented in Figure 2.3 adopted from chapter 3 of this thesis.   The regression model in 
case of one change without lag time is: 
                                                     (2.6) 
where,     series are time variables.    is a continuous variable starting from 1 to the last 
time point in series.        is a dummy variable coded zero for pre-intervention and 1 for 
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post-intervention time points.  The term         refers to time after the intervention.  It is a 
continuous variable counting number of time points after the intervention and coded 
zero for pre-intervention time points.   
In this model     estimates the level of outcome at time zero.      is the slope of the pre-
intervention segment and estimates the mean change in outcome per month before the 
intervention.  The coefficient      estimates the level of change immediately after the 
intervention.       estimates change in slope after the intervention ( α in Figure 2.3) and 
represents the monthly mean of the outcome variable. The sum of            is the slope 
of the post-intervention segment. The error term      represents normally distributed 
random error and an error term at time t that may be correlated to errors at preceding or 
subsequent time points. 
Estimation of intervention effect had the intervention not occurred for time      where n 
is a given time after the intervention is expressed in the following equation (ce in Figure 
2.3) : 
                                            (2.7) 
Change in level (ab in Figure 2.3) is the size of the immediate intervention effect, and 
change in slope represents the sustainability of the intervention effect.  
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Figure 2.3:   A model for interrupted time series analysis with segmented 
regression 
209
 
 
 The single most important thing to remember about time-series experiments is that they 
require long baseline periods to establish whether the process is stationary or non-
stationary.  In general it is difficult to say exactly how long a baseline must be for a time 
series experiment to reliably establish this.  It is found that time series of observations 
of a single individual are often stationary, particularly if you discard the first few points 
during which the subject may be acclimatising to the equipment or observation 
procedure.  On the other hand, time series based on large groups of persons - like 
classrooms, cities, or the population of an entire nation - are often non-stationary. 
198, 210
 
  
Time Series & Interrupted Time Series Analysis 61 
 
Sample size 
A sufficient number of time points before and after the intervention is needed to conduct 
segmented regression analysis. A general recommendation is for 12 data points before 
and 12 data points after the intervention, although this number is not based on estimates 
of power. Rather, with 24 monthly measures, the analyst can adequately evaluate the 
presence of, and account for seasonal variation (Figure 2.3).  There also needs to be a 
sufficient number of observations at each data point. A minimum of 100 is desirable at 
each data point of the time series to achieve an acceptable level of variability of the 
estimate at each time point. 
206, 208
 Additional change points may also serve to control 
for changes in the series that are not of primary interest but may influence the results.  
Examples include discontinuities in the series at time points other than that of the 
intervention because of administrative changes and lagged or multi-period 
interventions.
206, 208
 
It is important to account for lags in impact (the delayed effect of an intervention) and 
multi-period interventions in the analysis to avoid incorrect specification of intervention 
effects.  To model these effects, one can exclude from the analysis outcome values that 
occur during the lag or the period ‗during the intervention‘.  Alternatively, with enough 
data points, one can model this period as a separate segment. 
A major strength of segmented regression analysis is that in the absence of a control 
group the pre-intervention segment can reserve as a control group and baseline 
measurement. 
206, 207
 
ITS designs are subject to threats to internal validity that are related to history (such as 
seasonality) that influence the dependent variable, maturation bias where there is a 
pattern of improvement in the experimental group prior to the intervention, and 
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instrumentation bias.  For example changes in the way records are kept or the way the 
outcomes are measured and selection bias which could cause a differential drop out in 
the experimental group.
211
 
2.5.1 Quality Criteria for ITSA  
Ramsay et al. 
212
 developed the following quality criteria checklist from two sources, 
the Cochrane Effective Practice and Organisation of Care (EPOC) data collection list
211
 
and classification of threats to validity identified by Campbell and Stanley.
208
  High 
quality ITSA tends to have the following features: 
1- Intervention occurred independent from other changes over time  
2- Intervention was unlikely to affect data collection 
3- The primary outcome was reliable and assessed blindly or was measured 
objectively 
4- The shape of the intervention effect was pre-specified 
5- A rational for number and spacing of data points was described 
6- The study was analysed appropriately using time series analysis.    
It is possible that other events are responsible for the change after the intervention and 
for this reason it is preferable to employ a control group.
206, 207
  However, without 
having a control group if the dataset is large enough to give enough power it is possible 
to model more than one structural event.  
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CHAPTER THREE:  OUTCOMES OF AN 
INTERVENTION TO IMPROVE HOSPITAL ANTIBIOTIC 
PRESCRIBING IN DUNDEE: INTERRUPTED TIME 
SERIES WITH SEGMENTED REGRESSION ANALYSIS 
3.1 Background 
NHS Tayside has had a leading role in the UK for initiating prudent antibiotic 
prescribing through a series of audits, quality improvement projects and innovative 
service developments in primary and secondary care over the last two decades.
213-218
  
Nonetheless, there was a need for novel methods in evaluating interventions, 
implementing the new Drug Utilisation Review (DUR) methods to incorporate them 
into institutional goals to monitor, control and prevent inappropriate use of 
antibiotics.
219, 220
  This chapter consists of evaluation and management of antibiotic 
prescribing through evaluation of the Alert Antibiotic Intervention programme.  
3.2 Introduction 
In 2002, the Scottish Executive Antimicrobial Resistance Steering Group was 
established to gain commitment to a co-ordinated, focused approach at the local, 
national and international levels for prudent antimicrobial use in humans and set the 
surveillance of antimicrobial use and resistance as one of the key elements.
107
  
In UK 62% of the hospitals have a policy for antibiotic therapy but few had information 
systems for easy assessment of practice. 
219
 On the other hand, across the UK, the 
selection of indicators in studies to measure and monitor drug use especially in hospitals 
was very different so that it was difficult to compare data over time or within different 
regions, therefore, a new measure based on standard daily dosages is needed 
24
.   
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These units are not without their problems, but they avoid many of the deficiencies of 
the item.  The DDD adjusted for bed occupancy (DDD/100 bed-days) is a practical tool 
for measuring drug use in hospitals.  Despite the implementation of this indicator across 
Europe during the last two decades, it was rarely used in drug utilisation studies in the 
UK.  
At NHS Tayside Acute Services Division (ASD) Tayside Medicines Unit (TMU) used 
reported the annual drug usage and drug expenditure information but the data took time 
to gather because this involved manual addition of data on different formulations of the 
same drug.  Reports generated since 1999 show rates of expenditure by therapeutic class 
(e.g. anti-infectives) but only provide limited data about the utilisation of specific drugs. 
Furthermore, annual changes in the trend of anti-microbial prescribing were only 
identified when financial year end budget reports were produced.  It was difficult at that 
stage to identify why certain increases in expenditure or usage occurred or to effect any 
intervention that might have an impact on this trend.  A system allowing the prospective 
monitoring of prescribing practices and regular publication of usage figures should 
allow real-time feedback to prescribers, a much tighter management of these drugs and 
hopefully trigger more judicious prescribing during periods when usage appears to be 
getting out of control.  There could also be the potential for significant cost savings. 
In 2000, the Antibiotic Subcommittee of Tayside ASD devised an Alert Antibiotic 
Policy to reduce inappropriate use of key antibiotics, targeted because they should be 
reserved for infections caused by organisms that are resistant to the first line 
antimicrobials. I conducted the first evaluation of this intervention before the work 
reported in this thesis, and relied on analysis of the records of patients prescribed an 
Alert Antibiotic completed by the ward pharmacists.  The number of Alert antibiotics 
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records declined from 41 per month in the first year to 25 per month in the second year. 
The proportion of prescriptions that were appropriate was similar in the 2 years; 83% 
and 84%.  Two fundamental problems with using patient records as a measure of 
outcome of the Alert Antibiotics Policy were identified. Firstly, patient records are not 
an objective measurement of outcome.  Outcome measures such as appropriateness of 
care should be based on a questionnaire with known reliability and validity.  Moreover, 
outcome measures that are obtained by chart extraction or collected by an individual 
require two or more rates with at least 90% agreement or kappa greater than or equal to 
0.8. 
221
 Secondly, patient records provided no information about practice before the start 
of the intervention and consequently it was impossible to say whether the reduction in 
the number of records was the result of the impact of the intervention or simply a 
decline in the return of records by the pharmacists.
220-222
 
In this study routine data from the pharmacy stock control computer used to evaluate 
the intervention with an Interrupted Time Series Analysis (ITSA), in which a series of 
observations over time is interrupted by an intervention or treatment. 
206, 223
  
3.3 Aims 
 What is the impact of an Alert Antibiotic Policy on the use of antibiotics 
reserved for second line treatment of resistance organisms?  
 What is the cost of designing and implementing of the policy and to what extent 
are these costs offset by savings in drug costs? 
3.4 Methods  
3.4.1 Setting  
The intervention, an Alert Antibiotic Policy, was implemented in Ninewells Hospital 
which is a tertiary university hospital in Tayside, Scotland.   
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3.4.2 Design of the Alert Antibiotic Intervention  
The design of intervention to change prescribing was based on evidence about changing 
professional behaviour in the Effective Practice and Organization of Care (EPOC) 
section of the Cochrane Database. 
224-229
  From this evidence and an earlier systematic 
review of the literature on behaviour change 
230
 three key elements for the intervention 
were identified: development, dissemination and implementation.  The Tayside 
Antibiotic Subcommittee developed the Alert Antibiotics Policy, the committee is 
multi-disciplinary, chaired by a surgeon and includes representation from junior staff 
and the clinical groups in addition to local opinion leaders.  The committee‘s 
dissemination strategy was targeted at specific professionals and clinical teams via the 
clinical pharmacists.  The implementation strategy used immediate, concurrent feedback 
of information to the prescribers, who were contacted by the clinical pharmacist while 
their patient was still being treated. 
The Policy targeted the following drugs (Alert Antibiotics):  
(i)    Carbapenems: Imipenem and Meropenem  
(ii)   Glycopeptides: Teicoplanin and Vancomycin  
(iii)  Intravenous (IV) Amphotericin  
(iv)  Ciprofloxacin (IV) 
(v)  Linezolid (IV and oral)  
(vi)  Piperacillin-Tazobactam (Tazocin)  
(vii)  Third generation cephalosporins: Ceftriaxone, Cefotaxime and 
 Ceftazidime.  
 
In August 2000, the intervention was put into effect in up to 40 medical and surgical 
wards of Ninewells Hospital, excluding Haematology and Paediatrics.  Haematology 
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and Paediatrics were excluded because these wards had their own policies for 
prescribing Alert antibiotics.  Guidelines for prescribing use were evidence-based and 
agreed locally with the clinicians.  Clinical pharmacists were asked to identify 
prescribing of the Alert Antibiotics by the medical staff in their wards and confirm that 
their use was in line with the agreed guidelines.  If not, the pharmacists asked medical 
staff to review their choice of antibiotic and advised them to contact microbiology or 
infectious diseases physicians for advice if necessary. 
3.4.3 Evaluation of the intervention 
Segmented regression analysis of Interrupted Time Series (ITS) design allows us to 
assess, in statistical terms, how much an intervention changed an outcome of interest, 
both immediately and over time. When a separate control group is not available, 
analysis of the outcome of interest in the study group does not allow for other events 
that may have influenced the outcome if sufficient data are not available. Nonetheless, 
the level and trend of the pre-intervention segment serves as a control for the post-
intervention segment in single group time series, still addresses important threats to 
internal validity and represents a methodologically acceptable design for measuring the 
impact of interventions. Accounting for seasonally correlated errors usually requires at 
least 24 monthly data points. 
206
 Detailed description of statistical method used in this 
chapter is previously described in Chapter 2 of this thesis , time series analysis and 
interrupted time series.  Figure 3.1 is the graphic illustration of outcome measurements 
in segmented regression of interrupted time series analysis.  Three outcomes in the ITS 
analysis are: first, change in level immediately after the intervention (ab); secondly, a 
difference between pre-intervention and post-intervention slopes (α); and third, the 
estimation of monthly average intervention effects after the intervention (ce). 
206, 223, 231
  
In addition to the main outcomes of ITS analysis a further more conservative analysis 
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was performed.  For this, no increase was assumed after the intervention and the 
difference with the mean observed use and cost after the intervention calculated.  In 
Figure 3.1 conservative estimation is cd which is equal to ce-dc.  
Figure 3.1  Graphic illustration of interrupted time series analysis and 
measuring the outcomes according to the best-fitted lines for data points before 
and after the intervention. 
 
 
Usage and cost data were collected and analysed for 2 years before and 2 years after the 
intervention in order to minimise the effect of seasonal variation.  Data were adjusted 
for autocorrelation. For statistical analysis, autoregressive time series analysis method 
was implemented using SPSS® software. (SPSS Inc. 2002. SPSS Base 11 for Windows 
User's Guide. SPSS Inc., Chicago IL)  
Linezolid and Imipenem were excluded from the ITS analysis because there were less 
than 12 monthly data points before the intervention. The level of significance was 0.05.  
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3.4.4 Data collection  
After evaluation of the intervention using analysis of patient records and the related  
shortcomings of this method 
221
, pharmacy stock data were used.  During the 4 year 
period of analysis, the hospital pharmacy did not implement a restriction policy on 
dispensing the Alert Antibiotics and therefore the pharmacy data provided the best 
available independent indicator for evaluating the intervention.  The impact of the 
intervention on antibiotic prescribing was analysed using data about the quantity of 
Alert Antibiotics dispensed to the hospital wards per month for 2 years before and after 
the start of the intervention.  A program was written to collate data relating to the 
dispensing of all dosage forms of the relevant drugs and conversion of the total grams 
dispensed were converted into Defined Daily Doses (DDD). The DDD as defined by the 
WHO Collaborating Centre for Drug Statistics Methodology (WHO CC) as ‗the 
assumed average dose per day for a drug used on its main indication in adults.
232, 233
  
The DDDs were adjusted for bed occupancy and is presented as DDD/1 00 bed-days.  
3.4.5 Cost analysis  
As the average price of Alert Antibiotics dosage forms might have decreased during the 
post-intervention period, the average price of each dosage form over the 4 year period 
of the study was calculated and used to eliminate any effect of fluctuation in drug 
prices.  The final results were measured with £/bed-days/month but are presented in 
£/month. 
The total cost of the Alert Antibiotic Policy and clinical pharmacy intervention was 
calculated by measuring the time required for consultation, completion of the records, 
data entry and interpretation. The time required for additional meetings of the Antibiotic 
Policy Committee was quantified and additional consumable materials were recorded. 
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Time was costed using the average hourly rate for each staff grade in each of the years 
of the intervention, including employer‘s contributions and national insurance.  
3.5 Results  
Before the intervention, both use and cost of Alert Antibiotics were on the increase but 
after the intervention both use and cost declined – as shown in Figures 3.2 and 3.3. 
Figure 3.2: Changes in use of alert antibiotics 24 months before and after the 
intervention. 
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Figure 3.3  Changes in cost of Alert antibiotics 24 months before and after the 
intervention. 
 
 
The intervention was associated with a significant change in the level of use of 
Teicoplanin and Ceftazidime, but there was no significant change in the level for all 
Alert Antibiotics combined (Table 3.1). There was a significant change in the slope so 
that overall use of all Alert Antibiotics decreased by 0.27 DDD/100 bed-days per month 
(95% CI 0.19—0.34, P < 0.0001). There were also significant decreases in the slope for 
Amphotericin, Ciprofloxacin, Piperacillin-Tazobactam, Teicoplanin, and Vancomycin. 
The slope of Ceftriaxone usage increased significantly but there were no significant 
changes in slope for use of Ceftazidime, Meropenem or Cefotaxime. The results of 
statistical analysis of changes in cost were similar to change in use as shown in Table 
3.2  The analysis of change in the slope showed a reduction in cost of Alert Antibiotics 
by £1,908 per month in the two years after the intervention (95% CI £1,238- £ 2,578: 
P<0.0001).  
Over 2 years, it was estimated that the Alert Antibiotic Policy reduced use by an 
average of 4.03 DDD/100 bed-days per month (Table 3.1) and reduced cost by an 
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average of £23,852 per month (Table 3.2). The estimated use and cost of each 
individual drug was reduced, with the exception of Ceftriaxone, for which use and cost 
increased (Tables 3.1 and 3.2). The average reduction in use was greatest for 
Teicoplanin (1.02 DDD/l00 bed-days per month), Piperacillin-Tazobactam (0.80), and 
Vancomycin (0.78). The average reduction in monthly cost was greatest for 
Amphotericin (£8,075), Piperacillin-Tazobactam (£6,800) and Teicoplanin (£3,173). A 
more conservative estimate of effect size was calculated from the difference between 
the post-intervention line and the last point on the pre-intervention line (Figure 3.1). 
This conservative estimate was a decrease in total use by 1.60 DDD/l00 bed-days/month 
(95% CI 1.9-2.1, P <0.0001) (Table 3.1) and a decrease in cost by £9,590/month (95% 
CI £5,554- £ 13,626, P <0.0001) (Table 3.2). 
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Table 3.1:  Change in use of Alert Antibiotics after the intervention 
 
 
The maximum reduction in use was calculated from the difference between the observed values and the expected values, estimated by extrapolation of 
the pre-intervention line. The conservative reduction in use was calculated from the difference between the mean of observed values after the 
intervention and the intercept of the pre-intervention line in month 24, the last month before the intervention began. Data are presented in DDD/100 
bed-days. LCI and UCI are the lower and upper limits of 95% confidence interval. 
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Table 3.2:  Change in cost of Alert Antibiotics after the intervention 
 
 
The maximum reduction in cost was calculated from the difference between the observed values and the expected values, estimated by extrapolation of 
the pre-intervention line. The conservative reduction in cost was calculated from the difference between the observed values after the intervention and 
the  intercept of the pre-intervention line in month 24, the last month before the intervention began. LCI and UCI are the lower and upper limits of 95% 
confidence interval. 
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3.5.1 Costs of the intervention 
The cost of the first year of the intervention, which included setting up the programs for 
extraction, formatting and analysis, was £15,143 and the cost of running the 
intervention in the second year was £4,990 (Table 3.3). The total cost of the intervention 
(£20,133) over the 2 years was therefore well below the most conservative estimate of 
the reduction in cost of Alert Antibiotics, which was £133,296 (the lower boundary of 
the 95% CI for change in slope after the intervention,  £5,554 per month times 24 
months). However, assuming that the cost of Alert Antibiotics would have continued to 
increase without the intervention, the cost of Alert Antibiotics was estimated to have 
decreased by an average of £23,852 per month (95% Cl £18,154- £29,549, P <0.0001) 
(maximum estimate of reduction, Table 3.2). 
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Table 3.3:  Cost of the Alert Antibiotic Monitoring intervention and of the set-up and analysis of the ward antimicrobial supply database. 
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3.6 Discussion 
The study evaluated the intervention with one of the strongest quasi-experimental 
methods to evaluate the intervention.  A systematic review showed fundamental 
methodological flaws in 70% of published evaluations of interventions to improve 
hospital antibiotic prescribing, especially in interventions defined as interrupted time 
series in methodology.
148
  On the other hand, the cost- effectiveness analysis of the 
intervention that was performed in this study was a gap in previous studies.  In the same 
review Davey et al, 
148
  found reliable data about financial outcomes were provided by 
22 (34%) of the 64 studies, but only seven (11%) provided details about the intervention 
cost. The lack of cost of intervention was also mentioned in two other reviews. 
234, 235
 
Furthermore, in this study average drug prices were used to avoid over-estimation as a 
result of possible price reduction of newly introduced drugs during the 4-year period.  
The segmented regression analysis of a 4-year Interrupted Time Series showed that the 
Alert Antibiotics Monitoring Policy was associated with significant decreases in total 
use and cost in the 2 years after the Policy was introduced and implemented by clinical 
pharmacists.  Even the most conservative estimate suggested that the cost of the 
intervention was more than offset by savings in drug costs by the second year of the 
intervention.  Nonetheless, despite the success of the overall intervention, use and costs 
of Ceftriaxone increased.  The intervention needed to expand to cover all antibiotics in 
order to assess the degree to which reduced use of Alert Antibiotics is associated with 
an increase use of other drugs.
229
  Even if this does occur, the intervention, if continued, 
may remain cost-effective as the Alert Antibiotics are the most expensive anti-
infectives.  Therefore, this study provides evidence of a good financial case for targeting 
the inappropriate use of these drugs. 
The Alert antibiotic intervention was successfully delivered by clinical pharmacists.  
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Measurement of hospital antibiotic use is a good start but needs to be supported by more 
detailed analysis of indications for use and outcomes.  At present, collection of this 
information is laborious, requiring extraction from handwritten case records.  The move 
towards electronic patient records is welcome but will not solve all of the problems 
inherent in the evaluation of antibiotic prescribing.  Quality indicators require consensus 
about evidence-based clinical standards and about the information that must be recorded 
in order to evaluate compliance with standards.
220
  Audits from Ninewells Hospital 
showed that <50% of prescriptions for antibiotics were supported by any information 
for indication of antibiotic treatment. 
222
 These results are depressingly similar to an 
audit from the Central Middlesex Hospital over 20 years ago.
139, 140
  Electronic medical 
records will be easier to analyse than paper records, but the value of the information will 
be questionable unless the records include standardised, evidence-based minimum 
datasets for recording the indications for and outcomes of antimicrobial treatment.  
3.7 Conclusion 
The results showed that pharmacy stock data can be successfully and relatively easily 
used to assess the effect of interventions targeting antibiotics in hospitals.  Adjustment 
of data by defined daily dose and for bed occupancy provide simple and objective 
measures of prescribing.  The study is supported by a strong method for the evaluation 
of the intervention, quasi-experimental design to evaluate the overall impact of 
interventions to change prescribing.
206
 The methods addressed the fundamental 
methodological flows in evaluation of interventions in 70% of published studies to 
improve hospital antibiotic use
236
. The Cochrane review by Davey et at. has evaluated 
the effectiveness
 
and potential benefits of a range of interventions to improve
 
antibiotic 
prescribing practices for hospital inpatients and emphasised on interrupted time series 
analysis as a robust method for evolution of interventions.
148
 The Cochrane review 
Tayside Intervention 79 
 
identified that reliable data about financial outcomes were provided in 22 (34%, 22 out 
of 64 studies) of the 64 studies, but only seven (11%) provided details about the 
intervention cost.
148
  The lack of a control group could be seen as a limitation however, 
the change in Alert antibiotics use and cost (Figures 3.2 and 3.4) after the introduction 
of the intervention is so dramatic that we can be confident the effect is due to 
intervention.  
Clearly these data do not provide information about the indication of treatment or 
clinical outcomes.  However, clinical pharmacists or other staff can use ward supply 
data as a method of identifying wards with unusual usage pattern that could be targeted 
with more detailed audits. In Ninewells Hospital, these data provided important support 
for the continuation of the Alert Antibiotic intervention and for targeting interventions 
to improve the quality of antibiotic prescribing.
222, 237, 238
 Having established the 
intervention and demonstrated its cost-effectiveness, the intervention team was put in a 
stronger position to request additional resources to analyse time trends in microbiology 
results and indicators of clinical outcome, such as length of stay and readmissions.
25, 238-
240
  
As in this study, clinical and hospital pharmacists have a crucial role in surveillance, 
management and interventions to improve patient care. Their contribution has been 
imperative for hospitals to convey prescribing education, reduce length of stay and 
economic saving. 
148, 241-248
 
The results of this study provided evidence that this investment was likely to result in 
net savings by the end of the 3-year period.  The intervention team urged other UK 
hospitals to consider collection and analysis of these data.  The data were available; 
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assurances could be given that the techniques required were not difficult and the 
methods could be shared with others.  
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CHAPTER FOUR: EUROPEAN SURVEILLANCE OF 
ANTIBIOTIC CONSUMPTION (ESAC) PROJECT 
4.1 Introduction 
In this chapter an overview of three phases of the ESAC project phases are provided: 
firstly, ESAC-1 for which the need for the ESAC-2 HC project was identified; secondly 
ESAC-2‘s aims, objectives and structure; and thirdly, the impact of ESAC-2 HC on 
establishing ESAC-3 HC. 
The Hospital Care (HC) subproject of ESAC-2 consisted of three components namely 
longitudinal analysis of hospital antibacterial use, a point prevalence survey of 
antibacterials, and hospital characteristics.  All three components are foundations for 
chapters 5, 7 and 8 of this thesis.  Chapter 6 of this thesis is an additional survey in 
continuation of longitudinal survey of total antibacterial use.  
Within ESAC-2 HC, I contributed to leading the project by writing the project protocol, 
recruiting hospitals and designing project components, in addition to undertaking data 
collection, processing and statistical analysis and project management and monitoring 
the scientific side of the project presented in this thesis. 
4.2 ESAC-1 Project  
Following the Copenhagen Recommendations
44
 and acting on the Council of the 
European Union Recommendations of 15 November 2001 on the Prudent Use of 
Antimicrobial Agents in Human Medicine,
99
 the ESAC project (European Surveillance 
of Antibiotic Consumption) was officially launched during the European Conference on 
Antibiotic Use in Europe organised on behalf of the Belgian EU Presidency in Brussels 
from 15-17 November 2001. The long-term objective was to promote ―Good Antibiotic 
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Practice‖ and to contribute to a reduction of antimicrobial resistance in Europe. ESAC 
was led by Professor Herman Goossens at the University of Antwerp in Belgium. 
A pilot project was established from 2001 to 2003 (referred to as ESAC-1) which was 
funded by the European Commission (Directorate-General SANCO – Health 
Monitoring Program).  The goals of ESAC-1 was to document variations in antibiotic 
consumption and translate them into quality indicators for Public Health monitoring 
over time and place in order to target interventions and to assess the effectiveness of 
prevention programmes.  During ESAC-1 actions were taken to harmonise the 
registration of antibiotic consumption in all EU Member States, in countries signatory to 
the European Economic Area as well as the applicant countries of Central and Eastern 
Europe. The ESAC-1 project aimed to develop a data collection system allowing 
production of comprehensive national data on the volume of antibiotic consumption, in 
ambulatory and in hospital care.  Standardised national data were assembled in a 
European database for regional comparison of antibiotic use. 
249
 
Databases, which were available in certain countries using different systems for drug 
classification and for measurement of antimicrobial consumption, were further 
developed in a standardised, uniform and meaningful manner.  Data collection was 
aggregated to the level of the active substance (not at brand level), using the taxonomy 
of the Anatomical Therapeutic Chemical (ATC) classification system, as recommended 
by the World Health Organisation (WHO). Consumption was expressed in defined daily 
doses (DDD).  
Within the project the implementation of a standardised system for the exchange of 
antimicrobial consumption data between countries was necessary. Therefore a ―network 
of networks‖ was created between the different Member States of the European 
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Community, countries signatories to the Agreement on the European Economic Area 
and associated countries of Central and Eastern Europe in order to facilitate 
communication and collaboration.  This network approach allowed future 
communication and collaboration between all countries and could be broadened if other 
health related topics are found to be suitable for analysis in the same cross-nations 
way.
249
 
ESAC had connections to other relevant networks like the European Antimicrobial 
Resistance Surveillance System (EARSS). It had further created national networks, 
compiled registers of available antibiotics, developed health indicators of antibiotic use 
with validation via linkages to resistance patterns in EARSS, detected seasonal and 
regional variations in consumption, consolidated the collection of antibiotic 
consumption, disseminated the knowledge in this field through a website and trained 
public health workers in differing European countries on standardised procedures. 
250
 
Within ESAC-1, the data on antibiotic use in European hospitals were from a selection 
of countries.
251
 This was the first study at European level, but the hospital data in 
ESAC-1 had important limitations.  Firstly, the estimation of national aggregates of 
hospital drug consumption should have been more critically evaluated. Some countries 
derive a reliable estimate for national hospital exposure to antibiotics from wholesalers‘ 
data; others from detailed consumption registration in all hospitals. In other countries, 
national consumption data are derived from a sample of hospitals, expressed in DDD 
per 100 bed days. Secondly, there is the problem of the denominator in expressing 
hospital consumption. In this cross-national comparison, ESAC were forced to express 
the aggregated national antibiotic consumption data as a function of the population of 
the country (DDD/1000 inhabitants per day) and not as a function of the number of bed 
days in the country (DDD/100 bed days), as recommended by the WHO and as had 
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been done in previous published analyses of hospital drug consumption. The healthcare 
data collection systems in Europe are not able to provide trustworthy, timely and 
comparable national data on the number of hospital bed days for all European countries. 
For those countries the source of available data differed in being either wholesale data 
or data provided by health care systems. Additionally, because the most recommended 
clinical activity denominator data, bed-days, were not available, the data were presented 
as DDD/inhabitants for hospital antibiotic use.
251, 252
  
4.3 ESAC-2 project 
In 2004 the European Commission Directorate-General SANCO – Health Monitoring 
Program (DG SANCO) supported a second phase of the ESAC project to run till 2007.  
The aim of the ESAC-2 project was to deepen the knowledge of antibiotic consumption 
in four specific areas: ambulatory care, hospital care, nursing homes and socioeconomic 
determinants of use.  
The main objectives of ESAC-2 were: 
To consolidate the continuous collection of comprehensive antibiotic consumption data 
in all European countries, for ambulatory care and hospitals, 
- To disseminate its knowledge in the field of antibiotic consumption by the 
development of an interactive ESAC website, 
- To develop health indicators of antibiotic use based on consumption data, to 
validate these indicators and to use a set of core indicators to give feedback on 
antibiotic consumption in the participating countries, 
- To extend knowledge of antibiotic consumption, collecting additional data on a 
pilot basis, 
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- For ambulatory care, to link data on antibiotic use to patients‘ sex and age, 
prescriber and indication, 
- For nursing homes, to collect data for individual nursing homes and to assess the 
assignment of these data to either ambulatory care data or hospital care data, 
- For hospital care, to collect data for individual hospitals to link antibiotic use 
data to the hospitals‘ characteristics; 
- Additionally to perform a pharmacoeconomic evaluation, including an 
assessment of determinants of use and regional variation. 253, 254 
4.3.1 ESAC-2 Hospital Care (HC) Subproject 
The ESAC-2 Hospital Care (HC) subproject focused on consistent data collection from 
individual hospitals in order to develop a standard method that could be rolled out to 
other hospitals in the participating countries.  The study aimed to explore:  
– Trends in hospital antibiotic use over the study period; 
– Effect of using different denominators (bed days or admissions) on 
longitudinal analysis of hospital antibiotic use; 
– Relationship between the DDD calculated from total antibiotic use and the 
actual daily doses prescribed in each hospital. 
The project had two principal components. First a Longitudinal Study (LS) with 
monthly data over a 6 year period and second a web based Point Prevalence Survey 
(PPS) using the Swedish PPS web-based tool the STRAMA (Swedish Strategic 
Programme for Rational Use of Antimicrobial Agents and Surveillance of Resistance).  
Another component, Hospital Characteristics was added later to explore the differences 
in hospitals and how they can affect different aspects of antibacterial treatment.  The 
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preliminary target for the project was to recruit up to 15 hospitals so that the project 
could focus on ensuring that this was the first international project where data would be 
validated, processed and analysed, in order to provide a quality foundation for the 
future.  However, 22 hospitals were eventually recruited, including one each in: Austria, 
Belgium, Croatia, Czech, Republic, Denmark, Estonia, Finland, France, Greece,  Latvia, 
Lithuania, Malta, Netherlands, Norway, Poland, Slovenia, Sweden, Turkey and the four 
countries of the UK (England, Northern Ireland, Scotland and Wales). Clinical and 
hospital pharmacists were the leading clinical group in delivering the project (12 out of 
22  or 55% hospitals).   
Participation of the hospitals in project components was:  
- PPS and LS & Questionnaire: 14 hospitals;  
- PPS and LS: 2 hospitals; 
- PPS and one year (2005) longitudinal data and Questionnaire: 2 hospitals;  
- LS and Questionnaire: 2 hospitals; and 
- PPS and Questionnaire: 2 hospitals. 
For data privacy, each of the hospitals was assigned a number which is coherent in all 
the study components and publications and in this thesis.  The original project protocol, 
written by me supported by feedback form the core group, is provided in Appendix A.4. 
Any updates and changes to the original protocol are described in the methods section 
in each of the ESAC related chapters.  Findings from the ESAC-2 HC have been 
presented world-wide by me and the management team of the project either in 
international conferences or in formal ESAC meetings and other project related 
meetings.  
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4.4 ESAC-3 Project 
In June 2007 the ESAC proposal for phase 3 was successfully accepted by the European 
Centre for Disease Prevention and Control (ECDC) for 2007-2010.  ESAC-3 
maintained a continuous, comprehensive and comparable (using ATC/DDD 
classification) database on antimicrobial consumption for all Member States, candidate 
countries and EFTA- EEA countries, ensuring high standards of data collection, 
collation and validation (using national registers) in a timely fashion. The project was 
designed to improve and expand the scope of the database developed in the ESAC 
project on consumption data on antiviral, antimycotic and anti-TB drugs in consultation 
with the ECDC.  
The scope of ESAC-3 HC subproject was in-depth hospital care data collection. The 
objectives were to: 
– Adjust ESAC-2 PPS for routine use; 
– Organise a European-wide point-prevalence survey; 
– Cluster the hospital antimicrobial consumption in an LS study according to the 
characteristics of the institutions and to the regional neighbourhood based on the 
method that was used in ESAC-2;  
– Develop quality indicators of antimicrobial consumption in the hospital care sector. 
 
For ESAC-3 HC, Professor Peter Davey was the ESAC Advisory Board and UK 
Network Leader and Dr Faranak Ansari was the ESAC Management Team member and 
leader of the HC subproject and Hospital Clinical Scientist until September 2008.
255-257
  
During this time, I wrote, set up and designed the project protocol in five components: 
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web-based PPS, LS, in depth analysis of ESAC-2, LS of antimicrobial use and 
resistance (EARSS data), hospital characteristics for more than 50 hospitals in 32 EU 
countries.  I described the project components in ESAC-3 training workshops.  I 
contributed to hospital recruitment across the Europe through ESAC-2 network and 
ESAC national representatives for additional countries.  I assisted to hospital ground 
questions during the first PPS of the ESAC-3.  
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CHAPTER FIVE:  ESAC LONGITUDINAL SURVEY 1:  
ANALYSIS OF TOTAL ANTIBIOTIC USE IN HOSPITALS 
FROM 18 EUROPEAN COUNTRIES  
5.1 Background:  The dilemma of the use of numerators and 
denominators in longitudinal surveys 
Within the ESAC I project it was recognised that there is currently no unified hospital 
information on antibiotic use across the European countries.
251, 252
  The explanations 
include lack of standardised methods for producing valid data either for hospital 
antibiotic use or for denominator data related to clinical activity
251, 252
, such as occupied 
bed days or admissions.  This chapter describes the work carried out by me.  In my role 
as the co-lead for the ESAC-2 Hospital Care Project, I designed the study, recruited the 
hospitals and contributed to training workshops for participants.  In my role as the 
researcher, I collected , processed the data and performed the statistical analysis. A 
study from the Netherlands suggested that an apparent increase in total antibiotic use 
from 1997 to 2001 was eliminated when the denominator was admissions rather than 
bed days. 
189
  The explanation was that there had been an increasing number of 
admissions over the period with decreasing mean length of stay. 
5.2 Introduction 
ESAC (European Surveillance of Antimicrobial Consumption) was established in 2000. 
In the first phase of the ESAC project data collection was limited to national sources of 
information about antibacterial use. Data about antibacterial use in ambulatory care 
were available from 26 countries
258
 whereas only 15 countries could provide data about 
hospital antibacterial use.
259
 Moreover the data did not include reliable information 
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about the number of occupied bed days (OBD) or admissions for the hospitals so the 
results were expressed as Defined Daily Doses (DDD) per 1,000 inhabitants. This is a 
reasonable measure of antibacterial use at the regional level but does not provide useful 
information for comparison of hospitals 
259
. In the second phase of the ESAC project 
from 2004 to 2007 a hospital subproject was established to collect more detailed 
information from individual hospitals through longitudinal analysis of antibacterial 
consumption and point prevalence survey. The results of the first European point 
prevalence survey have been published.
260
 
Reports on hospital antibiotic use have lacked detail about definitions of the units of 
measurement, which makes it difficult to compare results between hospitals or 
countries.
261
 Longitudinal studies with well defined units of measurement have been 
published from multiple hospitals within the Netherlands
262
 and Germany.
191
  Both of 
these studies compared adjustment of antibiotic use for clinical activity with admissions 
versus occupied bed days and reported that total systemic antibacterial use increased 
when measured as DDD per 100 patient days, whereas it remained constant when 
expressed in DDD per 100 admissions. A possible explanation is that these hospitals 
had increasing numbers of admissions with shorter length of stay (LOS) over time.
191, 
261, 262
 However, it is not clear whether these results can be generalised to other 
countries. The aim of the ESAC longitudinal survey was to develop and test 
standardised methods for collection and statistical analysis of longitudinal data about 
hospital antibacterial use from different countries. 
5.3 Aims 
 What is the change in hospital antibiotic use over the study period?  
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 What effect do different denominators (bed days or admissions) have on 
longitudinal analysis of hospital antibiotic use? 
5.4 Methods 
ESAC national representatives were invited to participate in the study and recruit one 
hospital for the longitudinal survey.  One hospital was selected from each of the 
following 18 countries: Austria, Belgium, Croatia, Czech Republic, Denmark, England, 
Estonia, Finland, France, Greece, Latvia, Netherlands, Norway, Scotland, Slovenia, 
Sweden, Turkey and Wales.  With the exception of Turkey and Wales, the same 
hospitals also participated in the ESAC point prevalence study in June 2006.
260
 
Participants were asked to send data samples and to attend a workshop for discussion of 
the pilot data samples and for agreement on uniform databases was organised in January 
2006. Data were submitted during February to June 2006.  Hospitals were asked to 
provide monthly data for 6 years starting from January 2000 until December 2005: 15 
hospitals provided six years data; one hospital provided five years data and two 
hospitals provided four years data.  According to the project protocol total antibacterial 
dispensed were collected only to inpatient destinations, and clinical activity (occupied-
bed-days or patient- day, and admissions) data for all inpatient destinations.  Hospitals 
were not requested to separate their data by clinical groups and specialties because it 
was not possible for many participants and these data were not required to answer the 
study question.  
The study only used aggregated data about consumption of antibiotics from hospital 
pharmacies and did not require approval from a Research Ethics Committee.  
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5.4.1 Measurement of drug use  
The study focused on systemic antibacterials in the J01 sub-class according to ATC 
classification by the WHO Collaborating Centre for Drug Statistics plus, oral 
Metronidazole, Rifampicin, oral Vancomycin and Colistin 
263, 264
  Before submission of 
the main data, hospitals were asked to send a sample of their pharmacy stock data.  
Based on the samples, a simple Excel work sheet was proposed to the Study Group and 
discussed and agreed during the Prague workshop in January 2006.  Minimum database 
requirements were:  
- English drug names 
- With their own ATC/DDD assignments 
- Internal codes as an identifier for each product 
- Strength, dosage form, and package content for each product in grams or 
international units 
- Dispensing data for each antibacterial at product (code) level and on a monthly 
basis. 
5.4.2 Clinical Activity Data 
Participants also sent their monthly data on bed-days or patient-days and admissions 
together with the local definitions and methods of counting for each of these clinical 
activity variables.  The criteria for clinical activity data, as well as pharmacy stock data, 
were the exclusion of outpatient clinics, day cases - both in bed-days and admission data 
- and transfers between wards and clinical groups from admissions.   Since, in some 
countries, the administrative data on admission is, in fact, the sum of admissions to 
clinical groups and not to the hospital as one unit and, therefore, this could cause over 
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estimation of admissions to the hospital as a whole and under estimation of use if 
presented in DDD/admissions.  
Confidentiality in data was essential for some hospitals and so, additionally, the project 
aim was to present the results in a blinded form without trying to compare hospitals by 
name or country.  A number was assigned to each hospital which was coherent with the 
other components of ESAC-2 Hospital Care Project presented in chapter 6, 7 and 8 of 
this thesis, and in the reports, presentations and publications form ESAC-2 project.   
5.4.3 Data validation and analysis  
The total content per grams or unit of measurement was calculated for each product in 
all pharmacy stock databases.  They were also assigned ATC codes and DDD content 
and when necessary corrections were made.  The latest version of the ATC/DDD 
265, 266
 
was used.    Data processing was then applied to all 6-year data and were then put in a 
similar format to be analysed using Microsoft Access.  An Access tool was designed to 
be used for analysing all databases.  The following information was calculated 
automatically by the Access tool:  
-   Total use of antibacterials on a monthly, quarterly, and yearly basis given in 
DDDs, DDD/ 100 bed-days and in DDD/100 admissions. 
-   The same information for antibacterials included in the study subgroups at ATC 
level 4, and at substance level or ATC level 5. 
-  Similar information based on route of administration. 
-   Proportion of use for each substance according to route of administration. 
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For all variables from each hospital analysed, data were examined for homogeneity 
within time by examining the graphs and corresponding data. 
Clinical activity data could not be validated.  Team members obtained these data from a 
hospital‘s administration files and it would be time consuming and sometimes 
impossible for them to ask very detailed questions about the databases.  Therefore, these 
data were provided by hospital administration files against a backdrop of different 
policies and different definitions in different hospitals within one country or countries.  
5.4.4 Estimation of other clinical activity variables 
A stock adjustment process used to estimate two additional clinical activity variables: 
number of discharges and length of hospital stay (LOS) from the data about admissions 
and OBD. A stock adjustment process is an accounting mechanism which shows how a 
certain stock accumulates over time given its net flow over time.  In formula for the 
estimation of other clinical activity variables occupied bed-days denoted by B and 
number of in-patients admitted denoted by A, other clinical activity variables were 
obtained such as:  
- Number of in-patients discharged, denoted by R, using the stock adjustment 
equation below where DPM is the number of days per month,  
   1
1
t t
t t
t t
B B
A R
DPM DPM


   ;  (5.1) 
-  Length of stay by an average in-patient, denoted by L, using the approximation  
 
2
t
t
t t
B
L
A R


 (5.2) 
Professor Hassan Molana form Department of Economic Studies at the University of 
Dundee advised on the method for estimating other clinical activity variables.  
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For two hospitals the actual LOS for the study period were obtained to compare each of 
two datasets with estimated values. There was no statistically significant difference 
between actual and estimated values.   
5.4.5 Statistical Analysis 
Trends of use and clinical activity  
In nearly all of the published studies, the only statistical analysis method that has been 
used is simple regression and this mainly on yearly data.  Therefore, to acheive a better 
understanding of clinical and non-clinical users of the project with regard to the main 
research question, a simple regression analysis was first applied to all data including: 
DDD (defined daily dose), OBD (occupied bed-days or patient days), AD (admissions), 
LOS (length of hospital stay), DBD (DDD per bed-days or patient-days) and DAD 
(DDD per admissions).  The level of antibacterial use and clinical activity variables 
differed widely across the hospitals.  A method was needed to compare the change over 
time between similar variables and between different variables for each of the hospitals.  
Simple comparison of the slopes of regression lines was misleading. For example, a 
slope of 0.5 DBD/month (DBD is DDD/occupied bed-days) for a hospital with average 
or baseline use of 200 DBD is a change of 0.25% per month. In contrast,the same slope 
for a hospital with 50 DBD is a 1% change. Consequently, the slope of the regression 
line did not distinguish between a hospital with a higher level of baseline use but 
shallower slope versus a hospital with lower use but steeper slope.  Therefore the result 
was the product of the intercept (baseline) values and the gradient of the slope (trend). 
In order to compare change in each variable over time, the slopes were scaled with their 
intercepts to produce the mean annual change using the following formula:  
% Δ Variable = [(Slope * 12)/ Intercept] * 100       (5.3) 
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For each hospital mean annual change was calculated with   95% Confidence Intervals 
(CI). Changes were considered significant if the 95% CI for the % difference did not 
cross zero.  
Dynamic regression of time series 
A better understanding of what determines the pattern of usage of antibiotics in 
hospitals is essential for a more effective monitoring of their impact, development of 
resistance, etc.  To this end, DDD per bed-days or patient days or YPB (Y use in DDD/ 
Bed-days) constitutes the most commonly used measure analysed on the grounds that it 
represents the amount of antibiotic usage adjusted for ‗clinical activity‘.  This is because 
YPB is believed to discount trends and/or fluctuations in the level of clinical activity and 
also to provide a comparable measure across hospitals.  In fact a regression analysis can 
provide a more effective way of assessing whether such a scaling does take account of 
the level of clinical activity as well as allowing examination of the influence of other 
clinical activity indicators such as in-patient admissions, discharges and length of stay 
and the existence of exogenous trend and seasonality not captured by the latter 
explanatory variables. This involves estimating some version of the following general 
dynamic regression equation for each hospital:  
 
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           
 (5.4) 
where Y, A, B, R and L are the variables explained above; , , ,  and s s s s s      are the 
coefficients which capture the impact of these variables with s lags (assuming a finite 
lag order of S0); t refers to time associated with the observation date; the j  
coefficients capture the intercept and trend (assuming some finite polynomial in time of 
degree J0); iDM s are seasonal dummies which assumes 1 for month i and 0 otherwise 
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and whose coefficients, 
i s, capture the shift in month with i relative to the first month 
(January is set as the bench month and dummies are used for February to December  
i=2,...,12); 
kDI s are dummies which capture irregularities such as sudden shifts in the 
series or outlier observations and assumes 1 for the relevant dates and 0 otherwise, 
hence the 
k  coefficients capture the corresponding shifts thus dampening their impact; 
and  is a random disturbance term which, in general, can be allowed to follow an 
ARMA process.  It is worth noting that a time series model of type  
12
, ,
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   
        , (5.5) 
where 1t t tY Y Y     is simply a special case of the regression equation in (5.4), Y is 
total use in DDD, A is admissions, B is bed-days or patient-days, R is discharge, and L is 
length of stay.   
Y, A, B, R and L Statistical analysis was performed using EViews version 6 (QMS, 
Irvine, CA, USA).  Professor Hassan Molana advised on regression modelling of time 
series and supervised using the EViews for the first analysis.  However, due to changes 
in databases for a number of hospitals during re-validation of data and possible 
corrections for outliers the analysis had to be re-run and updated several times.  The 
regression model, statistical analysis process and its techniques, relevant tests for 
selection of the best fitted model for each of the hospitals were performed as described 
in the Chapter 2 on times series and interrupted time series analysis.  
5.4.6 Interpretation of Results 
From a public health perspective the key question is ―Is there evidence that the exposure 
of patients to antibiotics in this hospital may have increased or decreased over time?‖ 
The term ―exposure of patients to antibiotics‖ encompasses any or all of these factors: 
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number of patients treated, unit doses administered or duration of treatment because 
they could all influence the measure of antibiotic use (DDD).  The hospitals were 
separated into five groups based on the likelihood that change in exposure of patients to 
antibiotics had occurred: 
Very likely: statistically significant changes in DDD that were not explained by changes 
in clinical activity.  
Likely: statistically significant changes in DDD that were related to changes in clinical 
activity 
Possible: no significant change in DDD but significant change in the same direction for 
DAD (DDD per 100/ Admissions) or DBD (DDD per 100 OBD) 
Unlikely: change in the opposite direction for DDD and either DAD or DBD 
Very unlikely: no significant change in DDD, DBD or DAD 
5.5 Results 
Eighteen hospitals participated in the longitudinal survey.  Fifteen hospitals provided 
six years of data, one hospital provided five years of data and two hospitals provided 
four years of data.  Two hospitals provided data for the year 2005 only and were 
therefore excluded from the longitudinal survey. All drug databases were built from 
pharmacy dispensing data.   
Only a few hospital databases were patient-day in format with the definition of patient-
day being:  ―duration of stay minus one day to count day of admissions and discharge as 
one day‖.  In hospitals with bed-days data, the unit of measurement implied the number 
of occupied beds at a specific time, for example, at midnight 12:00 or at 8:00 in the 
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morning.  One hospital, number 9, provided discharge data instead of admissions data. 
Participating hospitals confirmed that their data excluded transfers within the hospitals.   
5.5.1 Hospital Characteristics 
The 18 participating hospitals had a total of 13,664 beds (mean 759, range 242 to 
2,459).  Detailed information about case mix was returned from 16 hospitals with 
12,411 beds, of which 12 were teaching hospitals with 11,164 beds (82% of the total) 
and seven were tertiary care hospitals with 7,572  beds (55% of the total).  At least one 
Intensive Care Unit was present in each hospital; 12 had paediatric units and seven 
hospitals had a pediatrics ICU; 13 hospitals had haematology units, 11 had renal 
dialysis units and 10 had Infectious Diseases departments.  Hospitals number 5 and 17 
were infectious diseases hospitals. Sixteen hospitals also participated in the ESAC point 
prevalence survey
260
 and were identified by the same numbers in both surveys. 
5.5.2 Data Validity 
During data validation and analysis the following problems captured in the databases:  
 Extracting and sending data directly from pharmacy stock without a control 
or testing the validity of them, 
 Product names, drug content and strength given in non English language, 
 Databases with trade names only, 
 Variations in the definition and understanding of the term ― generic name‖ 
across the countries, 
 Different database structures within the 6 year period from one hospital, 
 Errors in ATC codes and DDDs, 
 Mistakes by data providers in translating the trade name into a generic name 
- for a few products the real drug name could not be found in drug 
ESAC Longitudinal Survey 1 100 
 
dictionaries.  The name found in Google just had to be trusted and used and 
was passed to hospital colleagues. 
 More problematic trade names when the product was produced for use 
outside Europe and internet resources were difficult to find to search for the 
real drug name, 
 Similar internal codes for different products or for products with different 
strengths, 
 Different coding system across the whole 6-year period without rectifying or 
notifying this problem to the data analyst.  
 
Pharmacy stock data validation became the most time consuming phase of the project. 
Around 3,800 products were checked one by one and ATC/DDD assigned to each 
product before data analysis.  More discrepancies were found during and after data 
analysis.  Active communication with data providers could resolve some of the 
inconsistencies in databases.  Corrected parent product lists were sent back to hospitals.  
5.5.3 Preliminary analysis 
A preliminary time series showed two problems: first, one or more structural breaks and 
second, extreme outliers.  Discrepancies were discussed with data providers.  The data 
were cleaned to eliminate contamination or errors in data entry as much as possible.  
Nonetheless, some outliers and structural breaks could not be resolved. 
To enable a better understanding, time plots for all data are provided in Tables A.5.1.1 
to 7 in Appendix A.5.1.  Tables A.5.1.8-10 in Appendix A.5.1 represent the plots of 
unadjusted use versus bed-days, admissions and length of stay. 
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It is useful to look at pattern followed by the variables Y (use), B (bed-days) and A 
(admissions), L (length of hospital stay), and R(discharge) for which data were provided 
by the hospitals in Tables A.5.1.1-5 (Appendix A.5.1).  First, it is clear that there are 
great variations between the hospitals in either data or corresponding graphs.  However, 
some hospitals have more similar time series.  Disregarding the outliers, it is clear that 
in general these series contain a predictable component, and that the pattern followed 
for each variable varies across hospitals.  For example, looking at plots of Y, we see that 
(i) in some hospitals fluctuates around a positive or negative trend while in others it 
simply changes around a constant mean and (ii) the extent of unpredictability of these 
fluctuations vary across hospitals.  In addition to Y, B and A, it was observed that R and 
L (which were estimated) behave similarly with close values for most of the hospitals.  
As can be seen by comparing Tables A.5.1.3 and 5 (Appendix A.5.1), admissions and 
discharges follow a close pattern in all hospitals. Thus the difference between 
admissions and discharges seems to be a stationary mean zero random variable with a 
strong seasonal and autoregressive pattern.  Table A.5.1.4 (Appendix A.5.1) illustrates 
how hospitals also exhibit differences with respect to the length of time they keep an 
average in-patient since L shows fluctuations around a negative trend in some of the 
hospitals whilst in others it oscillates around a constant mean.   
5.5.4 Mean yearly change in antibacterial use 
Mean monthly total use was 14,190 DDD and ranged from 2,791 DDD in hospital 12 to 
53,195 DDD in hospital 17.  Total antibacterial use measured in DDD increased in 14 of 
the 18 hospitals and decreased in four (Figure5.1, Table 5.1). The changes were 
statistically significant for eight hospitals with increasing use (hospitals 2, 6, 7, 11, 12, 
14, 15 and 18) and for three hospitals with decreasing use (hospitals 1, 8 and 9, (Figure 
5.1, Table 5.1)  
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5.5.5 Adjustment for clinical activity 
Changes in clinical activity 
The mean number of admissions was 2,928, range from 659 to 7,269 per month.  
Admissions increased in 10 hospitals and decreased in 8 hospitals. Changes were 
significant in 5 hospitals (Figure 5.2, Table5.2). Mean monthly OBD was 18,222, range 
from 6,435 to 49,567. OBD increased in 5 hospitals and decreased in 13 hospitals 
(Figure 5.2, Table5.2).   
Comparing changes in admissions with OBD, only hospital 12 had a statistically 
significant increase in admissions and OBD. Of the remaining 9 hospitals with 
significant increases in admissions, five had no significant change in OBD (hospitals 2, 
6, 8, 16, 18) and three had significant decreases in OBD (hospitals 4, 9, 11). 
Mean LOS was 6.65 days, range from 3.0 days to 10.8 days. LOS decreased in 15 
hospitals and the change was significant in 13 hospitals (Figure 5.2, Table5.2). 
Hospitals 3, 12 and 13 had small increases in length of stay that were not statistically 
significant (Figure 5.2, Table5.2).  These changes in LOS probably explain most of the 
discrepancies between changes in admissions and OBD. The hospital with significant 
increase in both admissions and OBD (hospital 12) had a small, non significant increase 
in LOS (Figure 5.2, Table5.2).  In contrast, LOS decreased in all of the 8 hospitals with 
increase in admissions but either no change or decrease in OBD.   
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Table 5.1: Mean annual percentage of change in DDD, DDD per bed-days (BD), 
DDD per admissions (DAD) for each hospital given with confidence intervals (CI) 
and P values.  
Hospital 
Number 
DDD, CI and P value DBD, CI and P value DAD, CI and P value 
1 -2.95 (-4.66 , -1.41) >0.01 0.20 (-1.33 , 1.59) 0.8 -2.68 (-4.20 , -1.30) >0.01 
2 9.87 (8.79 , 10.84) >0.01 9.84 (9.02 , 10.60) >0.01 8.62 (7.52 , 9.61) >0.01 
3 2.02 (-0.31 , 4.00) 0.09 0.96 (-3.51 , 4.34) 0.6 0.87 (-2.89 , 3.82) 0.6 
4 1.10 (-0.17 , 2.26) 0.09 2.69 (1.37 , 3.89)  >0.01 -1.71 (-3.50 , -0.10)  0.04 
5 3.86 (-11.09 , 10.62) 0.5 15.86 (6.33 , 19.67) 0.01 9.98 (-2.95 , 15.39) 0.09 
6 6.17 (3.77 , 8.06) >0.01 5.31 (2.66 , 7.38) >0.01 3.64 (0.49, 6.03) 0.03 
7 6.68 (4.78 , 8.30) >0.01 13.15 (11.57 , 14.47) >0.01 8.94 (7.05 , 10.52) >0.01 
8 -3.44 (-6.41 , -0.93) >0.01 -3.46 (-6.62 , -0.83) >0.01 -4.59 (-7.65 , -2.01) >0.01 
9 -4.96 (-7.16 , -3.03) >0.01 -3.16 (-5.14 , -1.41)  >0.01 -6.58 (-8.91 , -4.55) >0.01 
10 0.56 (-0.70 , 1.71) 0.4 1.62 (0.47 , 2.69) 0.007 1.20 (-0.11 , 2.39) 0.07 
11 1.82 (0.62 , 2.92) >0.01 2.93 (1.83 , 3.95) >0.01 0.18 (-1.19 , 1.43) 0.8 
12 3.58 (-0.09 , 6.42) 0.06 -10.57 (-16.26 , -6.16) 
>0.01 
-10.26 (-15.73 , -5.60) >0.01 
13 0.10 (-1.76 , 1.74) 0.9 0.55 (-1.256 , 2.15) 0.5 0.86 (-1.08 , 2.56) 0.4 
14 4.21 (2.03 , 6.05) >0.01 4.91 (2.99 , 6.56) >0.01 2.40 (0.1, 4.35) 0.04 
15 2.57 (0.82 , 4.12) 0.01 8.42 (6.70 , 9.88) >0.01 5.05 (3.08 , 6.73) >0.01 
16 2.67 (-0.48 , 5.09) 0.1 3.87 (0.767 , 6.23) 0.02 -6.14 (-10.14, -2.99) >0.01 
17 -1.80 (-5.77 , 1.35)  0.3 0.64 (-3.11 , 3.59) 0.7 -0.25 (-3.99 , 2.72)  0.9 
18 1.26 (0.08 , 2.25) 0.04 0.38 (-0.90, 1.54) 0.5 -0.46 (-2.34, 1.21) 0.6 
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Table 5.2: Changes in clinical activity- Mean annual percentage of change in 
Bed-days (BD), and Admissions (AD), and Length of stay (LOS) for each hospital 
given with confidence intervals (CI) and P values.  
Hospital 
Number 
BD, CI and P-Value AD, CI and P value LOS, CI and P value 
 1 -3.08 (-4.25, -1.99) >0.01 -0.25 (-1.02 , 0.49) 0.5 -2.85 (-3.59 , -2.13) >0.01 
 2 0.13 (-0.66 , 0.89)  0.7 0.79 (-0.07 , 1.60) 0.07 -0.72 (-1.34 , -0.13) 0.01 
 3 0.64 (-2.45 , 3.17) 0.7 0.57 (-0.88 , 1.88)  0.4 0.39 (-2.96 , 3.09) 0.8 
 
4 -1.43 (-2.20 , -0.71)  
>0.01 
3.19 (2.14 , 4.15)  >0.01 -3.88 (-4.45 , -3.32) >0.01 
 5 -6.11 (-7.10 , -5.17) >0.01 -3.92 (-4.96 , -2.94) >0.01 -2.81 (-3.49 , -2.15) >0.01 
 6 0.65 (-1.00 , 2.11) 0.4 1.99 (-0.13 , 3.77)  0.06 -1.36 (-2.43 , -0.38) >0.01 
 7 -3.31 (-4.30 , -2.38) >0.01 -1.28 (-2.23 , -0.39) >0.01 -2.10 (-2.67 , -1.56) >0.01 
 8 -0.06 (-0.67 , 0.52) 0.8 1.45 (0.69 , 2.17) >0.01 -1.47 (-2.22 , -0.75) >0.01 
 9 -2.36 (-4.67 , -0.38) 0.02 2.87 (-0.05 , 4.66) 0.05 -4.10 (-5.17 , -3.10) >0.01 
 10 -1.02 (-1.80 , -0.28) >0.01 -0.64 (-1.48 , 0.16)  0.1 -0.41 (-0.86 , 0.02) 0.06 
 11 -1.01(-1.58 , -0.45) >0.01 1.61(0.73 , 2.43) >0.01 -2.43 (-2.98 , -1.89) >0.01 
 
12 26.28 (25.59 , 26.71) 
>0.01 
24.67 (23.80 , 25.27) 
>0.01 
1.43 (-3.37 , 4.97) 0.5 
 13 -0.38 (-0.91 , 0.13) 0.1 -0.61 (-1.43 , 0.17) 0.12 0.40 (-0.23 , 0.99) 0.2 
 
14 -0.44 (-1.06 , 0.15) 0.1 -0.16 (0.83, 2.31) 
>0.01 
-1.68 (-2.39, -1.01) >0.01 
 15 -4.30 (-6.11, -2.67) >0.01 -2.10 (-3.83 , -0.54) >0.01 -2.50 (-3.46 , -1.59)  >0.01 
 
16 -1.16 (-3.91 , 1.09)  0.3 19.35 (18.17 , 20.12)  
>0.01 
-8.09 (-10.61 , -5.92) >0.01 
 17 -2.31 (-2.64 , -1.99) >0.01 -1.48 (-1.99 , -0.98) >0.01 -0.93 (-1.22 , -0.64) >0.01 
 18 0.92 (-0.46 , 2.17) 0.2 1.93 (0.28 , 3.40) 0.02 -0.96 (-2.41 , 0.36) 0.2 
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Figure 5.1:  Hospitals ranked by mean percentage of change in total use, DDD 
 
 
Figure 5.2: Mean annual percentage of change for Clinical activity variables 
ranked by changes in OBD (occupied bed-days), AD (admissions), LOS (length of 
stay) 
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Total antibacterial use adjusted for admissions and occupied bed days 
There was considerable variation between hospitals in both measures of adjusted 
antibiotic use. Mean monthly use in DBD was 83.7, range 16.5 to 351, the ratio between 
highest and lowest hospital was 21.3. Mean monthly use in DAD was 505, range 171 to 
1,499, the  ratio between highest and lowest hospital was 8.8. With only two exceptions 
(hospitals 12 and 13) adjustment of DDD by OBD resulted in larger changes over time 
than adjustment by admissions (Table 5.1, Figure 5.3).   
For most hospitals adjustment for either bed days or admissions made little difference to 
the scale or statistical significance of changes in DDD (Table 5.1, Figure 5.3). For 
hospitals 5 and 10 the changes were in the same direction with DDD, DBD and DAD 
but only statistically significant for DBD.  However, in three hospitals changes in DDD, 
DBD and DAD were not in the same direction. Hospital 12 had significant change in 
the opposite direction to DDD for both DBD and DAD (Table 5.1, Figure 5.3). This 
hospital had a large (25%) increase in admissions with no significant change in length 
of stay, consequently adjustment of change in DDD for either admissions or OBD gave 
similar results, in this case a reversal of the trend in DDD because of the large increase 
in clinical activity measured with either admissions or OBD. For hospitals 4 and 16 
there was a non-significant increase in DDD with statistically significant increase in 
DBD but statistically significant decrease in DAD (Table 5.1, Figure 5.3). These 
discrepancies probably occurred because both hospitals had statistically significant 
increases in admissions with statistically significant decreases in length of stay.  
For a better understanding of changes in all variables, ranking hospitals by mean change 
in use and clinical activity variables is summarised in Figure 5.4.  
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Figure 5.3:  Mean annual percentage of change for DDD, DBD ( DDD/bed-days) 
and DAD ( DDD/ admissions) ranked by changes in DDD 
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Figure 5.4: Ranking hospitals by mean change in use and clinical activity 
variables. Significant changes are marked with star. Changes with P values 0.06 or 
0.07 are marked with positive.  (DDD defined daily dose, OBD: occupied bed-days, 
LOS length of hospital stay, DBD: DDD/100 bed-days, DAD: DDD per 100 
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5.5.6 Time series analysis 
The results of regression analysis of the time series for individual hospitals are given in 
this section. Complete output of the regression analysis for each hospital is provided in 
Appendix A.5.2. One of the regression models is provided in Figure 5.5 with 
explanation of the results.  Given that one of the aims in doing so is to find the extent to 
which B, A, R and L explain Y, this was done preliminary by checking the plots of Y 
against each of B, A, and L which are given in Tables A.5.1.8 to 10 (Appendix A.5.1).  
Again, disregarding those cases in which the existence of outliers distort the picture 
(mainly hospitals 5, 9, 12, 14, and 17), it is clear that the extent of correlation between 
these variables and Y varies significantly across the hospitals.  For instance, looking at 
Table A.5.1.8 (Appendix A.5.1), which shows plots of Y against B, we see that in 
hospitals 1, 2, 6, 9, 10, 14, 16, 17 and 18 exhibit some positive correlation while there is 
no evidence of any correlation for hospitals 3, 4, 7, 8, 12, and 13.  
The regression analysis is carried out using either the model given in formulas 4 and 5 
or the logarithmic version, to take account of the non-linearity in the underlying series 
as the starting point, and simplifies the estimated relationship to obtain a prudent 
empirical model which is statistically robust.  The results are summarised in Table 3 and 
are provided in detail in Appendix A.5.2 and suggest that, in general, hospitals behave 
differently in their antibiotic usage and, in particular, the clinical activity variables do 
not always play a significant role.  
It is found that in six of the hospitals (numbers 4, 7, 8, 13, 14, and 17) antibiotic use 
seems to behave autonomously, with no impact from the clinical activities being 
present; in hospitals 8 and 17 its behaviour has an autoregressive nature, in 7 and 14 it is 
driven by time trend, and in 4 and 13 the dynamics can be attributed to the disturbances.   
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In three of the hospitals (numbers 11, 16, and 18) the clinical activity variables that 
influence antibiotic usage exclude the most commonly used factor, therefore, B or 
occupied bed-days does not feature directly as a significant explanatory factor.  In 
hospital number 11, length of stay and discharge can explain the total use.  In hospital 
16, admissions is the only direct explanatory factor for total use and in hospital 18, all 
three other clinical activity variables play determining roles on total use.   
In the remaining nine hospitals (numbers: 1, 2, 3, 5, 6, 9, 10, 12, and 15) occupied bed-
days,  admissions, discharges and length of stay feature in one way or another as 
significant explanatory variables.  Only in three hospitals (number 1, 2, and 6) do 
occupied bed-days happen to be the only relevant clinical activity variable.  In hospital 
number 3, length of stay is the only clinical activity variable without direct impact on 
total use.  In hospitals 5 and 15, all clinical activity variables in the model can directly 
determine the total use.  
  
ESAC Longitudinal Survey 1 111 
 
 Table 5.3: Regression analysis of time series for each hospital, summary of the 
best fitted model.  Y: DDD, B: occupied bed-days, A: admissions, L: length of stay, 
R: discharge, AR: autoregressive order, MA: moving average order   
Hospital Regression equation model 
1 Y = 0.45 Bt – 17 
2 Yt = 0.9 Bt  - 0.73t
2 + 5175 
3 Yt = 24800 -  8 Bt  + 8 B t-1  + 242 At  - 245R + [MA(1)=0.34] 
4 ∆Yt = 56- 0.8  ∆Yt-1  - 0.49 ∆Yt-2 
5 
∆ Ln Yt  = 7.7 ∆Ln Bt – 342 ∆Ln At - 369 ∆Ln Rt - 710 ∆Ln Lt - 0.32 LnY t-1 +  
865 Ln Bt- 417 Ln A t-1 - 448 Ln R t-1 - 866 Ln Lt-1 + 6 
6 Yt = 0.43 Bt  + 13 t  – 1868 + [AR(1)= -0.39] 
7 Yt  =  4041 - 14 t + 0.46 t
2   
8 Ln Yt  =  0.002 t  + 9.7 + [AR(1)=0.40] 
9 Yt  = 0.74 B t-1 -2.85 A t-1  + 4354 + [MA(1)= 0.97] + [ AR (1) = - 0.60]  
10 Yt= 0.8 Y t-1 - 4 Bt + 30 At + 17917 Lt  - 123283 + [MA(1)=-0.98] 
11 Ln Yt = 0.98 Ln Rt + 1.17 Ln  Lt  + 0.01 t - 6.7E-05 t
2 - 1.1 
12 Yt = 0.34 Y t-1  -  0.09 Bt + 1.6 At + 169 Lt - 519 - 13 t     
13 ∆Yt = 0.5  - 0.9 ∆Y t-1 + [MA(2)= -0.96] 
14 Ln Yt = 10 + 0.02 t - 0.0002 t
2 
15 
∆Ln Yt =  500 ∆ Ln Bt  - 240 ∆Ln At – 263 ∆Ln Rt – 503 ∆Ln Lt - 0.1 LnY t-1+ 
483 Ln Bt - 1-230 Ln At-1 – 254 Ln R t-1 - 484 Ln L t-1 + 0.01 t + 12.4 
16 Yt  = 0.77 At  + 4131     
17 Yt = 42198 + [AR(1)=0.53]  
18 Yt = 3 At + 1.3 Rt - 3.6 R t-1  + 2296 Lt - 1130 L t-1 + 30t + 12989  
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Figure 5.5:  Interpretation of regression of time series results for one of the 
hospitals 
 
 
 
5.6 Discussion 
This is the first study to use a standardised method to collect data on antibacterial use 
from hospitals in different countries.  Previous studies have focused on individual 
hospitals or on multiple hospitals from single countries. 
191, 262, 267, 268
 Collection of data 
from hospitals in 18 different countries has provided a wide range of antibiotic use and 
of changes in clinical activity over time.  Measurement of drug use in DDD is the 
foundation of the WHO Collaborating Centre for Drug Statistics Methodology. It is 
especially important for international studies when drugs have different trade names and 
strengths in different countries.  In the ESAC HC Subproject ATC/DDD was assigned 
by a central team. This required considerable time and effort because and it was found 
that many hospitals did not assign ATC/DDD correctly.  Furthermore, in some hospitals 
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there were several trade names for one product, including a few that were manufactured 
for use in countries outside Europe.  Further research is required to understand the 
importance of these errors and improve the reliability of alternative methods for data 
collection, such as web based methods for assisting hospitals with ATC classification 
and calculation of defined daily doses. Central processing of data is unlikely to be 
sustainable in all countries. 
Use of antibacterials increased over time in 14 hospitals and decreased in four hospitals. 
The change was statistically significant in 11 hospitals (Figure5.1, Table5.1).  However, 
there were marked changes in clinical activity with decreasing length of stay in 15 
hospitals and increasing admissions in nine hospitals (Figure5.2, Table5.2). Analysis of 
changes in clinical activity is therefore critical for the final interpretation of results.   
5.6.1 Changes in clinical activity 
The WHO recommended method for surveillance of drug use in hospitals is to divide 
DDD by OBD.
269
 However, OBD is itself a complex measure determined by the 
number of admissions, their LOS and the hospital‘s occupancy rate 270 Our results show 
the importance of a clear, stepwise approach to the interpretation of the data. Overall 
our results supported the hypothesis that DBD would show greater annual change than 
DAD due to an underlying reduction in length of stay. However, this trend was not 
universally present. Moreover there were four hospitals with extreme results that clearly 
demonstrated the potential complexity of changes in admissions and LOS that are not 
obvious from measurement of OBD alone (Figure 5.3, Table 5.2), hospitals 4, 9, 12 and 
16). Our results support the recommendations to include both admissions and OBD in 
surveillance of antimicrobials
261
 but it is proposed that interpretation is facilitated by 
calculation of LOS from admissions and OBD (Figure 5.3, Table5.2).  
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5.6.2 Interpretation of results 
In addition to allowing multivariate adjustment for clinical activity the time series 
analysis accounted for outlier, extreme results and for structural breaks (step change) in 
the data.  The combination of analysis of mean annual change with time series analysis 
allowed us to separate the hospitals into five groups based on likelihood of change in 
exposure of patients to antibiotics (Table 5.4). Further research is required to assess the 
clinical importance of these distinctions. In order to test the hypothesis that likelihood 
of change in exposure of patients to antibiotics is related to changes in antimicrobial 
resistance.  ESAC is currently collecting data from a larger sample of hospitals that 
have participated in the European Antimicrobial Resistance Surveillance Scheme.
271
 In 
addition to analysis of total antibiotic use the time series model will also be used to 
analyse changes in use of classes of drugs such as Quinolones or third generation 
Cephalosporins that have been previously linked with changes in antimicrobial 
resistance and C difficile infection.
272
  The time series model proposed in this chapter 
will also facilitate the evaluation of interventions to change antibiotic use
148
 by 
identifying step changes or progressive changes that cannot be explained by change in 
clinical activity.  
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Table 5.4:  Overall interpretation of change in antibiotic exposure in the 18 hospitals from the results of statistical analysis of mean annual 
change and time series analysis of antibiotic use 
Likelihood of 
change in 
antibiotic 
exposure 
Change 
in DDD
1 
Hospitals Mean change in antibiotic use Time series analysis of antibiotic use 
Very likely 
Decrease 8 
Statistically significant change in the same 
direction for DDD
1
, DAD
2
 and DBD
3 
Change in DDD
1
 independent of clinical activity  
in all hospitals 
Increase 7, 14 
Likely 
Decrease 1,9 
Statistically significant change in the same 
direction for DDD
1
 and either DAD
2
 or DBD
3 
Change in DDD
1
 related to change in clinical 
activity in all hospitals 
Increase 2, 6, 11, 15 
Possible 
Decrease No hospitals 
No significant change in DDD
1
. Significant 
change in the same direction for DAD
2
 or DBD
3 
Change in DDD
1
 related to change in clinical 
activity for both hospitals 5 and 10 
Increase 5, 10 
Unlikely 
Decrease No hospitals 
Opposite change in direction for DDD
1
 and 
either DAD
2
 or DBD
3 
Change in DDD
1
 related to change in clinical 
activity in hospital 12, 16 and 18 but not in 4 
Increase 4, 12, 16, 18 
Very unlikely 
Decrease 17  
No significant change in DDD
1
, DAD
2 
or DBD
3 Change in DDD
1
 related to change in clinical 
activity in hospital 3 but not in 13 or 17.  
Increase 3, 13 
Abbreviations: DDD1 defined daily doses; DAD2 defined daily doses per 100 admissions; DBD3 defined daily doses per 100 occupied bed days
ESAC Longitudinal Survey 1 116 
 
5.6.3 Strengths and weaknesses 
Strengths of this study are that standardised methods were used to collect and analyse 
longitudinal data from multiple countries with a wide range of antibiotic use and clinical 
activity.  This study has addresses several of the weaknesses identified in previous 
studies by using a standardised method for conversion of drug use to DDD, clearly 
defined definitions of bed days and admissions and collection of monthly data.
261
  In 
this study the effects of additional denominator of clinical activity were further 
explored.   Furthermore, estimated were discharge and length of stay and used that in 
future studies can be replaced with actual data when available.  A new method for 
statistical analysis of trends over time and for the regression of time series analysis of 
antibacterial use was established.  Combination of analysis of mean change in antibiotic 
use per year with time series analysis enabled identification of hospitals in which 
exposure of patients to antibiotics probably has or has not changed over time.  Having 
established the model for the impact of clinical activity variables on total use and 
identified differences in changes over time with using different denominator of clinical 
activity, further studies are suggested to describe more explanatory factors for changes 
in antibiotic use and differences in changes between the hospitals. For example, in 
future studies it would be helpful to have data about changes in antibiotic policy and 
case mix over time.  Changes in antibiotic policy can affect the total use in DDD for 
example a shift in prescribing for intra-abdominal infection from a combination of 
amoxicillin plus Gentamicin plus Metronidazole, to monotherapy with Piperacillin-
Tazobactam would reduce the associated DDDs by two-thirds.  Information about 
hospital characteristics in the final year of data collection were collected but hospitals 
were unable to provide data about changes in case mix (e.g. proportion of paediatric 
beds) throughout the study period.      
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This study does have some potentially important weaknesses. It was impossible for a 
number of hospitals to exclude dispensing at discharge from their pharmacy supply 
data. However, none of the hospitals had changed their dispensing system over the 
study period so this should not have had a major influence on our longitudinal analysis. 
Nonetheless, LOS did reduce over the study period in most hospitals and therefore the 
number of patients with length of antibiotic treatment greater than length of stay is 
likely to be increasing. It would be helpful for future studies to document the impact of 
dispensing at discharge.  Only 18 hospitals were included in total and that the period of 
the longitudinal survey did not include the year of the point prevalence survey
260
 so 
there is no concurrent information about prescribed daily doses.. Having established the 
methodology ESAC is currently conducting a larger study with 50 hospitals that will 
provide longitudinal data linked with point prevalence data about prescribed doses and 
details about hospital characteristics.  
5.7 Conclusion  
This study required considerable time and effort to allow raw data collection, validation 
in different phases of the project, and processing and analysis.  This precision can 
hardly be applied to future projects with a larger number of hospitals or be applied to all 
of Europe.  The ATC/DDD method has been used for more than four decades.  Ten 
years ago the European Union passed agreements and laws on the standardised method 
of antimicrobial consumption surveillances.   Yet, the national networks are established 
only in a few countries.  Additionally, the European Union funded studies like ESAC 
for continuous data collection and monitoring.  In this and similar projects, countries 
participate on a voluntary basis and the funding for projects is not enough to pay for 
data collection of the participating countries even for a study like this that included one 
hospital per country.  The EU agreements on continuous surveillances on antimicrobial 
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use with standardised methods will not be feasible across the rest of Europe until 
countries agree on a budget allocation for the establishment of national networks for 
antibiotic use in hospitals.  The reader will recall from earlier in this chapter the  
problems associated with pharmacy stock databases and different data collection 
methods for clinical activity variables.  Therefore, central, preliminary data processing 
and analysis at national level would provide greater validity. 
In this study the extent to which using a similar numerator of use, DDD, can allow 
exploration of the effects of an additional denominator of clinical activity was proved.    
The strengths of this study are implementing standardised methods to collect and 
analyse longitudinal data from multiple countries with very different healthcare 
systems.  The methods have addressed several of the weaknesses identified in previous 
studies. 
192
  Furthermore, new methods for statistical analysis of changes over time 
using both slope and intercept, and for time series analysis of antibacterial use was 
developed.  In the other method - scaled trends in simple regression - it became feasible 
to compare the trends between hospitals and between different variables.  
The study described limitations in using one denominator of clinical activity and the 
overestimation caused by occupied bed days.   
Hospitals varied widely in their trends of use and clinical activity during the study 
period.    Some of the variations will be explained in chapter 7 and 8 when the point 
prevalence survey in the same hospitals and hospital characteristics will be discussed.  
This study could suggest a method for categorising hospitals.  
The results can be transferred to cross-sectional surveys, studies on antibiotic use and 
resistance in secondary care and also use of other medicines in secondary care.  
Weaknesses of this study are that it includes one hospital per country and only 18 
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hospitals in total. This is too small a sample size to explore determinants of change in 
antibacterial use. Having established the methodology, ESAC is currently conducting a 
larger study with 50 hospitals that will provide longitudinal data, point prevalence data 
and details about hospital characteristics.  
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CHAPTER SIX:  ESAC LONGITUDINAL SURVEY 2, 
TIME SERIES ANALYSIS OF TOTAL, PARENTERAL 
AND BROAD-SPECTRUM ANTIBACTERIAL USAGE 
6.1 Background  
This chapter is an additional study to the main components of the ESAC-2 hospital care 
sub-project.  The aim is to provide more in-depth analysis on longitudinal data to 
compare indicators of hospital antibiotic use.  Parenteral antibacterials, 
Fluoroquinolones and third generation Cephalosporins (CQ antibiotics) were selected 
for the study.  These are antibiotics associated with higher cost and risk of adverse 
effects, including for CQ antibiotics a greater risk of collateral damage (C difficile 
infection and microbial resistance).  Time series data on total use and use of selected 
antibacterials from each of the 18 hospitals were compared in this study.  The study 
focused on mean annual change in each indicator as the outcome measure.  
6.2 Aim 
To develop and validate more meaningful indicators of hospital antibiotic use that can 
be easily extracted from routine longitudinal data and, when added to indicators 
developed from point prevalence surveys, can build a set of core indicators that can be 
used to compare antimicrobial prescribing in hospitals in European countries.  
6.3 Research question 
 Are the same time trends present in use of total antibiotics, parenteral antibiotics and 
antibiotics with high risk of collateral damage? 
6.4 Introduction 
In addition to total antibiotic use, two other indicators of use were identified: firstly, 
parenteral antibiotics and secondly, use of third generation Cephalosporins (J01DD) and 
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Fluoroquinolones (J01MA).  The rationale for these additional indicators was that they 
are key targets for antimicrobial stewardship programmes in hospitals.
46, 49
  
Unnecessary parenteral antibiotic use exposes patients to additional risk and hospitals to 
additional costs without clinical benefit.
25, 46, 273
 Use of third generation Cephalosporins 
and Fluoroquinolones is associated with the prevalence of antimicrobial resistant 
bacteria (e.g. MRSA and multiple resistant gram negative bacteria) and C difficile 
infection 
46, 273-275
.  Interventions to reduce the use of these drugs have been associated 
with a significant reduction in the prevalence of antimicrobial resistance and C 
difficile.
276 
A seven-year survey (1980-86) in France revealed significant correlation 
between an increase in antibiotic use and a decrease in antibiotic susceptibility, 
especially for third generation Cephalosporins.
64 
A nine-year follow-up study in the 
adverse effect of parenteral treatment in chronic bone infections (CBI), that often 
requires prolonged parenteral antimicrobial therapy, showed that at least one- third of 
patients with CBI experienced adverse effects that were related to both the device used 
for IV administration and the antibiotics that were administered. 
277 
   
6.5 Methods 
In Chapter Five, the methods for collection, validating and processing and analysing 
raw pharmacy stock data were described.  In the current chapter, total antibacterial use, 
use of parenterals, and use of third generation Cephalosporins plus Fluoroquinolones 
during the study period were extracted from the data for each of the hospitals.  Each 
hospital was given a number consistent with the numbers in the point prevalence and 
longitudinal surveys in Chapters Five, Seven and Eight.  Three variables were 
constructed for each of the hospitals:  Total use (T), Parenteral use (P) and the sum of 
use of third generation Cephalosporins and Fluoroquinolones (CQ), so the database 
included 54 (3 18) times series.   
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Use of antibacterials was measured in DDDs as defined by the WHO Collaborating 
Centre for Drug Statistics Methodology.
265  
Data were not scaled by clinical activity 
denominator because the changes in any clinical activity variable should be equal and 
consistent for all three variables in each of the hospitals and any adjustment would be 
disregarded in a regression analysis of time series.  Hospitals were categorised based on 
findings from individual hospitals.  No comparison was performed between hospitals 
for the three series (T, P, and CQ).  
6.5.1 Statistical analysis 
The following steps were taken to prepare data for time series regression 
 Plot the data  
 Identify the outliers and structural breaks from plots and corresponding data  
 Contact the hospitals to find if there is any explanation for outliers and structural 
breaks 
 Correct the outliers in line with responses from those hospitals that could 
identify and correct their databases.  
 Run the statistical tests for stationarity and trend 
 Test if the outliers and structural breaks  exist after removing seasonality 
 Use the criteria  Q3 ± (3* IQR) limit (inter-quartile)  to find the far outliers and 
remove them if they were first or last data point and when they were in the 
middle of times series replace with the average of  the data points immediatly 
before and after the outlier. 
 Use dummy variable for structural breaks  
 
Details of the above steps are described as in the following.  
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Prior to a time series analysis, 54 series were tested for stationarity and trend using two 
statistical tests.  In time series analysis, if the data are not stationary there is evidence of 
a unit root that may happen in the presence of a trend in the series. 
197  
Data series were 
tested for stationarity using two statistical tests: Phillips-Perron (PP) and Kwiatkowski-
Phillips-Schmidt-Shin (KPSS) tests.
202, 278
  The two test results were not expected to be 
consistent with each other.  A time series is stationary if it exhibits a reversion around a 
constant long-run mean; has a finite variance that is time invariant; and has a theoretical 
correlogram that diminishes as the lag length increases. 
195  
While the PP test examines 
the reversion around a constant long-run mean, the KPSS test differs in that the 
productivity series is assumed to be (trend) stationary under the null hypothesis.
279
  The 
KPSS test is used for testing the null hypothesis that a time series is stationary around a 
deterministic trend.  The Phillip-Perron test checks the null hypothesis that a time series 
has a unit root against a stationary alternative. 
195, 279
   The PP test and KPSS tests can 
be compared in the following general interpretation:   
―Being declared guilty (PP test) is not the same thing as not being declared innocent 
(KPSS test)‖. 
Box-plot graphs and statistical tests were used to identify outliers in the series.  For this, 
the inter-quartile range (IQR), first (Q1) and third quartiles (Q3) were calculated.  The 
far outlier was defined as a data point that lies outside the Q3 ± (3* IQR) limit.  Near 
outliers were data points that lay outside the Q1± (1.5*IQR) limits.
280
  The far outliers 
were replaced with the average of immediate data points before and after the outlier.  If 
the far outlier was the first or last data point, it was deleted.  To deal with near outliers, 
if they existed in a series, the data were de-seasonalised to find whether or not the near 
outliers were in fact a seasonal pick and when they were not, they also replaced with the 
average value of immediate data points before and after the near outliers. Structural 
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dummies were assigned to those series with one or more sudden changes.  Time series 
analysis was conducted for 54 time series.  Each of the series was regressed over trend 
and seasonal and structural dummies.  
195 
  
In case of a structural break and to understand what the outcome would be a dummy 
variable was used, which can affect both the intercept and the slope coefficients.  If D is 
the assumed dummy variable for the structural break, it would be equal to 1 and 0 
otherwise.  
   
                           
                       
   195          (6.1) 
The following regression model was used.  
   =                          
195            
(6.2)
 
B3Dt and B4Dt were the interaction terms between constants and trends coefficients 
respectively.  The significance of B3Dt and B4Dt coefficients could also cautiously 
determine whether the structural break was real or they had been picked up by incorrect 
graphical interpretations.  
The series were regressed on trend (t) seasonal dummy variables with January as the 
reference month.  ARMA components were used to correct serial autocorrelation of 
residuals, where appropriate.  Selection of the best fitted model, as described in Chapter 
2, was based on the Jarque-Bera test for normality of residuals and Q statistics and 
Breusch-Godfrey Lagrange Multiplier statistics (B-G LM Statistic) for autocorrelation 
between residuals, see example in Figure 5.5 in Chapter 5.  For times series analysis, 
evaluation of the model based on R-Squared is misleading.  Even badly specified time 
series equations can give R2 of 0.999
.  195  
  Trends or change per month for the three 
series: total, parenteral and third generation Cephalosporins plus Fluoroquinolones for 
each of the hospitals cannot be compared directly, firstly because the two latter series 
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are fractions of total use and secondly, because a small trend built on a large constant 
may exhibit the same change with another series with a sharp trend with a low constant.  
From the best fitted regression model and where the trend was significant, the slope 
trend and constant (intercept) values were used to scale the change using the intercept.  
The mean annual percentage change was calculated using the formula below which was 
created in Chapter Five to scale the trends with constant and presented as a percentage 
of mean annual change.    
% Δ Variable = [(Slope * 12)/ Intercept] * 100       (LS 5.3) 
The pooled statistical outcomes for all hospitals were explored for correlation, first 
between changes in total and parenteral use, and second between changes in total and 
third generation Cephalosporins plus Fluoroquinolones.  The correlations were 
calculated regardless of whether the change values were significant.  
All statistical analyses were performed with EViews 6 software
 
(QMS, Irvine, CA, 
USA). 
6.6 Results 
6.6.1 Description and statistical analysis of time series 
Time series plots for Total (T), Parenteral (P) and third generation Cephalosporins plus 
Fluoroquinolones (CQ) are presented in Tables 6.1 to 6.3.  The series vary across 
hospitals with respect to trend, seasonality, instability and autoregressive patterns.  In 
some series, raw data series exhibit clear upward trends (H7P, H15CQ) or clear 
downward trends (H1T, H9T, H9CQ). However, several series do not exhibit any clear 
time trend (H13T, H16T, H8P, H13P and H13CQ).  
The results of 108 tests of stationarity with PP and KPSS test statistics for each series 
showed that the tests do not have similar powers to detect the trend and that the KPSS 
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test is more powerful.  An example of two test statistics for the H2T series with a clear 
trend is described in Table 6.4a.  Prior to the tests where the constant and trend are 
included in both, the series was tested on constant only and the KPSS showed non-
stationarity in favour of having a trend while the PP test did not.  This discrepancy was 
the same with most of the other series with or without trend, in the raw data series.  
Some series had structural breaks after removing outliers from some of them, where 
appropriate, based on the criteria that were explained in the methods section.  These 
series were:  H4T, H4P, H5T, H5P, H5CQ, H8T, H8CQ, H9CQ, H12T, H12P, H14P, 
H14CQ, and H17CQ (Tables 6.1 to 6.3).  In Table 6.4b two tests for stationarity are 
shown for H12T.  Both tests are in favour of non-stationarity with weak Durbin-Watson 
test statistics.  Furthermore the tests suggest a positive trend while later in regression 
analysis it was found that this series contains a significant negative trend if the 
structural break dummy is being included.  Therefore, in the presence of breaks, unit 
root tests are invalid.   
The regression of time series was conducted for all series.  The output for 54 of the 
series was too long to be included in this thesis.  For one series, the regression model is 
provided and described in Table 6.5.   
In hospital 14 for H14T, the model with best fit was usage measured in DDDs regressed 
over time squared (t^2) and time (t).  Therefore, a graph of the regression line was 
polynomial.  The curvature component was calculated and incorporated to extract time 
trend to allow the comparison to be comparable with two other series in the same 
hospitals,
281  
(and with advice through personal communication with  Dr Simon Ogston, 
Department of  Public Health, University of Dundee). 
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Table 6.1: Times series data on total use of antibacterials (T) by hospital number 
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Table 6.2: Times series data on use of parenteral antibacterials (P) by hospital number 
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Table 6.3:  Times series data on use of Cephalosporins and Fluoroquinolones (CQ) by hospital number 
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Table 6.4a and 6.4b:  Examination of Phillips-Perron and KPSS tests for one series with obvious trend, and another with structural break 
 1-
a) H2T- The Phillips-Perron t statistics, -6.70, is lower than critical values, the 
null hypothesis is rejected and the series are trend stationary. In left table, the 
KPSS t statistics, 0.98, is lower than critical values therefore the null 
hypothesis is rejected in favour of non-stationarity.  However the Durbin-
Watston stat for KPSS test shows autocorrelation of the residuals should be 
corrected for in regression of the series.  Two tests produced different results. 
 
 
 
 
1-b) H12T- This series contains one significant structural break. The Phillips-
Perron statistics, -2.94, is bigger than critical values so the null hypothesis is 
not rejected and the series has a unit root. But it shows a positive trend and 
highly correlated residuals.  The KPSS test stat, 0.21, is between 1% and 5% 
critical values so the null hypothesis is not rejected and the series are 
stationary. The estimated trend is 8.01 and the Durbin-Watson stat is far from 
2. The trend with both tests are positive, however later in regression of time 
series it will be found that the trend is negative. Therefore, none of the tests 
give valid results for structural break. Time series regression after this test 
showed that the trend was negative
Null Hypothesis: H2T has a unit root Null Hypothesis: H2T is stationary
Exogenous: Constant, Linear Trend Exogenous: Constant, Linear Trend
Bandwidth: 2 (Newey-West using Bartlett kernel) Bandwidth: 3 (Newey-West using Bartlett kernel)
Adj. t-Stat   Prob.* LM-Stat.
Phillips-Perron test statistic -6.70 0 Kwiatkowski-Phillips-Schmidt-Shin test statistic 0.098
Test critical values: 1% level -4.09 Asymptotic critical values*: 1% level 0.216
5% level -3.47 5% level 0.146
10% level -3.16 10% level 0.119
*MacKinnon (1996) one-sided p-values. *Kwiatkowski-Phillips-Schmidt-Shin (1992, Table 1) 
Residual variance (no correction) 576698 Residual variance (no correction) 608717
HAC corrected variance (Bartlett kernel) 558317 HAC corrected variance (Bartlett kernel) 870296
Phillips-Perron Test Equation KPSS Test Equation
Dependent Variable: D(H2T) Dependent Variable: H2T
Method: Least Squares Method: Least Squares
Sample (adjusted): 2000M02 2005M12 Sample: 2000M01 2005M12
Included observations: 71 after adjustments Included observations: 72
Coefficient Std. Error t-Statistic Prob.  Coefficient Std. Error t-Statistic Prob.  
H2T(-1) -0.79 0.12 -6.72 0 C 6,923.58 184.58 37.51 0
C 5,425.87 829.83 6.54 0 @TREND(2000M01) 56.50 4.49 12.59 0
@TREND(2000M01) 45.93 7.96 5.77 0
R-squared 0.40     Mean dependent var 49.67 R-squared 0.69     Mean dependent var 8929.47
Adjusted R-squared 0.38     S.D. dependent var 987.52 Adjusted R-squared 0.69     S.D. dependent var 1419.75
S.E. of regression 775.98     Akaike info criterion 16.19 S.E. of regression 791.27     Akaike info criterion 16.21
Sum squared resid 40945579     Schwarz criterion 16.28 Sum squared resid 43827639     Schwarz criterion 16.28
Log likelihood -571.65     Hannan-Quinn criter. 16.23 Log likelihood -581.65     Hannan-Quinn criter. 16.24
F-statistic 22.68     Durbin-Watson stat 2.01 F-statistic 158.58     Durbin-Watson stat 1.56
Prob(F-statistic) 0 Prob(F-statistic) 0
Null Hypothesis: H12T has a unit root Null Hypothesis: H12T is stationary
Exogenous: Constant, Linear Trend Exogenous: Constant, Linear Trend
Bandwidth: 2 (Newey-West using Bartlett kernel) Bandwidth: 6 (Newey-West using Bartlett kernel)
Adj. t-Stat   Prob.* LM-Stat.
Phillips-Perron test statistic -£2.94 £0.16 Kwiatkowski-Phillips-Schmidt-Shin test statistic 0.21
Test critical values: 1% level -£4.09 Asymptotic critical values*: 1% level 0.22
5% level -£3.47 5% level 0.15
10% level -£3.16 10% level 0.12
*MacKinnon (1996) one-sided p-values. *Kwiatkowski-Phillips-Schmidt-Shin (1992, Table 1) 
Residual variance (no correction) 234780 Residual variance (no correction) 508299
HAC corrected variance (Bartlett kernel) 208816 HAC corrected variance (Bartlett kernel) 2244012
Phillips-Perron Test Equation KPSS Test Equation
Dependent Variable: D(H12T) Dependent Variable: H12T
Method: Least Squares Method: Least Squares
Sample (adjusted): 2000M02 2005M12 Sample: 2000M01 2005M12
Included observations: 71 after adjustments Included observations: 72
Coefficient Std. Error t-Statistic Prob.  Coefficient Std. Error t-Statistic Prob.  
H12T(-1) -0.255478 0.08 -3.09 0.0029 C 2689.42 168.668 15.94505 0
C 656.2011 253.64 2.59 0.0118 @TREND(2000M01) 8.01 4.10025 1.952611 0.0549
@TREND(2000M01) 3.206735 2.92 1.10 0.2767
R-squared 0.13     Mean dependent var 16.14 R-squared 0.05     Mean dependent var 2,973.64
Adjusted R-squared 0.10     S.D. dependent var 521.89 Adjusted R-squared 0.04     S.D. dependent var 737.25
S.E. of regression 495.11     Akaike info criterion 15.29 S.E. of regression 723.06     Akaike info criterion 16.03
Sum squared resid 16669395     Schwarz criterion 15.38 Sum squared resid 36597549     Schwarz criterion 16.10
Log likelihood -539.75     Hannan-Quinn criter. 15.33 Log likelihood -575.16     Hannan-Quinn criter. 16.06
F-statistic 4.89     Durbin-Watson stat 2.37 F-statistic 3.81     Durbin-Watson stat 0.52
Prob(F-statistic) 0.01 Prob(F-statistic) 0.05
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Table 6.5:  An example for regression of time series on trend, hospital 6 Cephalosporins and Fluoroquinolones. 
Dependent Variable: H6CQ   
Method: Least Squares   
Sample (adjusted): 2002M02 2005M12  
Included observations: 47 after adjustments  
Convergence achieved after 4 iterations  
     
      Coefficient Std. Error t-Statistic Prob.   
     
     C 359.1840 155.5380 2.309301 0.0273 
@TREND 6.935118 2.509847 2.763164 0.0093 
DM_2 2.704457 99.30769 0.027233 0.978400 
DM_3 38.45616 115.9440 0.331679 0.742200 
DM_4 15.78228 120.8483 0.130596 0.896900 
DM_5 -82.84906 122.2737 -0.677570 0.502800 
DM_6 -5.704589 122.6196 -0.046523 0.963200 
DM_7 -37.82654 122.6258 -0.308471 0.759700 
DM_8 -77.69633 122.4768 -0.634376 0.530200 
DM_9 121.5047 122.0662 0.995400 0.326800 
DM_10 -17.16660 120.8437 -0.142056 0.887900 
DM_11 -45.07052 116.9856 -0.385266 0.702500 
DM_12 -67.52200 104.1202 -0.648500 0.521100 
AR(1) 0.326028 0.163657 1.992137 0.054700 
     
     R-squared 0.438732     Mean dependent var 679.7697 
Adjusted R-squared 0.217626     S.D. dependent var 172.9652 
S.E. of regression 152.9910     Akaike info criterion 13.14074 
Sum squared resid 772405.7     Schwarz criterion 13.69185 
Log likelihood -294.8074     Hannan-Quinn criter. 13.34812 
F-statistic 1.984263     Durbin-Watson stat 2.102717 
Prob(F-statistic) 0.055674    
     
     B_G LM Statistic:  1.019915 Prob. F(6,27)   0.433600 
Q Statistic  5.165800 Prob. Chi-  
Square(6) 
  0.396000 
 
 
Dm_2 to Dm_12 are monthly seasonal dummies. The series has a 
significant time trend. The trend coefficient is 6.94 with standard error 
of 2.51.  The Jarque-Bera equals to 3.33 with P-value of 0.19 so the 
residuals are normally distributed. Autocorrelation tests Q statistics and 
Breusch-Godfrey Lagrange statistics (B_G LM Statistic) with 6 lags 
which generally applies to monthly data are not associated with 
significant probability of chi-squared so there is no autocorrelation in 
the residuals. 
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Table 6.6 and Figure 6.1 summarise all statistical analysis for the multiple time series 
analysis followed by incorporating the trend and constant components into mean annual 
changes for the three series in each of the hospitals 
6.6.2 Comparison of trends in the three indicators of antibiotic use 
The research question was ―Are the same time trends present in use of total antibiotics, 
parenteral antibiotics and antibiotics with high risk of collateral damage?‖ In order to 
answer this question hospitals were grouped firstly for the changes in parenteral use 
versus total use and secondly for changes in use of CQ antibacterials versus total use.  
Comparison of average annual changes in all three indicators 
Average annual changes in total antibacterial use, measured in DDDs, were compared 
with changes in parenteral antibacterials and with the sum of Fluoroquinolones 
(J01MA) and third generation Cephalosporins (J01DD) for each hospital.  
In hospitals 1, 4, 9, 12 and 17, total use decreased from -2% to -4.7% per year. The 
change for hospital 17 was not significant.  In thirteen other hospitals, total use 
increased from 0.1% in hospital number 13 to 10.4% in hospital number 2. The 
increasing rate was not significant in hospitals 3, 10, 13 and 17.  In general, total use 
increased in 50% of the hospitals, decreased in 22%, and remained unchanged 
(insignificant change) in 28% (Table 6.6 and Figure 6.1).  
Use of parenteral antibacterials decreased in five hospitals (4, 8, 9, 13, and 15) from -
0.5% to -4.5% but this change was significant only in hospitals 4, 9 and 15. In thirteen 
other hospitals there were increasing changes from 0.8% to 17.7% and the upward 
change was significant in 12 hospitals.  In total for fifteen (83%) hospitals the changes 
were significant, increasing in 67% and decreasing in 17%.  In 17% of hospitals 
(hospitals 8, 10 and 13) there was no significance level of change.  
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The use of third generation Cephalosporins plus Fluoroquinolones decreased in five 
hospitals (hospital numbers 1, 9, 10, 12 and 13) from -0.28% to -7.6% but it was 
significant only for two hospitals. In thirteen other hospitals, use of these antibacterial 
groups increased from 1.4% to 96.1%.  The upward change was significant in eight 
hospitals.  In total, in 11% of hospitals the use decreased, while in 44.5% use increased 
and in 44.5% it remained unchanged (insignificant change). (Table 6.6 and Figure 6.1).  
 
Difference between change in total use and change in the other two indicators 
To compare the change values in each hospital between parenteral and total use and 
between uses of third generation Cephalosporins plus Fluoroquinolones (CQ), changes 
in total use were deducted from the other two indicators: ∆P-∆T and ∆CQ-∆T.  
The differences were considered positive ( >0) if: 
- The increases in P or CQ were more than increase in T or, 
- ∆P or ∆CQ was positive while ∆T was constant  or was not significant or, 
- ∆P or ∆CQ were positive while ∆T was negative. 
The differences were considered negative (<0) if: 
- ∆T increase more than ∆P or ∆CQ or, 
- ∆T was positive while ∆P or ∆CQ were negative or, 
- ∆T was positive and ∆P or ∆CQ was constant or insignificant or, 
- ∆T was negative but less than negative values for ∆P or ∆CQ.  
- The differences were considered as nearly equal (≈) if there were no change or 
no significant change in ∆T and ∆P or ∆CQ.   
The overall interpretation of differences and grouping the hospitals are presented in 
Table 6.7 (A & B).   
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Correlation between change in total use and each of two antibacterial groups 
There were non-significant correlations between changes in total use and change of use 
of parenteral antibacterials across the hospitals either for all data regardless of level of 
significance (correlation coefficient:  0.4070,  P-value: 0.09) or for thirteen hospitals 
with significant changes in 2 variables (correlation coefficient 0.41, P-value: 0.16). 
There was also non-significant correlation between changes in the total use and the 
changes in use of third generation Cephalosporins plus Fluoroquinolones for all 
hospitals (correlation coefficient:  0.388, P-value: 0.11) and for eight hospitals with 
significant changes in both variables (correlation coefficient:  0.18, P-value: 0.66).    
6.7 Discussion 
This was the first study to compare time trends for three indicators of antibacterial use 
in multiple hospitals.  Most previous longitudinal studies of hospital antibiotic use were 
focused on a single hospital and no previous study used statistical analysis to compare 
trends. 
282-284
   
The raw pharmacy stock data were assigned to ATC/DDDs by the central team in 
Dundee, with much time and effort put into data validation through repeated 
communication with data providers.  Nonetheless the local data providers could often 
not diagnose the source of irregular behaviour patterns of their data such as outliers and 
one or more abrupt changes.  Accordingly, a limitation of this study was that 13 of the 
54 series had abrupt change in level or presence of outliers even after checking of data 
with local providers (Tables 6.1-6.3).  This highlights a key problem of this kind of 
comparative analysis that routine data from different institutions and countries can be 
variable in ways that are difficult to explain or resolve.  The data should therefore be 
interpreted cautiously.  It is important to recognise that time series analysis and its 
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techniques are mainly applied to social and economic data for which there is supporting 
historical information about the reasons for irregular time series behaviours. In contrast 
for this study hospitals were unable to provide information to explain several outliers or 
sudden changes and breaks in the data. The availability of data about characteristics of 
hospitals that may explain differences between them is explored further in Chapter 8.   
In some series, there were variations from month to month in pharmacy stock data.  It 
may be that pharmacy stock data do not reflect changes in actual usage over time.  
Variations in drug dispensing systems and the impact of a ward buffer from month to 
month may explain some of the time trends observed in this study.  This study benefits 
from a robust, multistep statistical method based on monthly pharmacy stock data.  The 
statistical analysis of the time series used in this study did correct some of the 
irregularity in the time series and used published methods to extract the time trend for 
statistical comparison.  Nonetheless, the validity of methods for extraction of the trend 
component for a time series is still a matter of discussion between economists and social 
scientists.   
Despite these caveats the statistical analysis did answer the research question and 
showed that there was little relationship between changes in total antibiotic use and use 
of either parenteral or CQ antibiotics.  Importantly, the 18 hospitals included examples 
with significant increases or decreases in each of the three indicators. In 67% (11) of the 
hospitals change in use of parenteral antibacterials was greater than change in total use, 
in 28% (5) it was smaller and in 11% (2) of the hospitals both were constant (Table 6.6).  
Similarly in 56% (10) of the hospitals change in use of CQ antibiotics was increasing 
more than total use, in 28% (5) it was decreasing more and in 3% (3) the speed of 
exposure was constant.  Therefore in the majority of hospitals changes in total antibiotic 
use masked the changes in the use of either parenteral antibacterials or CQ antibiotics.  
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Finally, correlation analysis was used to compare changes between pairs of indicators 
for all 18 hospitals.  These showed non-significant correlations.  Moreover any apparent 
correlation should be interpreted with caution because it may be due to the influence of 
a small number of extreme data points.   
6.8 Conclusion 
With hindsight it could be said that the results of this analysis are not surprising 
however, it is well documented in this study.  I have shown that time series analysis can 
be used to compare changes in use of different antibiotics within a hospital and to 
compare trends in the same antibiotics between hospitals.  With running 54 pairs (108)  
KPSS and PP tests for trend and stationarity the inconsistency between these two tests 
was confirmed as it was suggested in literature.
279
  The results show clearly that 
potentially important changes in use of either parenteral or CQ antibiotics may not be 
apparent from changes in total use. The study had limitation of data validity for all 
times series.  In this chapter a series of methods and techniques used to minimise these 
problems.  However, my results imply that routine monitoring needs better data 
systems.  Pharmacy databases need to be regularly checked for unexpected values in the 
way that I established for Tayside university hospitals.  Resourcing of data checking at 
local level is an essential first step to making valid national and international 
comparisons.  
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Table 6.6: Percentage of mean annual changes for Total (T), Parenteral (P) and third generation Cephalosporins plus fluoroquinolones (CQ) 
for each of the hospitals (H). Significant changes are highlighted. 
Hospital & series %Change Confidence Intervals P value Hospital & series % Change Confidence Intervals P value 
H1T -2.97 -4.71, -1.50 <0.001 H10T 0.75 -0.46, 1.79 0.22 
H1P 3.18 1.55, 4.46 <0.01 H10P 0.80 -0.52, 1.91 0.22 
H1CQ -1.85 -5.67, 0.84 0.21 H10CQ -0.28 -3.10, 1.96 0.82 
H2T 10.42 9.46, 11.19 <0.001 H11T 1.70 0.62, 2.65 <0.01 
H2P 9.95 8.66, 10.93 <0.001 H11P 3.00 1.79, 4.01 <0.001 
H2CQ 49.33 39.56, 79.80 <0.001 H11CQ 3.14 1.40, 4.50 <0.01 
H3T 1.93 -0.37, 3.65 0.10 H12T -4.34 -8.99, -0.86 0.01 
H3P 4.97 2.51, 7.02 <0.001 H12P 17.72 14.26, 19.28 <0.001 
H3CQ 2.76 -0.66, 4.98 0.10 H12CQ -4.92 -19.91, 2.21 0.23 
H4T -1.61 -3.07, -0.35 0.02 H13T 0.01 -1.35, 1.10 0.99 
H4P -3.10 -5.41, -1.17 <0.01 H13P -0.48 -3.49, 1.70 0.70 
H4CQ 3.40 -1.54, 6.67 0.16 H13CQ -2.42 -4.27, -1.17 <0.001 
H5T 12.20 11.05, 13.03 <0.001 H14T 4.39 2.86, 5.83 <0.001 
H5P 11.73 9.53, 13.09 <0.001 H14P 4.77 0.74, 7.68 0.03 
H5CQ 45.27 36.75, 64.81 <0.05 H14CQ 10.83 8.88, 12.13 <0.001 
H6T 5.44 3.68, 6.70 <0.001 H15T 2.51 1.23, 3.58 <0.001 
H6P 12.20 9.57, 13.68 <0.001 H15P -2.49 -4.42, -0.88 <0.01 
H6CQ 23.17 21.37, 44.52 <0.01 H15CQ 96.14 61.46, 130.80 <0.001 
H7T 6.36 4.77, 7.60 <0.001 H16T 2.57 0.24, 4.39 <0.05 
H7P 9.26 8.25, 10.03 <0.001 H16P 6.77 7.06, 6.55 <0.001 
H7CQ 9.61 2.32, 12.83 <0.05 H16CQ 4.58 -32.96, 42.13 0.17 
H8T 2.58 -0.22, 4.72 0.07 H17T -2.01 -6.42, 1.13 0.24 
H8P -0.92 -4.29, 1.66 0.52 H17P 4.50 1.75, 6.54 <0.01 
H8CQ 4.07 0.59, 6.75 0.02 H17CQ 19.34 -38.22, 76.90 0.20 
H9T -4.74 -6.35, -3.34 <0.001 H18T 1.10 0.22, 1.88 <0.05 
H9P -4.51 -6.17, -3.06 <0.001 H18P 2.55 1.50, 3.45 <0.001 
H9CQ -7.61 -10.72, -5.09 <0.001 H18CQ 1.39 -1.24, 3.46 0.28 
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Table 6.7: Overall interpretation of difference in change between indicators 
 A: changes in total antimicrobial versus changes in parenteral antibacterial use.  
Interpretation of 
change in exposure to 
parenteral 
antibacterials 
compared with total 
antibacterials  
Outcome 
Number of hospitals 
(% form total 
hospitals) 
Hospital Numbers 
Exposure was bigger   ∆P>∆T 11(61%) 
1, 3,6,7,9,11,12, 
14,16,17,18 
Exposure was smaller ∆P<∆T 5 ( 28%) 2, 4, 5, 8,15  
Exposure was equal ∆P≈∆T 2 (11%) 10, 13 
∆: change, P: Parenteral antibacterials, T: total antibacterials 
 
B: Changes in total antimicrobial use versus changes in third generation Cephalosporins 
and Fluoroquinolones (CQ) use. 
Interpretation of 
change in exposure to 
parenteral 
antibacterials 
compared with total 
antibacterials  
Outcome 
Number of hospitals 
(% form total 
hospitals) 
Hospital Numbers 
Exposure was bigger   ∆CQ>∆T 10 (56%) 1,2,4,6,7,8,11,12,14,15 
Exposure was smaller ∆CQ <∆T 5 (28%) 5,9, 13,16,18  
Exposure was equal ∆CQ ≈∆T 3(16%) 3,10,17 
∆: change, CQ: third generation Cephalosporins and Fluoroquinolones, T: total 
antibacterials 
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Figure 6.1: Mean annual percentage of change in defined daily doses (DDD) of total antibiotics, parenteral antibiotics and 3
rd
 generation 
cephalosporins plus fluoroquinolones with 95% confidence intervals  
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CHAPTER SEVEN:  THE EUROPEAN SURVEILLANCE 
OF ANTIMICROBIAL CONSUMPTION (ESAC) POINT 
PREVALENCE SURVEY OF ANTIBACTERIAL USE IN 20 
EUROPEAN HOSPITALS IN 2006 
7.1 Background 
The most important advantage of cross-sectional studies is that can usually be done 
rapidly and since there is no follow-up, fewer resources are required to run the study.  
Cross- sectional studies are the best way to determine prevalence and are useful at 
identifying associations that can then be more rigorously examined using a cohort study 
or randomised controlled study.
285
  As a result, point prevalence surveys have been used 
to document antibacterial use in hospitals for over 20 years.  This chapter focuses on 
standardising the method for surveillance of antibacterial use in hospitals from different 
healthcare systems and identifying areas for quality improvement.  
7.2 Introduction 
Point Prevalence Surveys (PPS) can provide detailed clinical data to supplement 
information available from aggregated pharmacy stock databases, to provide a broader 
perspective on practice profile in studies of hospital drug utilisation. This clinical 
evidence can be used to improve guidelines and quality measurements for improvement 
of clinical practice (Figure 1.1
6
 in Chapter 1).  The value and limitations of Point 
Prevalence Surveys of hospital antimicrobial use was discussed in Chapter One of this 
thesis.  Despite the limitation of previously published evidence reviewed in Table 1.2 of 
Chapter 1, these studies together with numerous publications produced from other kinds 
of hospital record based studies, have provided evidence of existing practice and 
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contributed to improvement of methods and measures.  Data about antimicrobial use 
have been also collected in surveys of hospital acquired infections.  For example, a 
national survey of 11,608 inpatients in all acute hospitals in Scotland in 2005-6 reported 
that 32.1% were receiving antimicrobials and provided details about the drugs used but 
not about the doses, routes of administration or indications. 
286
  In Sweden, Swedish 
strategic programme for rational use of antimicrobial agents and surveillance of 
resistance (STRAMA) established a method for national Point Prevalence Surveys of 
antibacterial use with web-based reporting. 
161
 STRAMA have co-ordinated three 
national point prevalence surveys of hospital antibacterial use in 2003, 2004 and 
2006.
287
 In addition, regional benchmarking studies have been conducted in Sweden 
with web based reporting systems.
118
 
As described in ESAC introductory Chapter, the ESAC-1 project found measurement 
methods and therefore accuracy varied widely, limiting the conclusions of previous 
European-wide studies, and of ESAC-1 itself.
251
  In the second phase of the ESAC 
project from 2004 to 2007, a hospital subproject was established to collect more 
detailed information from individual hospitals.  The study aimed to collect data from 
hospital pharmacies for longitudinal analysis of antibacterial consumption and to 
establish the first European Point Prevalence Survey.  The STRAMA web based data 
collection form was selected because it included key information about drug doses and 
routes of administration for prophylaxis and treatment in children and adults that would 
facilitate interpretation of data about antibacterial consumption.  
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7.3 Aims  
To standardise a method for Point Prevalence Survey of antibacterial use in European 
hospitals from different healthcare systems, based on the STRAMA data collection and 
reporting method.  
To collect, and make publicly available, data about prescribed daily doses (PDD) of 
antibacterials in hospital practice for comparison with WHO DDDs to inform the 
interpretation of data about antibacterial use from hospital pharmacies.  
To identify targets for quality improvement.  
7.4 Methods 
ESAC national representatives were invited to participate in the study and to recruit one 
hospital to perform a Point Prevalence Survey of all inpatients on a single day. The 20 
countries that took part were Austria, Belgium, Croatia, Czech Republic, Denmark, 
England, Estonia, Finland, France, Greece, Latvia, Lithuania, Malta, Netherlands, 
Northern Ireland, Norway, Poland, Scotland, Slovenia and Sweden. 
Neotide®, the Finnish company that maintains the software for the STRAMA, produced 
an English language version.  The software was customised for each hospital in that 
forms were based on their specialties and drug list.  All hospitals collected data by case 
note review. A preliminary workshop was held during the ESAC annual meeting in 
September 2005 to agree the main components of the survey and to adopt the modified 
STRAMA form for a Europe-wide Point Prevalence Survey.  A workshop for training 
on the methods for the Point Prevalence Survey and use of the web based software was 
organised in January 2006 in Prague. The training meeting reviewed pilot data from 
each of the participating hospitals and also used specimen cases from one hospital for 
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training in data entry in order to ensure consistency of interpretations of the indications 
for antibiotic use. 
Hospitals sent their antibacterial and department lists to the central team in Dundee to 
aggregate them according to the STRAMA protocol for generic drug names and 
standard department lists.  Although it was possible for STRAMA to adapt the lists 
there could be no change to the PPS protocol and therefore, STRAMA protocol for data 
collection in for Swedish hospitals was used.  Another open workshop was held to test 
the final version of the ESAC-STRAMA during an ECCMID (European Congress of 
Clinical Microbiology and Infectious Disease) meeting in April 2007. 
The survey was completed during two calendar weeks between 1st April and 31st May 
2006. Surgical wards were surveyed on Tuesday, Wednesday or Thursday in order to 
capture information about prophylaxis in the previous 24 hours.  Medical wards were 
surveyed on Monday, Tuesday, Wednesday or Thursday.  Depending on the number of 
beds, the hospitals could decide to complete the survey over one or more days.  
However, the protocol specified that all beds in each administrative unit (e.g. Internal 
Medicine, General Surgery) should be completed in a single day.  
Hospitals were asked to identify survey staff familiar with reading patient notes (e.g. 
infectious diseases specialists, microbiologists, pharmacists, infection control nurses).  
Hospitals could decide whether to have the survey completed by a single person or a 
team of people with relevant expertise.  
All patients who were in the hospital at 8.00 a.m. on the days of the survey were 
included in the study.  Patients who were receiving antibacterials at 8.00 a.m. on the day 
of the survey were identified and the details of the prophylaxis or therapy recorded on 
the data sheet.  For surgical patients, administration of prophylactic antibacterials was 
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recorded in the previous 24 hours.  The reason for this was to code the duration of 
prophylaxis as either one dose, one day or >1 day. 
ESAC- PPS data collection form and a screenshot of STRAMA web-based patient 
registry are presented in Appendices A.7.1 and A7.2.  
The diagnosis and indication for prophylaxis or treatment used the same diagnosis 
group, which was anatomically related to an organ or system.  In addition to looking at 
all patient records, staff could request additional information from nurses, pharmacists 
or doctors. However, there was no discussion about the appropriateness of prescribing 
because previous studies have shown very poor inter-rater reliability for measurement 
even after training.
288
 
152
  Hospitals were given an option to assess whether the 
antibiotic prescribed was consistent with their local antibiotic policy.  
The World Health Organisation‘s Anatomical Therapeutic Chemical (ATC) 
Classification of medicines was used to code antibacterials used.
265, 266
 All systemic 
antibacterials in J01,  and selected drugs from J04AB (only Rifampicin), A07AA (only 
oral Vancomycin and Colistin) and P01AB (only oral Metronidazole) classes were 
included.  Actual prescribed doses were recorded both for adults and children for single 
and combination antibacterials (e.g. 960mg of Co-trimoxazole).  Antibacterials are 
either presented by group (e.g. Cephalosporins) or by individual chemical substance 
(e.g. Cefazoline).  Where necessary, the route of administration has also been specified. 
The survey form and a print screen of the STRAMA data entry page are provided in 
Appendices 7.1 and 7.2. 
No personal patient data were collected and each patient was given a number during 
data collection and the same number was used during data entry therefore, approval of 
ethical committee was not considered for this survey.  
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This chapter presents key results. More comprehensive descriptive findings can be 
found in Appendix A.7.3  
7.4.1 Statistical analysis 
The 95% confidence intervals for the proportion of patients who received antibacterials 
in any hospital and for the ratio between prescribed daily doses and WHO Defined 
Daily Doses were calculated.
289
  The ratio of PDD to DDD was used to compare two 
measures for each of the antibacterials. These ratios were also used to compare 
differences between PDD and DDD for different antibacterials.  Hospitals were ranked 
by the percentage of patients who received antibacterials, and 95% confidence intervals 
(CI) for the ranks
290
 calculated using Monte Carlo simulation for repeated sampling 
from the normal distribution around the observed value for each hospital.
291
  Ten 
thousand simulations were performed in the calculation of 95% confidence interval of 
the rank. STATA version 9.2 was used for Monte Carlo simulations. 
7.4.2 Data validity 
STRAMA provided an online reporting system for most of the measures.  However, 
there were some inconsistencies, for example due to hospitals using drug trade names in 
different languages, and in some entered doses with implausible values. The whole 
database was therefore downloaded for cleaning and validation (including contacting 
hospitals to check inconsistencies and potential errors). The analysis presented here is 
based on the cleaned and validated database.  Published paper was performed directly 
on to the downloaded database.  
7.5 Results 
The twenty participating hospitals had a total of 15,593 beds (mean 778, median 672, 
range 247 to 2,459); fifteen were teaching hospitals with 14,360 beds (92% of the total) 
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and ten were tertiary care hospitals with 10,422 beds (67% of the total).  All hospitals 
had at least one Intensive Care Unit (ICU), sixteen had paediatric units and nine had a 
paediatric ICU.  Two hospitals (number 5 and 17) were infectious disease hospitals with 
747 beds and ten of the remaining hospitals had Infectious Diseases departments.  
Haematology and renal dialysis units were present in twelve hospitals and nine hospitals 
performed organ transplantation.  
On the day of the survey there were 11,571 patients in the 20 participating hospitals, of 
whom 3,483 (30.1%) were receiving antibacterials.  Of the treated patients 1,653 
(47.5%) were female and 371 (10.7%) were children <17 years old, of whom 145 (39%) 
were <5 years old. 
The proportion of patients receiving antibacterials ranged from 19% to 59% (Figure 
7.1a), with relatively narrow 95% CI for these proportions. On the face of it, this 
implies that it is relatively easy to distinguish hospitals with high and low proportions of 
patients treated with antibacterials. However, the 95% CI for the rank for each hospital 
show much greater uncertainty than the 95% CI for the proportion of patients receiving 
antibacterials (Figure 7.1b). For 12 of the hospitals the 95% CI for their rank crosses the 
median (10th) position so it is not possible to say with confidence that they are in the 
upper or lower half of the distribution for antibacterial use. However we can be 95% 
confident that four hospitals (5, 17, 2 and 20) are in the top 50% of antibacterial use and 
four hospitals (15, 9, 19 and 16) are in the bottom half. 
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Figure 7.1a:  Percentage of patients treated with antibacterials with 95% CI 
(vertical bars) for 20 hospitals in the ESAC Point Prevalence Survey 
 
 
 
 
 
 
 
 
Figure 7.1.b:  Estimated true ranks from 1 (highest) to 20 (lowest) users of 
antibacterials with 95% CI for ranks for the 20 hospitals in Figure 1a. 
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Treated patients received a total of 4,748 antibacterials. The indications were 
community acquired infection in 48.4% (n=2,299), hospital acquired infection in 30% 
(n=1,425), surgical prophylaxis in 15% (n=707), and medical prophylaxis in 6.7% 
(n=317). Examples of medical prophylaxis included long term prevention of recurrent 
urinary tract infection and prophylaxis in patients who were immunocompromised.  
Samples for bacterial culture were obtained before therapy for a similar proportion of 
adults (43.0%, 1,822/4,242) and children (54%, 275/506).  There was information about 
the indication for treatment in the case notes for 3,056 (64.4%) antibacterials.  
The commonest anatomical systems identified as the site of infection were the 
respiratory tract (28.9%) for treatment, and intra-abdominal (22.9%) for prophylaxis 
(Table 7.1).  The anatomical system was undefined for 569 (15.8%) antibacterials. Of 
these 275 (48%) were prescribed for sepsis with no defined site of origin, 168 (30%) for 
bacteraemia with no defined site of origin, and 126 (22%) antibacterials were prescribed 
to patients with completely undefined site of infection and with no systemic 
inflammation.  
The antibacterials used for community acquired pneumonia were mainly broad 
spectrum: quinolones accounted for 11.2% and third generation cephalosporins 10.3% 
of therapies, whereas beta-lactamase sensitive penicillins only accounted for 3% of 
therapies (Table 7.2). 
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Table 7.1:  Anatomical sites recorded for treatment and prophylaxis. The total 
(3,599) is greater than the number of patients treated (3, 483) because some 
patients had antibacterials prescribed for more than one anatomic site. 
System 
Site of 
infection 
% Prophylaxis 
% of 
prophylactic 
use 
Treatment 
% of 
treatment 
use 
Respiratory 867 24.1% 69 8.2% 798 28.9% 
Skin, Bone & Joint 650 18.1% 131 15.6% 519 18.8% 
Undefined 569 15.8% 103 12.3% 466 16.9% 
Intra-abdominal 540 15.0% 192 22.9% 348 12.6% 
Urinary tract 471 13.1% 99 11.8% 372 13.5% 
Otorhinolaryngology 163 4.5% 113 13.5% 50 1.8% 
Genital 133 3.7% 78 9.3% 55 2.0% 
Cardiovascular 108 3.0% 29 3.5% 79 2.9% 
CNS 86 2.4% 21 2.5% 65 2.4% 
Eye 12 0.3% 4 0.5% 8 0.3% 
Total 3599  839  2760  
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Table 7.2: Antibacterials for community acquired pneumonia (n=580 
antibacterials for 428 patients) 
Antibacterial group Number % 
Penicillins with betalactamase inhibitor 139 24.0% 
Macrolides 88 15.2% 
Fluoroquinolones 65 11.2% 
Third generation cephalosporins 60 10.3% 
Broad spectrum penicillins 56 9.7% 
Second generation cephalosporins 56 9.7% 
Other aminoglycosides 22 3.8% 
Penicillinase sensitive penicillins 17 2.9% 
Imidazol derivatives 13 2.2% 
Lincosamides 12 2.1% 
Carbapenems 10 1.7% 
Tetracyclines 9 1.6% 
Co-trimoxazole 7 1.2% 
Glycopeptides 6 1.0% 
Beta-lactamase resistant penicillins 5 0.9% 
Nitroimidazol derivatives (oral Metronidazole) 5 0.9% 
First generation cephalosporins 4 0.7% 
Fourth generation cephalosporins 3 0.5% 
Antituberculosis drugs (only rifampicin) 3 0.5% 
Sum 580  
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Duration of surgical prophylaxis  
In surgical departments 511 patients received 616 therapies for surgical prophylaxis.  
The duration of antibacterial prophylaxes for surgery were one dose in 26% (155/602), 
and one day in 16 % ( 99/602).  The duration of antibacterial prophylaxis for surgery 
was >1 day in 57.3% (384/602) of all patients who received prophylaxis, ranging from 
42.9% for paediatrics to 90.0% for otorhinolaryngology (Table 7.3, Figure 7.2). Single 
dose pre-operative prophylaxis was used in 25.2% of patients, ranging from 6.7% for 
otorhinolaryngology to 45.1% for gynaecology (Table 7.3, Figure 7.2).  
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Table 7.3: Duration of surgical prophylaxis for patients in surgical departments  
Department 
Number of patients  % of total for Department % of total for duration 
One 
dose 
One day > 24h Total 
One 
dose 
One day > 24h 
One 
dose 
One day > 24h 
General Surgery 66 36 137 244 27.0% 14.8% 56.1% 51.2% 42.9% 46.8% 
Orthopaedics 14 32 43 89 15.7% 36.0% 48.3% 10.9% 38.1% 14.7% 
Gynaecology 32 5 34 71 45.1% 7.0% 47.9% 24.8% 6.0% 11.6% 
Urology 7 6 43 56 12.5% 10.7% 76.8% 5.4% 7.1% 14.7% 
Otorhinolaryngology 2 1 27 30 6.7% 3.3% 90.0% 1.6% 1.2% 9.2% 
Paediatrics 8 4 9 21 38.1% 19.0% 42.9% 6.2% 4.8% 3.1% 
Total, all departments 129 84 293 511 25.2% 16.4% 57.3% 100% 100% 100% 
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Figure 7.2: Duration of surgical prophylaxis by anatomic site presented as 
percentage antibacterial therapy per duration from total antibacterials used for 
surgical prophylaxis. 
 
 
Comparison between average PDD and WHO DDD in adult patients 
For adult patients, a WHO DDD was available for 59 parenteral antibacterials and 47 
oral antibacterials that were used in the Point Prevalence Survey (Tables 7.4 and 7.5).
292
 
There was no difference in reported PDDs and WHO DDDs for 5 (10.6%) oral 
antibacterials and 11(18.6) parenteral antibacterials. The PDD exceeded the WHO DDD 
for 21 (44.7) oral antibacterials and 30 (50.9%) parenteral antibacterials.  The PDD was 
less than WHO DDD for 21 (44.7%) oral antibacterials and 18 (30.5%) parenteral 
antibacterials. In order to identify variables that might explain the relationship between 
PDD and WHO DDD, in this study the preliminary focus was on the ten most 
commonly prescribed antibacterials for adults.  In descending order these were: oral 
Ciprofloxacin (n=328), parenteral Cefuroxime  (n=307), oral Amoxicillin plus enzyme 
inhibitor (n=285) parenteral Metronidazole (n=264), parenteral Amoxicillin plus 
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enzyme inhibitor (n=253), parenteral Ciprofloxacin (n=198), Piperacillin plus enzyme 
inhibitor (n=160), Cefazolin (n=157), Ceftriaxone (n=139), Gentamicin (n=104) (Tables 
7.4 and 7.5).  It was not possible to analyse the relationship between PDD and WHO 
DDD by hospital because the range of use of all 10 drugs was from 22 to 291 therapies 
per hospital and not one of the 10 drugs was recorded in every single hospital.  
Therefore, the relationship between PDD and WHO DDD for the top three indications: 
respiratory, intra-abdominal and skin or soft tissue infections (Figure 7.3) were 
analysed.  We have only included eight drugs because there were less than 10 
treatments for respiratory infections with Cefazolin or gentamicin. The data do not show 
any consistent relationship between indication and the ratio between PDD and WHO 
DDD.  The 95% CI overlap for all drugs, suggesting that any differences are likely to be 
due to chance variation (Figure 7.3).  Although there are only two oral antibacterials 
represented the data clearly show that the relationship between PDD and WHO DDD is 
formulation dependent.  However, divergence may be different based on route of 
administration (for Amoxicillin plus enzyme inhibitors, the PDD to DDD ratio is higher 
for the oral formulation whereas the opposite applies to Ciprofloxacin). 
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Table 7.4: Average Ratio of PDD (prescribed Daily Dose) to WHO DDD 
(Defined Daily Dose) for oral antibacterials prescribed more than 10 times for 
adults with corresponding confidence intervals (CI)  
 
Substance  Count  Average PDD/DDD  CI 
1 Ciprofloxacin 328 0.99 0.47- 1.52 
2 
Amoxicillin and enzyme 
inhibitor 
285 1.82 0.06-3.58 
3 
Sulfamethoxazole and 
trimethoprim 
108 0.72 -0.43-1.87 
4 Metronidazole 105 0.61 0.43- 0.80 
5 Amoxicillin 103 1.71 0.05- 3.37 
6 Clarithromycin 79 1.74 0.80- 2.68 
7 Clindamycin 50 1.06 0.28- 1.84 
8 Doxycycline 44 1.67 0.30- 3.04 
9 Flucloxacillin 37 1.92 -0.97- 4.80 
10 Cefuroxime 35 1.70 0.69- 2.71 
11 Norfloxacin 29 0.97 0.60- 1.33 
12 Cefalexin 28 0.84 0.08- 1.61 
13 Ofloxacin 28 0.93 0.58- 1.28 
14 Trimethoprim 28 0.95 0.56- 1.33 
15 Phenoxymethylpenicillin 27 1.03 -0.34- 2.40 
16 Erythromycin 26 1.25 0.24- 2.27 
17 Moxifloxacin 23 1.22 -0.45- 2.88 
18 Rifampicin 22 1.31 0.10- 2.52 
19 Nitrofurantoin 20 0.87 -0.04- 1.77 
20 Vancomycin 13 0.25 0.12- 0.38 
21 Fusidic acid 11 0.94 0.55- 1.33 
22 Pivmecillinam 11 1.00 0.23- 1.77 
23 Dicloxacillin 10 1.33 0.37- 2.28 
24 Azithromycin 10 1.60 -0.84- 4.03 
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Table 7.5: Average Ratio of PDD (prescribed Daily Dose) to WHO DDD 
(Defined Daily Dose) for parenteral antibacterials prescribed more than 10 times 
for adults with corresponding confidence intervals (CI). 
  Substance  Average 
PDD/DDD 
Count     CI 
 1 Cefuroxime 0.97 307 0.14- 1.80 
2 Metronidazole 0.98 264 0.42-1.55 
3 Amoxicillin and enzyme inhibitor 1.12 253 0.23-2.00 
4 Ciprofloxacin 1.45 198 -0.70-3.59 
5 Piperacillin and enzyme inhibitor 0.93 160 0.50-1.36 
6 Cefazoline 0.97 157 -0.09-2.03 
7 Ceftriaxone 1.05 139 0.06-2.04 
8 Vancomycin 0.80 131 0.02-1.58 
9 Gentamicin 1.14 104 -0.90-3.17 
10 Ampicillin and enzyme inhibitor 3.85 93 1.21-6.48 
11 Benzylpenicillin 2.00 86 -0.52-4.52 
12 Clindamycin 0.95 85 0.28-1.62 
13 Imipenem and enzyme inhibitor 0.97 68 0.30-1.64 
14 Cefotaxime 1.46 67 0.10-2.82 
15 Ampicillin 2.43 57 0.37-4.49 
16 Meropenem 1.55 55 0.11-2.98 
17 Ceftazidime 1.09 50 0.28-1.90 
18 Flucloxacillin 3.36 37 -3.88-0.60 
19 Cloxacillin 3.26 35 0.37-6.14 
20 Amikacin 0.96 33 0.36-1.56 
21 Oxacillin 2.51 33 -0.06-5.08 
22 Teicoplanin 1.16 30 -0.04-2.36 
23 Cefoxitin 0.45 28 -0.06-0.95 
24 Amoxicillin 4.39 26 -2.16-10.95 
25 Ticarcillin and enzyme inhibitor 0.96 19 0.61-1.31 
26 Levofloxacin 1.38 17 0.31-2.45 
27 Cefipime 1.96 17 0.44-3.47 
28 Spiramycin 0.72 12 -1.00-2.44 
29 Netilmicin 0.79 11 -0.06-1.64 
30 Sulfamethoxazole and trimethoprim 1.45 11 -1.76-4.67 
31 Tobramycin 1.70 10 -0.30-3.70 
32 Erythromycin 2.07 10 -0.56-4.69 
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Figure 7.3: Ratio of prescribed daily dose (PDD) to WHO Defined Daily Dose 
(DDD) for eight formulations of antibacterials that were prescribed to at least 10 
adults for each of the three commonest indications for therapy.   
 
 
 
 
 
 
 
 
Bars show 95% confidence intervals.  Key: O=oral, P=parenteral, AMX+ENZ = amoxicillin plus enzyme 
inhibitor, PIP+ENZ = Piperacillin plus enzyme inhibitor, CZL = Cefazoline, CTX = Ceftriaxone, CIP = 
Ciofloxacin, MET etronidazole. 
Abbreviations: O AMX+ENZ: Oral Amoxicillin and Enzyme inhibitor.  P AMX+ENZ:  
Parenteral Amoxicillin and Enzyme inhibitor.  P PIP-ENZ: Parenteral Piperacillin and 
Enzyme inhibitor.  P CZL: Cefazoline.  P CFX: Parenteral Cefuroxime.  O CIP: Oral 
Ciprofloxacin.  P CIP: Parenteral Ciprofloxacin.  P MET: Parenteral Metronidazole. 
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7.6 Discussion 
This study showed that a web based method for collection of point prevalence survey 
data with automatic reporting could be implemented successfully in all 20 participating 
hospitals. The dataset that was analysed was limited than the original STRAMA dataset.  
Three measures in STRAMA protocol and PPS data collection forms (Appendix A.7.1), 
namely, assessment of the appropriateness of antibacterial therapy, information about 
implanted devices, and immunosuppression were not analysed.  Assessment of 
appropriateness was highly dependent on existing a local policy and personal judgments 
and two latter measures were rarely recorded.  However, a consistent method was 
established for collection of basic data about antibacterial use that will facilitate future 
cross-sectional and longitudinal comparison between hospitals and countries.  However, 
hospitals and policy makers need to be aware that data collection and processing are too 
time consuming to make frequent international hospital wide surveys a sustainable 
solution to the problem of overuse of antibiotics.  
Previously published studies show wide variation in the prevalence of antibiotic use, 
from 16.6% to 49.3% (Table 1.2, Chapter 1). However, this range of use is likely to be 
explained at least in part by the inconsistency of data collection with respect to the 
population of patients and the inclusion or exclusion of surgical prophylaxis (Table 1).  
It is striking that the STRAMA national surveys in Sweden in 2003 and 2004 reported 
almost identical prevalence (30.9% and 31.9%), which suggests that prevalence of use 
may remain stable over time.
293
   
In this survey there was wide (three fold) variation in antibacterial consumption 
between European hospitals (Figure 7.1a).  Nonetheless there was considerable 
variation in the ranking of hospitals and only 8 or the 20 hospitals could be reliably 
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placed in the top or bottom half of ranking by antibacterial use (Figure 7.1b).  Ranking 
is a notoriously unreliable method for comparing the performance of hospitals.
294
 The 
purpose of ranking was to assess the reliability of classifying hospitals as relatively high 
or low users of antibacterials as a precursor to understanding the hospital characteristics 
that may explain variation in antibacterial use.  For example, two of the four hospitals 
with antibacterial use reliably in the top half of the distribution were specialist 
infectious diseases hospitals.  Policy makers need to resist the temptation to rank 
hospitals by antibacterial use as a performance measure for two reasons.  First most of 
the variation in ranking cannot be distinguished from chance.  Second a significant 
proportion of systematic, non-chance variation in ranking is likely to be explained by 
differences in case mix.
295
 
Three targets were identified for quality improvement.  First, the duration of pre-
operative prophylaxis was >24 hours for the majority of patients in all surgical 
specialities.  While there is continuing debate about the effectiveness of single dose 
prophylaxis versus additional post-operative doses, 
296
 there is no evidence to support 
prolonging surgical prophylaxis for more than 24 hours.
297
  The target for prophylaxis 
>24 hours should therefore be 0% for all specialties.  
298
 Second, the range of 
antibacterials used to treat pneumonia was not consistent with evidence based 
guidelines that are in place in most European countries.
299
  In particular the use of 
penicillinase sensitive Penicillins was very low (Table 7.2).  Third, the documentation 
of antibacterial therapy is still poor.  Although the average for documentation of 
indication (64.4%) was higher than in previous audits 
300
 it is still unacceptably low. 
Documentation should be the rule, meaning that >95% recording should be expected.
298
  
The WHO DDD is the single most commonly prescribed daily dose worldwide.  
Because the use of antibiotics is much commoner in ambulatory care than in hospitals it 
ESAC PPS 160 
 
is expected that doses in ambulatory care would be lower than in hospitals so that the 
WHO DDD would be consistently lower than PDD, especially for oral drugs.  However, 
this study showed that the WHO DDD was almost as likely to be greater than PDD for 
oral and parenteral medicines.  Shifts between drugs could result in substantial change 
in DDDs used at hospital level that is purely due to changes in the drugs prescribed, not 
the number of patients treated.  For example a shift in antibiotic policy from parenteral 
Ciprofloxacin to parenteral Amoxicillin plus enzyme inhibitor would result in a 50% 
fall in DDD even if the same number of patients were treated for the same number of 
days (Figure 7.3). Consequently, differences between hospitals in antibacterial use 
measured in DDDs are explained at least in part by differences in the choice of drugs 
that are used, in addition to differences in the number of patients treated or the duration 
of therapy.  These results add to the evidence from ESAC ambulatory care studies, 
which suggests that the WHO DDD should not be used as the sole measure of 
antimicrobial use.
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7.7 Conclusion 
In conclusion, the strengths of this study are that web based PPS methodology can be 
applied successfully to surveillance of antibacterial prescribing in hospitals from 20 
different countries and that the results identify targets for quality improvement.  In 
providing a range of analysis for anatomic sites together with indications and most 
commonly used antibacterials, this chapter could provide an insight into hospital 
antibiotic use and highlight the areas that require further investigation.  The study could 
introduce a feasible standardised, reproducible, simple, and cost-effective system that 
can be used as a tool to improve quality of care in hospitals at regional, national, local, 
and hospital level.  The results could help countries develop cost-effective public health 
strategies and to inform best practises of management for individual patients.  It could 
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provide a tool that will allow recording of indicators and setting of targets for audit 
purposes which can be utilised to improve management of the individual patient, 
monitoring of antimicrobial policy, and to reduce antimicrobial selective pressure on 
hospital micro-organisms. 
The weaknesses of the study are that only included one hospital per country was 
recruited and the hospitals were very heterogeneous in size and specialty mix.  The 
method will require further testing with more hospitals in order to fully assess 
generalisabilty.  In 2006, the ESAC team made a successful bid to the European Centre 
for Disease Control (ECDC) to continue funding the project.  This bid included the 
method for Point Prevalence Survey that tested in this study.
302
  ESAC has developed 
and tested an online database in 52 hospitals in 2008 with the aim of conducting a much 
larger survey in 2009 in order to investigate hospital characteristics that explain 
variation in antibacterial use.  This study also added the value of a new collaboration 
with the World Health Organisation for point prevalence surveys on use of 
antimicrobials in children in the ARPEC project (Antimicrobial Resistance and 
Prescribing in European Children.
303
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CHAPTER EIGHT:  THE EUROPEAN SURVEILLANCE 
OF ANTIMICROBIAL CONSUMPTION (ESAC) – 
HOSPITAL CHARACTERISTICS 
8.1 Background 
Quality indicators measure various aspects of the quality of care provided.  They can 
apply to structures, processes or outcomes of care.
304
  Structural indicators focus on 
organisational aspects of care provision, such as the availability of specific clinics, 
appointment systems or equipment.  Longitudinal and Point Prevalence Surveys were 
the two main components of the ESAC-2 Hospital Care project (Chapters 5, 6 and 7).  
A questionnaire about a country‘s health-care system and hospital demographics was 
designed to identify potential explanatory variables in future comparisons between 
countries or hospitals.  In this chapter the characteristics of the hospitals that 
participated in the ESAC-2 HC Subproject are described.  The study used a mixed, 
partially close-ended and open-ended questionnaire to collect data about case-mix and 
organisational factors that might explain variation in longitudinal and cross sectional 
measures of antibiotic use. 
8.2 Aims 
To identify structural characteristics of European hospitals that might explain variation 
in the use of antibiotics. 
8.3 Introduction 
Different determinants at different levels, such as cultural, organisational and 
behavioural factors, might influence hospital antibiotic prescribing and cause antibiotic 
use to vary in different hospitals.  Understanding these hospital characteristics at 
regional, national, and international level can lead to improvements as these 
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determinants can provide a base on which to build strategies to enable more appropriate 
use of hospital antibiotics.   
As early as the 1970s it was recognised that to achieve effective control of hospital 
antibiotic use a combined approach from all levels and disciplines within and across the 
organisations was required.
305-307
  Establishment of a multi-disciplinary committee for 
antibiotic management as a separate team or as a part of a drugs and therapeutic 
committee helped organisations to promote their antibiotic prescribing activity.  Key 
functions of antibiotic committees that were identified in these early studies included 
development of local formulary and guidelines, evaluation of antibiotic use through 
regular audits, providing feedback to physicians, identifying areas requiring further 
study by hospital ward or by disease or antibiotic and education of students or staff.
305-
307
  Recent studies have emphasised the importance of integrating hospital infection 
control committees and hospital antibiotic management committees, with hospital 
therapeutics committees and pharmacy and microbiology departments are important 
steps toward improving antimicrobial use and reducing collateral damage from 
antibiotics in secondary care.
19, 238, 276, 308-311
 Nonetheless, despite over forty years of 
accumulated evidence about the benefits of antibiotic policies not all of hospitals adhere 
to elements of effective leadership in antibiotic prescribing.  The ARPAC study found 
that only 57% of 170 European hospitals had antibiotic policies.
312
 
Avorn stated that in teaching hospitals, prescribing decisions are frequently made by 
those with the least clinical experience (interns and residents) and, at the same time, 
each year hospitalised patients become more acutely ill and their cases increasingly 
complex.  These factors, combined with the continuous pressure of keeping length of 
hospital stays short, make it difficult to pursue a course of watchful waiting in managing 
a fever of unknown origin. 
313
  Such control is particularly difficult if the prescribing 
ESAC – Hospital Characteristics  164 
 
physician has been in practice for only a few months. The first priority becomes the 
prevention of disaster within the next 24 hours, a goal often thought to be met best by 
broad-spectrum antibiotics or a combination of narrower-spectrum agents used in 
combination.
313
   In a study of 145 hospitals across Germany university affiliation was 
associated with a comparatively high use of antibacterials measured in DDD/ patient-
day in the whole hospital, in the ICU and Haematology wards.  The authors suggested 
that in comparative analyses of hospital antibiotic consumption, data needed to be 
adjusted at least for university affiliation and haematology-oncology units.
283
  
Nonetheless, in 13 Norwegian hospitals despite variations in total use, the type of 
hospital did not have any association with total antibacterial use but type of therapeutic 
choice of antibacterial agents differed and university hospitals used more 3rd generation 
Cephalosporins. 
314
  In a multicentre study in 83 French hospitals being a public 
teaching hospital (OR= 10, P value=0.02) and having non-acute care beds less than or 
equal to 25% (OR=5.6, P value 0.03) were associated with higher antibiotic use.  
However, use of a nominative delivery form to record individual patient use of 
antibiotics was associated with significantly lower total use (OR= 0.3, P=0.04).  Other 
factors had no significant effect. 
315
   These studies suggest that hospital type affects 
antibiotic use and makes it more complex, however, this factor acts in different ways in 
different regions or countries.   
Antibiotic use in Intensive Care Units and Haematology units was much higher than 
medical and surgical wards in groups of hospitals in France and Germany.
315, 316
  In 47 
teaching hospitals in the US while all hospitals had antibiotic policies,  teaching 
hospitals were significantly more likely than other hospitals to have clinical practice 
guidelines for the treatment of community acquired pneumonia (OR, 4.2; CI95, 1.03-
17.4) or the use of Vancomycin (OR, 3.8; CI95, 1.03-14.3).  In the same study, hospitals 
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that routinely used either informal or formal pharmacy consultations for initial 
antimicrobial choice were less likely to have restriction policies (OR, 0.24; CI95, 0.07-
0.88).  However, a similar association was not found between hospitals reporting the 
routine use of infectious disease (ID) consultations to influence initial antimicrobial 
selection and having restriction policies (OR, 0.87; CI95, 0.24-3.12). 
317
 
Patients on maintenance haemodialysis are at a high risk of infection because of the 
prolonged need for vascular access, particularly in haemodialysis centres where many 
patients are receiving dialysis concurrently.  In this setting there are repeated 
opportunities for person-to-person transmission of pathogens, directly or indirectly, via 
contaminated devices, equipment and supplies, environmental surfaces, or the hands of 
health care workers.  These patients are at high risk of being colonised with 
antimicrobial-resistant bacteria like MRSA, VRE, Vancomycin-resistant enterococci, 
and multidrug-resistant gram-negative bacteria.  The use of antimicrobials in renal 
dialysis patients is much higher than in other patients.
318, 319
  In other hospital wards like 
haematology and organ transplant, patients are immunodeficient and receive multiple 
antibiotics for prophylaxis therefore, the use of antibiotics in hospitals with these 
specialities may be higher. 
 A multicentre survey included 2,000 patients with Community Acquired Pneumonia 
(CAP) treated at 5 different outpatient sites in 3 different regions of Canada.  The 
patients were prescribed a total of 23 different antibiotic regimens.  Significant 
variations in prescribing rates occurred for 17 of these antibiotics regimens across the 
different sites.
320
  Such variation suggests that local factors, such as formulary 
restrictions and opinion leaders, have a strong impact on actual patterns of antibiotic 
prescribing.  On the other hand, there is little evidence to suggest that national 
guidelines have much impact on individual antibiotic prescribing decisions.  In the same 
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study, only 46% of outpatients were prescribed antibiotics consistent with the American 
Thoracic Society guidelines.
321, 322
  For a cross-sectional questionnaire study about 
antibiotic treatment choice for CAP in the US, a sample of 400 generalist physicians 
and 429 infectious diseases specialists were selected.  The authors found that both 
generalists and ID specialists were more likely to prefer newer and broad spectrum 
antibiotics compared with older agents recommended by national guidelines.  The 
majority (64%) of infectious disease specialists disagreed with the statement that new 
drug development would keep pace with the problem of antibiotic resistance compared 
with 49% of generalists, yet the infectious diseases physicians had much stronger 
preferences for using newer drugs (e.g. Azithromycin rather than Erythromycin).
322
   
A study to assess the knowledge of junior doctors found that only 48 and 67%, 
respectively, could define severe sepsis and shock correctly.  Only 40% used the local 
sepsis protocol and 26.7% used microbiology or ID physician advice.  From the total, 
65% did not recognise that parenteral antimicrobials were significantly (10-fold) more 
expensive than oral antimicrobials which may contribute to excessive use of parenteral 
use and a late switching from parenteral to oral antibiotic therapy. 
323
 Another survey 
investigating the knowledge and attitudes of junior doctors about microbial resistance 
and antibiotic prescribing in 2 teaching hospitals in Scotland and France with different 
cultural contexts revealed that collectively from 139 participants, only 63% believed 
that resistance was a problem in their clinical practice and the perception that resistance 
was a problem was not influenced by their past training experience.  Trainees in two 
centres seemed to behave differently in seeking advice from senior colleagues, 
microbiologists and pharmacists in their prescribing decision. 
324
  Hospital antibiotic use 
is a multidisciplinary decision in conjunction with medical microbiologists, junior 
doctors, pharmacists and infection control nurses.  Nonetheless in a systematic review 
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of interventions to improve hospital antibiotic use only 17% of 66 eligible studies used 
multidisciplinary teams.
148
  Nosocomial infections are associated with low nurse/patient 
ratios. 
325
  Infection control nurses lead interventions like reducing the unnecessary use 
of urinary catheterisation in urinary tract infections 
326
 and campaign to target hand 
hygiene
327
 besides contributing to control measures such as barrier precautions hand 
washing, gloving, gowning, and isolation.   
The aim of this study was to document the availability of data that might explain 
variation in use of antibiotics by hospitals and to analyse the relationship between these 
data and two measures of hospital antibiotic use: point prevalence and total use in the 
previous year.  The literature reviewed suggested that five specialties are likely to have 
higher use of antibiotics: Haematology/Oncology, Infectious Diseases, Intensive Care, 
Renal Dialysis and Organ Transplant. Consequently beds were grouped from these five 
specialties and assessed the relationship between antibiotic use and the high user beds as 
a % of total.  
8.4 Methods 
8.4.1 Design of the hospital questionnaire 
A first version of the hospital questionnaire was designed from published literature and 
practice based knowledge. It was then reviewed by 28 members of the ESAC-2 Hospital 
Care project.  The team included ID consultants, microbiology consultants, ID 
pharmacists, epidemiologists, and ID nurses, all from the secondary care sector. During 
a workshop in January 2006 the questionnaire was developed and revised with 
reduction in the number of questions and clarification of key issues.  The final version 
had 45 questions in five categories covering a 6-year period starting from year 2000 on 
a yearly basis.  The questionnaire included both closed, quantitative questions and open 
ended descriptions.  It included five groups of questions: 1) population and hospital 
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demographic characteristics, 2) economic factors, 3) information about pharmacy stock 
and dispensing; 4) microbiology related factors, 5) managerial factors (Appendix 
A.8.1). 
Concerning population and hospital related factors, participants were asked for the 
following information:  the estimated population coverage of the hospital, number of 
beds, hospital category (teaching versus non-teaching) secondary or tertiary versus 
general district hospital.  The rest of the questions in the first block were about presence 
of specific specialities and the proportion of beds from the total.  The specialties were:  
ICU, paediatrics ICU, Paediatrics, infectious disease, renal dialysis, haematology, organ 
transplant, and long term care like psychology.  In the same block, hospitals were also 
asked about the number of pharmacists, ID physicians, microbiologists, and infection 
control nurses.  
Concerning economic factors, hospitals were asked about source of drug expenditure 
nationally and within the hospital, contribution of patients to drug expenditure, and 
financial incentives related to antibiotic prescribing. 
The third section had 10 questions about pharmacy stock and dispensing factors.  They 
included those factors that might influence collection of data in the ESAC longitudinal 
survey, which were supposed to be only from inpatient destinations. Examples were 
antibiotic supply from sources other than hospital pharmacy, exclusion of wasted drugs, 
of drugs returned drugs to the hospital pharmacy and the ability to identify antibiotics 
prescribed for administration in the community (prescriptions on hospital discharge or 
from outpatient clinics. There were also questions about occasional antibiotic shortages, 
removal of antibiotics from supply lists, drug donations or changes in dispensing 
strategies over the last 6 years.  
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Concerning microbiology related factors, changes in policy and facilities in quality and 
the selection criteria of patients‘ specimens was considered. 
The last group of questions included 13 questions on the presence of: Infection Control 
Committee (ICC) and Antibiotic Management Group (AMG), training medical students 
targeted at antibiotic prescribing, antibiotic guidelines in printed or electronic formats,  
online decision support systems against antibiotic prescribing as a routine basis, regular 
feedback on antibiotic use and resistance, interventions to improve antibiotic 
prescribing, and activities to improve antibiotic prescribing or infection control and 
hospital cleanness. 
Each hospital was allocated the same number as in the ESAC longitudinal and point 
prevalence surveys. 
8.4.2 Descriptive Analysis 
For continuous variables, in addition to standard deviations, the coefficients of variation 
(CV) were calculated.  In statistics, the CV is normalised and therefore a comparable 
measure of dispersion. 
   
                 
    
 
The standard deviation of data must always be understood in the context of the mean of 
the data.  The coefficient of variation is a dimensionless number.  So when comparing 
between datasets with different units or widely different means, one should use the 
coefficient of variation for comparison instead of the standard deviation. A CV <1 (or 
<100%) is considered as small variation, CV>1(or <100%) shows big variations in the 
outcome and a CV around 3 (or 300%) suggests complete dispersion.  The CV cannot 
be calculated when the mean of a variable is zero but this did not apply to any of the 
variables in this study.  
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8.4.3 Statistical analyses  
Various recommendations exist for the minimum number of observations for a valid 
multiple regression. With N being the number of observations and m being the number 
of predictor variables, Green 
328
 suggested: N ≥ 50 + 8m, where m is the number of 
predictor variables. Where assumptions are violated, greater sample sizes may be 
required.
328, 329
  In this study, the number of hospitals was too small to conduct a 
multivariate regression for any independent variable obtained from the PPS or LS 
projects.  Accordingly, simple regression was used to investigate the influence of each 
of the hospital characteristics on:  
1) Proportion of patients receiving antibiotics / total admitted patients in PPS and  
2) Total antibacterial use in year 2005 measured as DDD per number of beds.  
The information drawn out of the questionnaire consisted of continuous and categorical 
variables.  Correlations between the variables were examined, however the number of 
observations limited the method and number of variables that could be included.  The 
Phi (Φ) test is the same as Pearson correlation, for two categorical variables which is 
also a function of the chi-square of fourfold table.  Its improved versions are: Cramer‘s 
W and Cohen's W (the latter one for tables with more than 2 rows or columns). 
330
 The 
number of observations in each cell of a cross-tabulated table should not be less than 6. 
331
  In this study, all pairs of categorical cross-tabs had one or more cells with the 
number of observations less than 6.  The other way of finding correlation between 
categorical variables was logistic regression.  Logistic regression uses a maximum 
likelihood to get the estimates of the coefficients. According to Long, 100 is a minimum 
sample size, and at least 10 observations per predictor are needed. 
332
  Accordingly, for 
this study the pairs of categorical characteristics could not be tested for autocorrelations.  
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Pairwise correlations among variables of hospital characteristics were tested for those 
pairs where at least one was a continuous variable.   
STATA version 9.2 was used for statistical analysis.  
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8.5 Results 
The response rate was 90% (20 out of 22 hospitals). These hospitals also participated in:   
- PPS and LS: 14 hospitals  
- PPS and one year (2005) longitudinal data: 2 hospitals  
- LS only: 2 hospitals 
- PPS only: 2 hospitals. 
 
The majority of the hospitals submitted their questionnaire with only one year, 2005, 
data.  In total 34 questions were answered by nearly all hospitals from which 22 were 
categorical variables.  These variables were coded as no (1), to some extent (2), and yes 
(3) in the statistical analysis.  
8.5.1 Main characteristics 
In 20 hospitals, the total number of beds was 15,845.  1,841 beds (12% from total) were 
in 5 (25%) non-teaching hospitals and (88%) were in 15 (75%) teaching hospitals.   
There was 65% variation in hospital size which was less in non-teaching hospitals than 
teaching hospitals (39% versus 55%) (Table 8.1).  The definition of secondary and 
tertiary hospitals varied in different European countries so the outcomes of being a 
secondary or tertiary hospital were combined.  Only one hospital was a general district 
or primary care hospital.  The other 19 hospitals were secondary or tertiary and the 
variation in the number of beds was 62%, a little less than the total for hospitals because 
the general district hospital was a relatively small hospital.  
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Table 8.1: Descriptive data and coefficient of variation test results for general 
hospital characteristics and number of special hospital beds 
 
Number of 
hospitals 
Number of beds 
Total  (Range) 
Mean ± SDᶝ CV† 
Number of beds 20 15,845(243-
2459) 
793 ± 514 0.65 
Teaching  15 14,360(247- 
2,459) 
934 ± 517 0.55 
Non teaching  5 1,841(243-593) 368 ± 144 0.39 
General district  1 243   
Secondary or 
tertiary   
19 
15,611(247- 
2,459) 
822 ± 511 0.62 
Special Beds 
Number of 
hospitals 
responded 
(with non-
zero values) 
Range in 
percentage from 
total beds 
  
ICU 19 (19) 0.93- 9.1 3.4±2.1 0.62 
Paediatric ICU 14(9) 0-3.6 1.0±1.1 1.1 
Paediatrics  19(16) 0-38.1 10.2±10.2 1.0 
Infectious diseases   18(12) 0.0-100 7.2±23.2 3.2 
Infectious diseases  
excluding hospital 5  
17(11) 0.0-6.2 1.8±2.1 1.2 
Haematology  17(13) 0.0-6.0 2.4±1.9 0.8 
Renal dialysis  16(11) 0.0-4.3 1.4 ±1.4 1.0 
Organ transplant   15(3) 0.0-6.4 0.6 ±1.7 3.0 
Total special beds 
cause higher 
antibiotic use 
19 1.34-106.1 14.9 ± 22.7 1.5 
ᶝ: Standard deviation.  †: Coefficient of variation.  Number of special beds was not 
available from hospital 19. 
 
8.5.2 Special beds 
The second part of Table 8.1 presents the number of special beds which are assumed to 
be associated with higher or lower antibacterial use than the average use in each 
hospital.  The special beds do not necessarily correspond to the existence of a specific 
ward in all hospitals.  In some hospitals the specialty existed but the number of 
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allocated beds was not fixed.  All hospitals had ICU beds, except one.  Sixteen hospitals 
(84%) had paediatrics.  The frequency of having haematology, renal dialysis, and 
infectious disease beds were 68%, 58%, and 63%, respectively.  Only 3 hospitals had 
organ transplant beds.  Hospital 5, was an infectious disease (ID) hospital with 100% ID 
beds.  Excluding this hospital changes the range of ID beds from 0-100% to 0-6.2%.  
Paediatrics beds had the second largest range 0-38.1% with 100% variation.  The CV 
was lowest for ICU beds (62%), followed by haematology beds (80%). Variations for 
paediatrics ICU, ID beds (excluding one of the ID hospitals) and renal dialysis were 100 
to120%.  For organ transplant beds, the outcome (CV=300%) is completely dispersed. 
The total number of beds associated with higher antibiotic use ranged from 1.34% in 
hospital 22 to 106.1% in hospital 5 with a CV of 150% (Table 8.1).   
Figure 8.1 shows, by hospital presentation, the total percentage of beds with high 
antibiotic use and paediatrics.  The hospitals are grouped into teaching and non-teaching 
categories.  Hospital 5 is excluded from the first group (high user beds) as an outlier 
from the graph.  There was no information from hospital 19 in this set of questions.  
Hospitals 7, 16, and 17 had no paediatrics beds.  Hospitals 2, 12, 17, 18, and 1 with 
more than 15% special beds were teaching hospitals except for hospital 1. Hospitals 12, 
5, 11, and 18 with more than 15% paediatrics beds were all teaching hospitals. In 
teaching hospitals, the percentage of total special beds associated with a higher use of 
antibiotics and paediatrics was 16.8%±24.5%, CV=150% and 11.9% ± 11.3%, CV= 
95%, respectively.  In non-teaching hospitals, the average number of high user beds and 
paediatrics beds were 8.2%±5.4%, CV=66% and 5.4%±5.2%, CV =95%, respectively.  
In total the percentage of high user beds was 14.9%± 22.7%, CV= 153% and that of 
paediatric beds was 10.1% ± 10.3%, CV= 101%.  
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Figure 8.1:  Percentage of total number of high antibiotic user beds from total 
hospital beds (including: ICU, infectious disease, haematology, renal dialysis, and 
organ transplant) and percentage of paediatrics beds, low user beds. No 
information was available from hospital 19. Hospital 5 with 100% ID beds is 
excluded from the first group. 
 
 
 
 
 
 
 
 
 
8.5.3 Key specialities  
The next part of the questionnaire was the percentage of full-time employee (FTE) of 4 
clinical disciplines; ID physician, pharmacist, microbiologist, and infectious control 
nurse.  Hospital 13 could not provide data for the number of pharmacists.  
In 6 hospitals (4, 8,13,17,19, and 22), four of which were teaching hospitals, the number 
of ID physicians was zero (Table 8.2 and Figure 8.2).  There were more than 300% 
variations in the number of ID physicians including hospital 5 with 21 ID physicians per 
100 beds.  However, excluding hospital 5, the variation reduces to 110%.  Pharmacists 
were the largest group of clinicians (mean 1.5) and variations across the hospitals were 
80%.  The average number of pharmacists per 100 hospital beds in Europe was 
estimated to be 0.93. 
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pharmacists per 100 beds (hospitals: 20, 16, 21, 8, 7, 9, 14, 3, and 12), (Figure 8.2).  It 
included 36% of teaching hospitals but 60% of non-teaching hospitals.  The average 
number of pharmacists in teaching hospitals was 1.4 FTE/100 beds and 1.8 FTE/100 
beds in non-teaching hospitals.   
Figure 8.2:  Total number of full-time employee (FTE) specialties.  Hospital 5 
was excluded. Hospital 13 could not provide information about number of 
pharmacists. 
 
Table 8.2: Descriptive data and coefficient of variation test results for the 
number (%) of full time employee (FTE) specialties per 100 beds. 
Discipline 
Number of 
Hospitals
#
 
Range Mean ± SD* CV† 
ID Physicians 14(70%) 0.0-21.1 1.5 ± 4.6 3.1 
ID physicians 
excluding  
hospital 5 
13(65%) 0.0-1.9 0.5 ± 0.6 1.1 
Microbiologist  20(100%) 1.5-2.4 0.6 ± 0.6 1 
Pharmacist 19 (100%) 0.2-4.4 1.5 ± 1.3 0.8 
Infection control 
nurse  
20(100%) 0.1-1.3 0.4 ± 0.2 0.6 
# : Number of hospitals refers to hospitals with non-zero values. One hospital could not 
obtain data for number of pharmacists. *: Standard deviation.  
†:
 Coefficient of variation 
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The mean number of microbiologists in all hospitals was 0.6 FTE/100 beds with 100% 
variation (Table 8.2).  The mean number of microbiologists in teaching hospitals was 
0.66/100 beds and 0.44/100 beds in non-teaching hospitals. A greater number of 
microbiologists (>0.9/100beds) was present in four (20%) of the hospitals (numbers: 5, 
17, 9 and 4).  Hospitals 5 and 17 were ID hospitals (Figure 8.2). All hospitals had 
infection control nurses. The number of infectious control nurses was fewer than other 
clinicians (mean: 0.4/100 beds) ranging from 0.1/100 bed in hospital 12 to 1.3 in 
hospital 7 which was a non-teaching hospital. In two ID hospitals (5 and 17) the number 
of infection control nurses was close to the mean (Figure 8.2). Antibiotic management 
factors aggregated for all hospitals are presented in Figure 8.5.   
8.5.4 Pharmacy stock data and pharmacy dispensing policies 
Data were available from 19 hospitals.  One of the hospitals, hospital 13, could not get 
any information from its pharmacy department.  In 17 hospitals (90%), all antibiotics 
were supplied only by pharmacy stock while in two other hospitals, the drugs 
sometimes might be provided from out of hospital sources.  In 74 % (n=14) of hospitals, 
prescriptions at discharge were excluded from inpatient dispensing data. In 79 % (n=15) 
of outpatient clinics were excluded from in-patient destinations. In 53% (n=10) wasted 
drugs were deducted from pharmacy stock data and in 60 % (n=11) of hospitals 
returned drugs from hospital wards were deducted from pharmacy stock data (Table 
8.3).   
ESAC – Hospital Characteristics  178 
 
Table 8.3:  Pharmacy dispensing characteristics.  
 
To break down the information by hospital, the questions were split into 2 groups. 
Firstly, by factors which were likely to have a greater impact on the accuracy of 
pharmacy dispensing data – these were the exclusion of prescriptions at discharge and 
outpatient clinics.  Secondly: by factors which probably had less influence on the 
accuracy of pharmacy dispensing data – these were the supply of all antibiotics by 
hospital pharmacy, and the deduction of wasted and returned antibiotics from pharmacy 
stock data. Only Y answers (positive) were counted and T answers (to some extent) 
were excluded. Three (16%) teaching hospitals (2, 4, and 10) had the most precise 
pharmacy dispensing data with Yes answers to all questions. Twelve hospitals (63%) 
responded Yes to both major factors from which 8 were teaching hospitals (57% from 
14 total teaching) and 4 were non-teaching hospitals (80% from 5 total non–teaching 
Figure 8.3). This difference was not statistically significant (Chi-square with Yates‘ 
correction 2.1, p>0.1. 
 
Number of hospitals (percentage from total number of 
hospitals) 
Yes No To some extent 
All antibiotics provided by  
hospital pharmacy 
17(89.5) 1( 5.3) 1 (5.3) 
Prescriptions at discharge 
excluded 
14(73.7) 4 ( 21.1) 1 (5.3) 
Outpatient clinics excluded  15(79) 3(15.8) 1(5.3) 
Wasted drugs deducted from 
data 
10(52.6) 9(47.4) 0 
Returned drugs deducted from 
data 
11(57.9) 5(26.3) 3(15.8) 
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Figure 8.3: Precision of pharmacy dispensing data for measurement of antibiotic 
use by hospital inpatients. The maximum possible number of positive answers was 
two for major factors and three for other factors.  
 
8.5.5 Antimicrobial management factors 
Responses to this section of the questionnaire are summarised in Table 8.4 and Figure 
8.5.  Ninety-five % (n=19) of the hospitals had Infection Control Committees and 75% 
(n=15) had an established Antimicrobial Management Group.  In 80% (n=16) of 
hospitals there were locally developed antibiotic formulary and guidelines.  In 60% 
(n=12) of hospitals the guidelines were available electronically.  In 70% (n=14) of the 
hospitals the microbiology test results were available in electronic format.  In 26 % 
(n=5) of hospitals electronic prescribing for antibiotics was in use, however in most of 
the hospitals (58%, n=11) there was no form of electronic prescribing.  In 16% (n=3) of 
the hospitals this system was in place for specific antibiotics.  There was only one 
hospital with an online and patient specific decision support system for antibiotic 
prescribing.  In 60% (n=12) of the hospitals there was regular feedback to physicians 
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about antibiotic use and resistance, while in 40% (n=8) there were no established 
systems for audit and feedback.  None of the hospitals had financial incentives or 
penalties for physicians related to their performance on antibiotic prescribing or 
infection management.  Most 60% (n=12) of the hospitals conducted special sessions on 
antibiotic prescribing for final year medical students or junior doctors as a part of their 
education, while in the other 40% (n=8) there were no education programmes on 
antibiotic prescribing. Most hospitals had interventions to improve antibiotic 
prescribing, in 35% (n=7) these were continuous and in 30% (n=6) the interventions 
were not intermittent.  However 35% (n=7) of hospitals reported no interventions.  In 
40% (n=8) of the hospitals restriction policies were in place for specific antibacterials 
and in 45% (n=9) there were no restrictions on antibiotic prescribing.   
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Table 8.4:  Antibiotic prescribing management factors. Y: Yes, N: No, T: To 
some extent 
 
Number of hospitals (percentage from total number 
of hospitals) 
Y N T 
Infection management 
committee 
19(95) 1(5) 0 
Antibiotic management group 15(75) 4(20) 1(5) 
Local formulary/guidelines on 
use of antibiotics against 
diagnosis 
 
16(80) 3(15) 1(5) 
Electronic antibiotic 
policy/guidelines 
12(60) 7(35) 1(5) 
Online and patient specific 
decision support system for 
antibiotic prescribing  
1(5) 19(95) 0 
Regular feedback to physicians 
on antibiotic use and resistance 
12(60) 4(20) 4(20) 
Electronic prescribing 5(26) 11(58) 3(16) 
Electronic microbiology results 14(70) 3(15) 3(15) 
Financial incentives for the 
physicians based on their 
prescribing 
0 20(100) 0 
Antibiotic prescribing training 
for medical students and 
doctors targeted at antibiotic 
prescribing as a part of their 
education or on a regular basis? 
 
12(60) 8(40) 0 
Intervention to improve 
antibiotic prescribing 
7(35) 6(30) 7(35) 
Restrictions in supply of 
medicine e.g. a restricted drug 
procurement list against an 
approved formulary, stop orders 
8(40) 9(45) 3(15) 
 
This section included 12 questions.  Number 1 and 0.5 were assigned to two possible 
positive responses: ‗Yes‘ and ‗To Some Extent‘ respectively.  Hospitals 4 (9.5), 11 (9), 
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13 (8.5), and 1(8) had higher positive responses.  Hospital 20 had the lowest score of 
2.5. The mean of the scores was 6.7 ± 1.8.  It seems that there were fewer variations in 
this group of responses than other groups, however, statistically the standard deviation 
is not very indicative of variation when the maximum score is limited to 12 or even 11 
(none of the hospitals had financial incentive policies).  The mean score for teaching 
hospitals was 6.9 and for non-teaching hospitals was 5.8 (Figure 8.4).  
 
Figure 8.4:  Antibiotic management factors.  ‘Yes’ answers were regarded as 1 
and ‘To some extent’ as 0.5.  Total number of non-negative answers was added up 
for each of the hospitals. 
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Figure 8.5:  Antibiotic management factors aggregated for all hospitals given 
with the percentage of hospitals.  
 
 
8.5.6 Association between antibiotic use and hospital characteristics 
A simple regression was performed to assess the impact of hospital characteristics on 
hospital antibiotic use. Two measures of hospital antibiotic use were used separately: 
prevalence (% of patients receiving antibiotics on the day of the 2006 PPS) total 
antibiotic use in (DDD per 100 bed days in 2005). Since pharmacy dispensing 
characteristics are irrelevant to the number of treated patients in the PPS, this part of the 
questionnaire was excluded from PPS regression. The results are presented for 
significant regression coefficients and for two pre-specified variables: % of high user 
beds (Haematology/Oncology, ICU, Infectious Diseases, Organ Transplant, Renal 
Dialysis) and % of paediatric beds.  
The percentage of ID beds, number of ID physicians, number of microbiologists and the 
presence of electronic prescribing were associated with higher prevalence of antibiotic 
use in PPS 2006.  The presence of a training programme for medical students and 
doctors targeted at antibiotic prescribing as a part of their education or on a regular basis 
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in year 2005 was associated with lower prevalence antibiotic use in PPS 2006 (Table 
8.5).  
The number of organ transplant beds, and microbiologists was associated with higher 
total antibiotic use in DDD/100 beds in 2005. An antibiotic prescribing training 
programme for medical students and junior doctors was associated with lower total 
antibiotic use in 2005 (Table 8.5).   
The % of high user beds did have a positive association with antibiotic use measured by 
prevalence in 2006 or total use in 2005 (Table 8.6). However, association was weak and 
not statistically significant.  As expected there was a negative association between % of 
paediatric beds and total antibiotic use in DDD in 2005 but this was not statistically 
significant (p=0.174). There was a weak positive association between % paediatric beds 
and prevalence of antibiotic use in 2006 (p=0.067, Table 8.6). 
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Table 8.5:  Univariate regression analysis for independent variables: ratio 
patients received antibiotics/admissions and antibiotic in PPS, and use in DDD/Bed 
with hospital characteristics. Only significant results are reported. 
 
Dependent 
Variable 
Independent 
Variable 
Number of 
hospitals 
included in 
the analysis 
Regression 
Coefficient 
P-Value 
Treated 
patients/admitted, 
PPS 2006 
Percentage of  ID 
beds 
16 0.003 0.001 
 
Number of ID 
physicians per 100 
bed  
18 0.014 <0.001 
 
Number of 
microbiologist per 
100 beds 
18 0.102 <0.01 
 
AB prescribing 
training 
18 -0.09 0.03 
 
Electronic 
prescribing 
18 0.062 <0.01 
Antibiotic use in 
DDD/Bed, 2005 
    
 
Percentage of  
organ transplant 
beds 
13 150.6 <0.001 
 
Number of 
microbiologist per 
100 beds 
18 223.9 0.04 
 
AB prescribing 
training 
18 -266.94 0.04 
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Table 8.6:  Regression analysis of antibiotic use measured as prevalence in PPS 
2006 or total use in DDD/100 beds for 2005 over % of High User beds or Paediatric 
beds. High user beds were Haematology/Oncology, ICU, Infectious Diseases, 
Organ Transplant and Renal Dialysis 
  
Prevalence 
PPS 2006  
Total Use 
LS 2005 
High user beds with 
Hospital 5 
Regression coefficient 0.004 1.7 
 P value 0 0.6 
High user beds without 
hospital 5 
Regression coefficient 0.003 8.1 
 P value 0.3 0.6 
Paediatric beds Regression coefficient 0.005 -8.4 
 P value 0.07 0.2 
 
Pairwise correlations with a level of observational statistical significance are presented 
in Table 8.7.  Hospitals with a higher ratio of ICU beds were more likely to have a 
higher percentage of paediatric beds.  There was a negative association between the 
percentage of ICU beds and the supply of all antibiotics by hospital pharmacy.  The 
percentage of ID beds had a positive correlation with the number of ID physicians/100 
bed (correlation coefficient =1, P- value 0.000) and with the number of microbiologists 
/100 beds.  In hospitals with a higher ratio of ID beds the outpatient prescriptions were 
more likely to be excluded from pharmacy stock data.  The ratio of paediatric beds had 
a negative association with the supply of all antibiotics by hospital pharmacy.  This 
correlation has little value since there were 2 hospitals whose hospital pharmacy did not 
supply all the antibiotics.  Electronic prescribing systems for antibiotics were more 
likely to be present in hospitals with a higher proportion of paediatrics beds.  The 
percentage of renal beds and haematology beds were positively associated.  The 
percentage of haematology beds was positively correlated with the percentage of organ 
ESAC – Hospital Characteristics  187 
 
transplant beds, exclusion of prescription at discharge and outpatient dispensing, and 
existence of AMG in the hospital.  The percentage of ID physicians had a positive 
correlation with the percentage of microbiologists but a negative correlation with the 
exclusion of the supply of antibiotics to outpatient clinics in pharmacy stock data. The 
ratio of infection control nurses had a negative association with the existence of ICC but 
a positive association with having electronic microbiology results systems in the 
hospital.  In hospitals with a higher percentage of microbiologists it was less likely that 
returned drugs were deducted from pharmacy dispensing data.  Hospitals with a higher 
percentage of microbiologists were more likely to have interventions to improve 
antibiotic prescribing.  The number of beds was higher in teaching hospitals.  Larger 
hospitals were more likely to have restriction policies on prescribing antibiotics and less 
likely to have electronic microbiology test results.  Hospitals with a higher proportion of 
pharmacists were more likely to have electronic antibiotic guidelines and policies.  The 
number of pharmacists/100 bed had a negative correlation with being a secondary or 
tertiary hospital.  The number of pharmacists /100 beds had a negative association with 
the presence of an established AMG group.   
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Table 8.7: Pairwise correlations between the hospital characteristics. Only the significant correlations are reported. 
                       Pair of variables Correlation coefficient, P-Value, Number of observations 
1 % ICU beds % Paediatrics beds 0.52,0.02, 19  
2 % ICU beds All antibiotics by hospital pharmacy - 0.64, 0.003, 19 
3 % ID beds Number of ID physicians/100 bed 1, 0.000, 18 
4 % ID beds Microbiologists/100 beds 0.77, 0.000, 18 
5 % ID beds Outpatient prescriptions excluded pharmacy stock -0.55, 0.2, 17 
6 % Paediatrics beds All antibiotics by hospital pharmacy -0.66, 0.003, 18 
7 % Paediatrics beds Electronic prescribing 0.49, 0.04, 18 
8 % Renal beds %Haematology beds 0.53, 0.05, 14 
9 % Renal beds Patient pay for prescription 0.52, 0.04, 16 
10 %Haematology beds %  Organ transplant beds 0.56, 0.04, 14 
11 %Haematology beds Discharge Excluded from pharmacy stock data 0.51, 0.05, 16 
12 %Haematology beds Outpatient prescriptions excluded pharmacy stock 0.52, 0.04, 16 
13 %Haematology beds Antibiotic management group 0.53, 0.03, 17 
14 ID physician %100 beds Microbiologists/100 beds 0.79, 000, 20 
15 ID physician %100 beds Outpatient prescriptions excluded pharmacy stock -0.52, 0.02, 19 
16 Infection control nurses/ 100 
beds 
Infection management committee -0.84, 0.00, 20 
17 Infection control nurses/ 100 
beds 
Electronic laboratory results 0.44, 0.05, 20 
18 Microbiologists/100 beds Returned drugs are deducted from dispensing data -0.55, 0.01, 19 
19 Microbiologists/100 beds Intervention 0.53, 0.02, 20 
20 Number of beds Teaching  0.49, 0.03, 20 
21 Number of beds Electronic laboratory results -0.57, 0.01, 20 
22 Number of beds Restriction policy on prescribing antibiotics 0.49,0.03, 20 
23 Number of pharmacists/100 
beds 
Secondary or tertiary -0.50, 0.03, 19 
24 Number of pharmacists/100 
beds 
Antibiotic management group -0.58, 0.01, 19  
25 Number of pharmacists/100 
beds 
Electronic antibiotic policy and guidelines 0.44, 0.05, 19  
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8.6 Discussion 
Strengths of this study are that it used two different measures of antibiotic use with 
central processing and checking of data and that the participating hospitals were 
involved in the design of the questionnaire about hospital characteristics. Weaknesses of 
the study are that the number of participating hospitals (n=20) was too small for 
multivariate analysis, complete data on use and questionnaires were only available for 
16 (73%) of the hospitals and these hospitals were only able to answer the questionnaire 
for the previous year. The approach of the ESAC Hospital Care team was to collect high 
quality data from a small number of hospitals. However, the participating hospitals did 
not receive any additional funding for data collection and the results show the 
limitations of what can be achieved even with support for central data processing and 
analysis. The lack of readily available longitudinal data about hospital characteristics is 
likely to be a serious limitation for future surveillance studies that seek to explain 
variations in hospital antibiotic use. In larger, multinational studies such as ARPAC
312
 
the advantage of increased sample size is offset by concerns about data quality.
183
 
Regional or national networks of hospitals have been able to collect reliable data about 
antibiotic use
161, 190, 315, 316
 but only one study has also included detailed data about 
hospital characteristics from multiple hospitals.
315
 Collection of standardised, 
longitudinal data about hospital characteristics should have a higher priority in 
antibiotic surveillance.  
The ARPAC (Antibiotic Stewardship And Consumption) project published their 
findings from the questionnaire survey form 170 European hospitals.
312
  In ESAC-2 
hospitals, included in this chapter, 75% of hospitals had an Antibiotic Management 
Group (AMG) which is higher than 52% of the hospitals in the ARPAC study.  Local 
antibiotic formulary guidelines were in place in 80% hospitals in the present study 
ESAC – Hospital Characteristics 190 
 
 
whereas it was 77% with antibiotic formulary and 57% with antibiotic policy in 
ARPAC study. It seems that hospitals in the ESAC studies had more antibiotic control 
measures in place than the hospitals included in ARPAC study. In general, responses to 
detailed antibiotic management factors were similar across the ESAC hospitals. Only 
four (out of 12) factors had a prevalence of <50%; electronic prescribing, intervention, 
online decision support. Teaching hospitals had a wider range of antibiotic management 
scores compared to non-teaching hospitals with a bigger mean (Figure 8.4).  Therefore, 
teaching hospitals had more organisational support. However, in nearly half of hospitals 
(47%) and 60% of teaching hospitals the number of pharmacists was less than the 
average in European hospitals or 0.93%. 
333
  For example, hospital 2, a university and 
non-ID hospital in a western European country, was one of the extremely high antibiotic 
users in the PPS and LS, while this hospital had the lowest number of pharmacists 
0.17/100 beds, <1/5
th
 of the average number of pharmacists in the European countries.  
In six (30%) of hospitals there were no ID physicians. Guidelines on antibiotic 
stewardship emphasise the importance of pharmacists and ID physicians. 
148
 
46
  
Five specialties were identified likely to be associated with higher antibiotic use 
(Haematology/Oncology, Infectious Diseases, Intensive Care, Renal Dialysis and Organ 
Transplantation).  It was also expected that the % of paediatric beds would be associated 
with lower antibiotic use measured in DDD because prescribed daily doses for children 
are usually lower than the WHO DDD.  The variance in high antibiotic use beds 
(dispersion 150%) and paediatric beds (dispersion 100%) was considerably greater than 
the variance in total beds (dispersion 65%).  Nonetheless there were only weak, non 
significant associations between either of the measures of antibiotic use and either % of 
―high user‖ bed or % of paediatric beds.  However, number of Organ Transplant beds 
was associated with higher total use in 2005.  The interpretation of the results for 
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paediatric beds is limited by an outlier (Hospital 2), the hospital with highest paediatric 
beds and with high use of antibacterials in LS 2005 and in PPS.  Another likely 
explanation for these results is interaction (Table 8.6). For example, there was a 
significant positive correlation between the % of paediatric beds and % ICU beds or 
electronic prescribing. Hospitals with electronic prescribing had significantly higher 
total use than other hospitals (Table 8.3) so this plus % ICU beds is likely to have 
balanced the effect of % paediatric beds. Similarly the % of high user beds (e.g. 
Haematology) was positively associated with two Pharmacy characteristics: discharge 
prescriptions and outpatient prescriptions excluded from pharmacy stock. This means 
that antibiotic use in hospitals with lower % of haematology beds would be biased (over 
estimated) by inclusion of data about antibiotics dispensed at discharge or to 
outpatients. There were also potentially important interactions between the number of 
antibiotic specialists (ID Physicians, Microbiologists, Pharmacists) and variables that 
were associated with higher antibiotic use (Table 8.6). All of these findings suggest that 
meaningful analysis of hospital characteristics will require multivariable analysis.   
One positive finding from this study was that training on antibiotic prescribing for 
medical students and doctors as a part of their education was associated with lower 
antibiotic use by both measures, prevalence in 2006 and total use in 2005 (Table 8.6). 
However, this finding requires further validation, preferably through intervention 
studies. Overall the results of the present study demonstrate three key limitations of 
observational data for evaluation of the impact of antibiotic control measures. The first 
limitation is that the hospitals were unable to provide information about the timing or 
duration of the antibiotic control measures.  The second limitation is that in this study 
equal weights were given to all antibiotic management factors by assigning of 1 to all 
Yes responses, whereas some measures may have more impact than most.  A third 
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limitation is that the presence of a control measure does not mean that it has been 
implemented effectively. For example, an AMG is said to be critical for antibiotic 
policy, interventions, training, and audit and feedback
46
 the presence of an AMG does 
not guarantee that any of these interventions actually occur. For example, hospital 9 had 
no AMG but did have training, audit and feedback and interventions whereas hospital 3 
had an AMG but no training programme and non-continuous audit and feedback.  It can 
be concluded that an established AMG does not necessarily equal a dynamic leadership 
in antibiotic management, which may explain why there was no correlation between 
AMG and total use of antibacterials.  The final and arguably most important limitation 
is to question whether total use of antibiotics or prevalence of antibiotic use are good 
indicators to evaluate an  AMG or other antibiotic control measures. The ARPAC study 
also found no correlation between total antibiotic use and the presence of an AMG, 
antibiotic policy or formulary. 
312
  However, in the same study the same antibiotic 
control measures were all correlated to lower use of Cephalosporins, Macrolides, third 
generation Cephalosporins and Aminoglycosides. 
312
  It is likely that antibiotic 
prescribing management factors (Table 8.4) will be targeted at specific antibiotics or 
infections and are therefore better evaluated with intervention studies and more specific 
outcomes. Valid evaluation can be achieved with quasi-experimental designs including 
interrupted time series analysis.
148, 276
 
8.6.1 Study limitations 
The questionnaire did not include the impact of the pharmaceutical industry but 
advertising and promotion by the pharmaceutical industry is a major and powerful 
source of information for prescribers. 
334
  In a review of the literature on the interactions 
between physicians and the pharmaceutical industry, it was concluded that there was 
strong evidence that these interactions influence prescribing behaviour. 
335
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In this study, with one hospital per country with differences in health care system, it is 
especially hard to make judgments based on the comparison of a teaching hospital in 
one country with a non-teaching hospital in another country.   
Although the analysis of pairwise correlations was statistically justified, it can be 
affected by a low number of observations and high variations and the outlier hospital 5 
with the highest number of ID beds and ID physicians.  If this hospital was excluded,  
the number of observations would not only weaken the statistical analysis by reducing 
the number of hospitals, it could also undermine the nature of data that corresponded to 
variations in hospitals. Additionally, there might be other correlations that could not be 
justified by statistics.  In categorical variables a common cause of variance restriction is 
binning of continuous data, by reducing the original full range to a finite set of 
categories such as high/medium/low.  
For this set of hospitals there were none with financial incentives for prescribers and 
only one with online decision support systems.  However, these variables may be 
important factors for a study with higher number of hospitals from all European regions.  
8.7 Conclusion 
Although limited to 20 hospitals this study has identified potentially important 
descriptive information about hospital structure that was not addressed in previous 
studies 
312
 or current European projects. 
336
  
The information collected revealed potentially important differences between hospitals 
in case mix, hospital pharmacy data, organisational factors, and antibiotic management 
measures.  Furthermore, identified were potentially important interactions between 
these variables and suggest that future observational studies should be large enough to 
allow multivariable analysis. However, hospitals were unable to provide information 
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about these variables for more than one previous year and this is unlikely to change 
unless there are incentives for hospitals to collect and record the data.  Future studies of 
determinants of hospital antibacterial use from multiple European countries will need to 
define a standard dataset to be collected prospectively. 
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CHAPTER NINE:  CONCLUSION 
In this thesis I improved and implemented a series of methods that arise when drug 
utilisation research (DUR) is used to evaluate and manage hospital antimicrobial use.  I 
started to test and use the methods in Tayside followed by applying them to a set of 
European hospitals.  For the European study, ESAC, the research hypotheses needed 
design and implementation of new methods to identify and overcome barriers   to 
Europe–wide DUR of antimicrobials. In all studies in this thesis, clinical and hospital 
pharmacists had the central role in delivering the intervention and surveillances.    
In Chapter one, 1.2, the literature review described the importance of antimicrobial use 
in general as a worldwide issue.  Antimicrobials, like any other drug group, need regular 
research for their appropriate use.  Nonetheless, antimicrobials are fighting transferable 
diseases and their inappropriate use has resulted in transferable collateral damage in the 
form of antimicrobial resistance and Clostridium difficile infections.  The impact of 
these life threatening infections extends well beyond patients who receive antibiotics 
and they result in huge costs to the health care system.  Inappropriate use of 
antimicrobials is also affected by inappropriate use in the community either in primary 
care or through over the counter use.  Nonetheless, inappropriate use in hospitals is 
arguably a more important target for intervention because   hospitals are confined 
environments with more vulnerable patients and intensive, prolonged antimicrobial use 
where cross-infection is more likely to occur.  Standardised measurement of antibiotic 
use is an essential first step towards improvement of hospital antibiotic prescribing.   
In Chapter 1-3, I reviewed different measure and methods of evaluating hospital 
antibiotic use and showed that no single method can capture all quality outcome 
measures.  A combination of different methods can provide an accurate assessment of 
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hospital antimicrobial use and improve the reliability, discrimination and feasibility of 
the measures.  Few hospitals in Europe have electronic systems that can capture 
information about antibiotic prescribing to individual patients. Nonetheless, patient 
specific DUR through point prevalence surveys (PPS) combined with longitudinal 
surveys (LS) of total use and hospital demographics can capture comprehensive 
information about antimicrobial prescribing practice that can be used to assess use over 
time or compare use in different geographic areas. Nonetheless, my literature review 
identified important gaps in evidence about measurement of hospital antibiotic use.  The 
issues raised from previous studies showed that firstly, there are common 
inconsistencies in the methods together with misinterpretations and miscalculations.  
Secondly previous studies used single methods (either PPS or LS) to interpret hospital 
antimicrobial use.  In previous LS studies there was no statistical analysis or the 
methods used were not appropriate for longitudinal time series.  Finally, there was 
unresolved debate about methods for adjustment for clinical activity.  These gaps in the 
evidence about assessment of hospital antimicrobial use were addressed in this thesis.  
In Chapters 3 and 5 to 8, I applied the WHO ATC/DDD methods for drug classification 
and measurement. However, through point prevalence survey I was also able to 
document PDD (prescribed daily dose) in order to assess antimicrobial prescribing 
against patient and disease specific guidelines.  
In Chapter 2, time series analysis (TSA) and interrupted time series analysis (ITSA) 
methods, were reviewed and described.  By documenting the methodological and 
statistical issues in application of TSA and ITSA this chapter provides potential 
resources for researcher and policy makers.  The ITS and TSA techniques used in this 
thesis have rarely been applied to published studies of hospital drug use.  The ITSA 
method in chapter 3 used to assess the use and cost of the intervention reflected the gap 
Conclusion 197 
 
 
identified in review articles. 
148, 236, 276
  This study helped researchers to apply and 
improve method for evaluation of intervention and has been cited by 51 studies (ISI 
Web of Science 2009).  One limitation of the study was lack of comparator for the study 
hospital.  I implemented and improved my learning from ITS and TSA techniques for 
the statistical analysis of  evaluating the impact of devolution in UK 1995 and  increase 
in age exemption from prescribing charges in Wales in 2002 on antibacterial prescribing 
in primary care in four UK administrations with Belgium as the control country(cited 9 
times  in ISI Web of Science 2009, although only published in 2008).
337
   
In Chapter 3, I used ITSA techniques and DUR study to evaluate the impact of Alert 
Antibiotics intervention in Ninewells hospital.  I showed that evaluation of the 
intervention based on the clinical pharmacist records could be biased because there was 
no way to conceal allocation after the intervention and because very little data had been 
collected before the intervention.  Longitudinal analysis for two years before and after 
the intervention required record linkage between pharmacy stock data and clinical 
activity data.  It was time consuming and laborious since no systems were in place 
before this study.  The recommendations from this study were implemented in two other 
projects.  This study supported the intervention team, Tayside Antibiotic Subcommittee, 
to add a new tool for continuation of antimicrobial stewardship programmes in Tayside.  
Hence, I established records linkage assigned with the WHO ATC/DDD methodology 
for all anti-infectives included under BNF chapter 5 for Ninewells and Perth Royal 
Infirmary hospitals at hospital ward and clinical group  during 1999- 2004.  The written 
program was then embedded to regular pharmacy stock data.  Preliminary reasons was 
firstly, to evaluate the use and cost of Alert Antibiotic intervention on a continuous 
basis and secondly, to extend DUR from Ninewells to Perth Royal infirmary and 
thirdly, to put a system in place for regular feedback to clinical groups and evaluate 
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interventional programmes.  Results were reported to Tayside Antibiotic Subcommittee 
and presented in conferences.  The regular DUR system allowed further research. 
275
  
Having established the record linkage producing DUR of all anti-infectives was then 
used in a change programme for continuous quality improvement (CQI).  I collaborated 
to this phase, as the Quality Improvement Co-ordinator for Antibiotic Prescribing as a 
member of Steering Group.  During this time the Alert Antibiotic intervention was re- 
launched, quarterly DUR reports were provided for each Clinical Directorate in their 
meetings, area of more concern were highlighted for future interventions.  Under 
supervision of the CQI Steering group, I used statistical process control (SPC) as a 
simple tool to monitor antimicrobial resistance.  I tested the PDSA (Plan, Do, Study, 
ACT) as recommended by IHI (Institute for Healthcare Improvement) as simple 
interventional tool.  Finally, I contributed to establishment of Scottish Antimicrobial 
Group.  This Tayside experience contributed to a governmental recommendation 
338
 and 
further improvement in hospital antibiotic prescribing in Scotland. 
339
   
In Chapters 5 and 6 I applied TSA to pharmacy stock data and clinical activities.  In 
Chapter 5, the preliminary aim was to assess whether two denominators of clinical 
activity (admissions and bed-days or patient-days) may affect total use.  Furthermore, 
length of hospital stay and discharge were also estimated and included in regression 
model.  All outcomes were used to group the hospitals.  In chapter 6 through a series of 
complex statistical processes the trends in use of parenteral antibacterials, and 
Quinolones and third generation Cephalosporins were extracted and normalised by 
constants to produce the ―change‖ rather than ―time trends‖ so that the hospitals could 
be compared.  One key finding from these two chapters was that more than one clinical 
activity variable should be used to interpret changes over time.  Processing hospital data 
at product level, as mentioned in Chapter 5, was too laborious and time consuming.  
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After submission of the first report to ESAC in summer 2006, I re-validated databases 
several times so that the database became ready in November 2008.  However, I still 
encountered problems with outliers and structural breaks as described in Chapters 5 and 
6. 
In Chapter 7, the ESAC PPS I applied a statistical method for calculation of confidence 
intervals for ranking and concluded that this method should be applied in future 
comparison between organisations for their performance indicators.  The PPS chapter 
provided additional indicators of hospital antibiotic use.  The comparison of some of LS 
( pharmacy stock data) and PPS (patient specific data) outcomes for example: total use, 
proption of each drug from total use, proportion of use of parenterals and broad –
spectrum antibacterials after preliminary analysis were included in the report to ESAC 
and comprehensively presented for participating hospitals and are presented in the 
Appendix.  Nonetheless, there were too few hospitals to allow statistical analysis so 
these results were not included in the main body of the thesis.  The findings from 
chapters 5, 6 and 7 confirmed that no single measure can be used to evaluate antibiotic 
prescribing practice in hospitals.    
In Chapter 8, I showed that differences in hospital characteristics may explain some of 
the between hospital variation in antibiotic use identified in Chapters 5-7.  Nonetheless, 
lack of available longitudinal data about hospital characteristics is likely to be a serious 
limitation for future surveillance studies that seek to explain variations in hospital 
antibiotic use.  Furthermore the presence of an antibiotic control measure does not mean 
that it has been implemented effectively.  The study emphasises that central data 
collection and processing about hospital characteristics, case mix, and functionality of 
control measures is as important as central processing of antimicrobial use data.  
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In conclusion, this thesis provided evidence that there is no ―gold standard‖ for 
measurement of hospital antimicrobial use.   
I provided feedback of the results, covering more topics than those discussed in this 
thesis, to ESAC-2 participating hospitals within the preliminary report and various 
meetings.  By the end of the project and when ESAC-3 was launched, I designed a 
questionnaire and asked the ESAC-2 team to reflect on their experience from 
participating in ESAC-2 and the results of the study.  The common points raised from 
reflections were: 
 They presented the report in their hospitals or at regional and national level and 
got organisational support for continuous audit and feedback. 
 They implemented measurement of the duration of surgical prophylaxis in their 
regular audit and interventional studies at hospital or national level 
 They compared their results with other ESAC hospitals and presented these in 
their institutions 
 They found PPS very useful, easy to perform and have continued to use this 
method following the ESAC 2006 PPS  
The ESAC studies described in this thesis supported the ESAC project to continue and 
apply ESAC-2 methods to a larger number of European hospitals. 
253, 254, 256, 257, 340
  The 
experience from the Scottish hospital, from ESAC-2 was implemented across Scotland 
by the Scottish Antimicrobial Prescribing Group (SAPG) as the Hospital Medicines Use 
Database, launched in April 2010 (http://www.nelm.nhs.uk/en/NeLM-
Area/Evidence/Medicines-Management/References/2010---June/14/Development-of-a-
system-to-allow-comparison-of-Secondary-Care-medicines-utilisation-across-
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Scotland/).  SAPG used the same indicators recommended in the PPS chapter and set 
two targets for continuous quality improvement of hospital antimicrobial use across 
Scotland (>95% compliance with surgical prophylaxis <24h and with all empiric 
antibiotic prescriptions in medical or surgical admission units being compliant with 
local antibiotic policy) .  They also decided to use pharmacy stock data for LS which are 
analysed centrally at national level. 
341
 
342, 343
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What I learned from this thesis 
In this thesis I learned a series of analytical and statistical methods for each of the 
chapters.  I established regular DUR and feedback to clinicians and participated in a 
change programme in health system across Europe.  The foundation of standard DUR 
reports for Tayside took one year.  I applied and extended the findings to 20 hospitals in 
different European countries.  For this project, data were analysed centrally mainly by 
myself.  The databases were so different and laborious to work on that took more than 2 
years to make them ready for a PhD thesis.  Nonetheless, there is still uncertainty about 
raw data.  Administrative data result in errors that can be very large because of 
multiplication factors.  Additionally, even very extreme results in this thesis were not 
identified as being implausible by the staff responsible for data entry.  Comparison 
across countries and hospitals therefore requires both careful training of local data 
collectors, and a central checking process.  Pharmacy stock data and clinical activity 
data should be analysed centrally by each country and where the country has a large 
population by regions.  The ESAC project was unable to apply this possibly because of 
the limited budget.  Nonetheless, if the surveillance of hospital antibiotic is a global 
issue, the European Union and EU countries should allocate more resources to establish 
national or regional networks with central data processing.  The national networks for 
centralised process and analysis of hospital antimicrobial have been established in 
Sweden, Norway, and Netherlands.  In Scotland, SAPG and ISD (Information Services 
Division) have worked together to establish national antibiotic surveillance that can be 
linked to microbial surveillance through Health Protection Scotland.  The task of the 
central data process will be much easier for specialised computer programmers than for 
researchers.   
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During and after the ESAC- PPS 2006 with face to face feedback and discussions 
during ESAC, I learned that the structure of survey team affects collected data.  
Additionally, in one hospital one person performed the PPS whereas in another a multi-
professional team consisted of 20 members did the survey.  The information of the 
survey forms was entered into STRAMA by different people that in some cases had to 
estimate uncompleted information.  During set up the ESAC-3 proposal and after 
several feedback meetings, I found that even people from the same research background 
are different in their perceptions from a simple PPS form.   
Therefore, I conclude that DUR researchers should be supported by mathematicians, 
statisticians, econometricians, social scientists, and qualitative researchers.   
Finally, I learned that big studies, specially concentrating on total antimicrobial use are 
not enough.  DUR researchers need to move from big studies with big targets to 
interventional studies with simple and easy but clinically important outcomes.  As 
presented in Figure 9.1 improvement in hospital antimicrobial use like other health care 
change programmes consists of linked components.  Although, big studies like ESAC 
are successful in identifying the gaps and improve indicators of antimicrobial use, they 
need to be implemented and improved and translated into local needs.  Clinicians are 
supported with published evidence and guidelines.  Nonetheless, simple and easy audit 
and interventional tools like SPC and PDSA can produce more meaningful evidence for 
them in their daily practice.  
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Figure 9.1  The Path of Change 
   
 Recommendations for further studies 
The methods developed in ESAC-2 have the potential for further studies.  Evaluation 
the use of Alert Antibiotics can provide use of reserved antibacterials between European 
hospitals.  This study is suggested for LS and PPS data.  In this thesis I did not compare 
the detailed utilisation pattern of antibacterials across the hospitals.  However, I have 
contributed to paper entitled ―Drug Utilization 75% (DU75%) in 17 European Hospitals 
(2000 - 2005)‖  ESAC-2 Hospital Care Sub Project‖ which is submitted currently.344  
To implement a more comprehensive indicator of antibacterial use it was more 
appropriate to apply DU90% to capture the bigger bulk of use.  Nonetheless, for this 
manuscript with large number of hospitals it was technically difficult to include all 
antimicrobials in DU90% segment for one publication. 
From PPS data further analysis are suggested for use of antibacterials therapy in SSTBJ 
(skin, soft tissue, bone and joint) and for urinary tract infection.  
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In this thesis the potentially important interactions between hospital characteristic 
variables and use of antibacterials were identified.  Number of hospitals in ESAC-2 
project was small therefore, it is suggested to include enough hospitals in future studies 
to allow a multivariable and multilevel analysis. 
For future interrupted time series analysis, depending on study aims and design and 
when sufficient data are available use of control group may be appropriate.   
Key findings 
 Patient specific data (PPS) together with LS and hospital demographic can 
capture comprehensive  information about antibiotic use 
 Statistical methods should be used  in future DUR studies 
 Central data processing is important for minimising errors but is time consuming 
and is not available in most European countries 
 Lack of accurate longitudinal data and hospital characteristics limits the ability 
of observational studies to explain variation in antibiotic use 
 DUR researchers need to move from big observational studies to focused, 
interventional studies. 
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APPENDIX A.4: ESAC II- PROTOCOL FOR HOSPITAL 
CARE SUBPROJECT (HC), VERSION 3 JANUARY 2006 
Background  
In 2004 DG SANCO of the European Commission supported a second phase of the 
ESAC project for 2004-2007. The aim of the ESAC II project is to deepen the 
knowledge of antibiotic consumption in four specific areas: ambulatory care, hospital 
care, nursing homes and socioeconomic determinants of use. 
The aims of the ESAC II project are:  
- To consolidate the continuous collection of comprehensive antibiotic 
consumption data in all European countries which was established in ESAC I.  
- To develop health indicators of antibiotic use based on consumption data, to 
validate these indicators, and to use a set of core indicators to give feedback of 
the antibiotic consumption in the participating countries. 
- To deliver economic data on antibiotic consumption. 
The Hospital Care Subproject 
Within the ESAC I project it was recognised that there is currently no unified hospital 
information on antibiotic use across the European countries. The explanations include 
lack of standardised methods for producing valid data either for hospital antibiotic use 
or for denominator data related to clinical activity, such as occupied bed days or 
admissions. A recent study from the Netherlands suggested that an apparent increase in 
total antibiotic use from 1997 to 2001 was eliminated when the denominator was 
admissions rather than bed days. 
1
  The explanation was that there had been an 
increasing number of admissions over the period with decreasing mean length of stay. 
In order to prepare and agree on detailed objectives, methods, and recruiting meetings 
have been held in February 2005, June 2005, Sep 2005 and January 2006. Future 
meetings will be held on Sunday 2
nd
 April 2006 from 12:00-14:00 during 16
th
 ECCMID 
meeting in Nice where the final software will be demonstrated. ESAC cannot provide 
funding for this meeting, but will organise the meeting room.  Most probably there will 
be a final meeting at ECDC in Stockholm in September 2006.      
ESAC II- HC will focus on consistent data collection from individual hospitals in order 
to develop a standard method that can be rolled out to other hospitals in the participating 
countries. The project will start with one hospital in each of 23 countries. 
Structure  
Members of ESAC II- HC come from 23 countries: Austria, Belgium, Croatia, Czech, 
Republic, Denmark, Estonia, Finland, France, Greece, Germany, Latvia, Lithuania, 
Malta, Netherlands, Norway, Poland, Slovenia, Sweden, Turkey and the four countries 
of the UK (England, Northern Ireland, Scotland and Wales). From participating 
hospitals two hospitals (Lithuania and Malta) will participate in point prevalence study 
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and one-year (2005) longitudinal study and another hospital (Wales) will participate in 
longitudinal study only. 
The Project is lead by Prof Peter Davey from UK and co-ordinated with the ESAC 
project by Prof Herman Goossens.  The data management team (Faranak Ansari and 
Angela Johnston) is based in the Health Informatics Centre at the University of Dundee.  
Research Questions:  
What is the trend in hospital antibiotic use over the study period?  
What effect do different denominators (bed days or admissions) have on longitudinal 
analysis of hospital antibiotic use? 
What is the relationship between the DDD calculated from total antibiotic use and the 
actual daily doses prescribed in each hospital? 
Objectives & Deliverables 
Objectives  
1. Numerator definition 
2. Denominator definition 
3. Basic hospital statistics 
4. Standardised data reporting 
5. Identification of potential explanatory variables for future studies 
Deliverables 
1. Standardised longitudinal drug use data from at least one hospital per country 
2. Checklists for good practice in reporting longitudinal data and intervention 
studies 
3. Pilot web based methodology for point prevalence studies to measure use plus 
other patient specific data. 
4. Strategy for regional and national roll out 
5. Identification of potential explanatory variables and intervention targets for 
future research studies 
 
Methods 
Longitudinal Study 
Setting 
One hospital has been selected from each country (including one hospital each from the 
four UK countries, England, Northern Ireland, Scotland and Wales). For countries with 
pre-existing networks of hospitals the ESAC national representative has been asked to 
identify one hospital that will be able to support both the longitudinal and point 
prevalence components of the HC subproject. 
Given that the main question of the study requires analysis of time trends in 
antibacterial use, the details of country and hospital demography are of lesser 
importance. Nonetheless, a questionnaire about country health-care system and hospital 
demographics was designed and agreed to identify potential explanatory variables in 
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future comparisons between countries or hospitals. No European benchmarking will be 
performed in this subproject. 
Numerator: Antibiotic Use  
The study will focus on systemic antibacterials in the J01 sub-class according to ATC 
classification by the WHO Collaborating Centre for Drug Statistics plus oral 
metronidazole, oral vancomycin and colistin.  
Participants will provide number of dosage forms dispensed from hospital pharmacy to 
hospital as a whole.  Minimum database requirements are: 
- Dosage form with complete information on strength, package and route of 
administration 
- The inpatient destinations for dispensing 
- Preferably in generic name and in English language however French, Dutch and 
German language can be accepted. 
The amount of each product will be converted to WHO Defined Daily Doses (DDDs). 
DDDs will be those which are current when the analysis begins. Any products without a 
WHO DDD will be assigned a temporary ESAC DDD.  
Estimated PDD (Prescribed Daily Dose) will be provided by participant hospitals based 
on their local antibiotic policy or local or national formularies.  These data will be 
compared with actual PDD data collected in the point-prevalence survey. It is 
anticipated that estimated PDDs will be inaccurate and that this information will be 
important in demonstrating the added value of cross sectional, point prevalence studies.    
Denominator: Clinical Activity  
The project will compare two denominators: bed days and admissions. It is anticipated 
that annual increments in antibiotic use will be less when the denominator is based on 
number of patients (admissions or discharges) versus number of bed days. 
1
   
We will ask hospitals to define the methods that they use to measure bed days or 
admissions. We anticipate that the following methods are in use but will record other 
methods if they arise. 
Bed days  
1. Occupied bed days (OBD) calculated from daily census of the number of 
occupied beds at a specified time (e.g. midnight).  
2. Hospital care days calculated from daily census of the number of patients that 
have occupied each bed in a 24 hour period (can be >1 patient per day).  
3. Patient days (based on length of stay, e.g. date of discharge-date of admission -
1) 
Admissions 
1. Does the number of admissions include day cases? If so can day cases be 
excluded? If not does the hospital have data about % day cases by year?  
2. How are birth admissions included? Do they count as one admission or two? 
Has a consistent method been used throughout the study period? 
Time period 
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Monthly data will be collected for 5 years starting from January 2000 until December 
2005.  
Use indicators- DDD/100 bed-days and DDD/100 admissions will be the study 
indicators. 
Analysis- Time trends in antibacterial usage will be analysed for each participant 
hospitals within the 5-year period using time series analysis with statistical test for trend 
based on linear regression. 
 
Point Prevalence Study  
The STRAMA (Swedish Strategic Programme for the Rational Use of Antimicrobial 
Agents and Surveillance of Resistance)
2
 web based system for recording national 
Swedish point prevalence surveys will be used for the ESAC point prevalence survey. 
Mats Erntell has already worked with the Finnish company that maintains the software 
to produce an English language version:  
 
https://www.neotide.fi/esac  
Login: pps 
Password: **** 
To start the soft-ware: Login/password ****/**** 
 
The software has to be customized for each hospital that uses it based on their 
specialties and drug list. Therefore the pilot will be confined to one hospital per country. 
A workshop for training on the methods for the Point Prevalence Survey and use of the 
web based software was organised in January 2006 in Prague.  The hospital selected for 
the longitudinal study must also participate in the cross sectional point prevalence 
survey.   
 
Participating hospitals will provide: 
 List of specialties and subspecialties as administrative unit 
 List of available antibacterials (ATC class J01, J04AB, A07A, P01AB) in the 
hospital, with ATC codes and route of administration.  There are two columns 
for entering drug names. The generic name of the drug should be entered in 
English in Column 1 (e.g. amoxicillin, ciprofloxacin). The second Column 
should be used for the name that hospitals want to appear in the pull down menu 
for their web page when they enter data. This can either be one or more trade 
names for the drug or a translation of the generic name into their language. 
Hospitals also need to provide the maximum prescribed daily dose for each 
product. This will be used as an upper limit as a warning in the program but it 
will be possible to enter higher doses, so this should be the maximum dose that 
is likely to be prescribed for any patient.  
When: 
The survey should be completed during two calendar weeks between 1st April and 31
st
 
May 2006. Surgical wards should be surveyed on Tuesday, Wednesday or Thursday in 
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order to capture information about prophylaxis in the previous 24h. Medical wards can 
be surveyed on Monday, Tuesday, Wednesday or Thursday.  Depending on the number 
of beds hospitals can decide to complete the survey over one or more days. However, all 
beds in each administrative unit (e.g. Internal Medicine, General Surgery) should be 
completed in a single day.  
 
Who will perform:   
The person should be familiar with reading patients notes (ID specialist, microbiologist, 
pharmacist, infection control nurse). Hospitals may decide to have a team of people 
with specialist expertise in microbiology or infectious diseases. The HC Hospital lead 
will be responsible for training other members of the team. 
 
Who will be included: 
All patients who are in the hospital at 8 am on the days of survey should be included in 
the study. The number of admitted patients at 8 am at the departments is entered in the 
special form. 
Patients who are receiving antibiotics at 8am on the day of the survey should be 
identified and the details of prophylaxis or therapy recorded on the data sheet. 
For surgical patients administration of prophylactic antibiotics should be checked in the 
previous 24h. If so the details will be recorded as surgical prophylaxis.  The reason for 
this is to code the duration of prophylaxis as either C1 (one dose), C2 ( one day) or 
C3(>1 day). This information is recorded in the “Indication” field on the data entry form 
and website. 
 
What is the anatomical site of infection or prophylaxis? 
The diagnose and indication for prophylaxis uses the same “diagnosis group”,  ie most 
often related to an organ - skin, lungs etc. The aim is to find out what the physicians 
think they are treating.  For this we will look at all patient records, and may request 
additional information from nurses, pharmacists or doctors. There will be no discussion 
about the appropriateness of prescribing.  The staff should not have the feeling that we 
are checking them and there is no intention to change prescribing. 
 
Which drugs to include: 
Systemic antibacterials in J01, J04AB, A07A and P01AB classes.  Actual prescribed 
dose should be recorded both for adults and paediatrics for single and combination 
antibiotics (e.g. 960mg of co-trimoxazole).   
 
Technical support 
Prof Mats Erntell has kindly accepted to be the "help desk" for software problems 
during the PPS.  The software will be hosted on the STRAMA server 
Core data for the cross sectional point prevalence survey will be: 
Appendix A.4 254 
 
Feb 06 
- Proportion of patients treated with antibacterials 
- Patients’ age and gender 
- Antibiotic 
- Dose per administration 
- Number of doses per day 
- Route of administration 
- Anatomical site of infection or target for prophylaxis according to the list of 
diagnosis groups 
- Indication for therapy (community acquired infection, hospital acquired 
infection or prophylaxis) 
Possible optional fields:  
- Immunosuppression 
- Foreign material present 
- Relevant culture before therapy 
- Indication for given therapy in medical records 
- Assessment of given treatment against local (hospital, regional or national) 
antibiotic policy 
All of the fields (core and optional) are on the web based data record.  
Fields must be recorded for all patients in the survey. Hence, for a hospital’s data to be 
included in the PPS all of the core fields must be completed for all patients in the 
survey.  
The decision about optional fields is entirely at the discretion of each participating 
hospitals and can be left until the time of the survey. If a hospital finds that it does not 
have the resources to complete an optional field for all patients in the survey then this 
field will not be included in the analysis for that hospital. 
The training meeting reviewed pilot data from each of the participating hospitals and 
also used specimen cases for data entry at the meeting. 
Dissemination 
The results will be published on the ESAC website. The study team in Dundee and the 
STRAMA website will provide concurrent feedback to the participants and they will 
disseminate the results to their hospitals and local authorities. 
The study will be published by the ESAC hospital subproject principle investigators 
with ESAC Subproject Group as co-authors.  Feedback of the results for each hospital 
will be given to the country participants and they can publish their own individual 
hospital results with themselves as lead authors. 
Timetable 
The time schedule for the project is set out in Table 1 with progress achieved by the end 
of January 2006 coded with symbols: 
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  Table 1: ESAC II- Protocol for Hospital Subproject (HC)- Time table 
 Heading Update:  Date Due Status 
1.   Set up the project needs  
1.1 Decide on communication policy  Group 7
th
 Sep 05  
1.2 Confirmation of participant countries Group 7
th
 Sep 05  
1.3 Confirmation of participant hospitals Group 7
th
 Sep 05  
1.4 Confirmation of included drugs in the study  Group 7
th
 Sep 05  
1.5 Design a questionnaire about country and hospital demographics Dundee team, MF  30 Oct 05  
1.6 Providing the completed questionnaire     Group 15 April 2006  
1.7 Providing final software for PPS Group plus STRAMA 1 April 2006  
2.   Longitudinal Study 
2.2 Provide the Dundee team with a sample of database    Group 15 Oct 05   
2.3 Communication to clarify database specifications for Dundee team Dundee team, Group 15 Oct 05 – Apr 06  
2.4 Send monthly  pharmacy data from January 2000-Decmber 2005 Group 01 Feb- 01 April 06  
2.5 Send monthly admissions and occupied bed day data Jan 2000-Dec 05 Group 01 Mar- 01Apr 06  
2.6 Sending the PDDs for the systemic antibacterials  Group 01 Mar- 01Apr 06  
2.7 Data process and analysis     Dundee team 01Apr-01Oct 06  
2.8 Final report  Dundee team 01 Dec 06  
2.9 Dissemination on ESAC website ESAC team 01 Feb 07  
2.10 Manuscript Submission Group 01 Mar 07  
3. Point Prevalence Survey 
3.1 Confirmation of participant countries      Group Dec 2005  
3.2 Confirmation of participant hospital from each country  Group Dec 2005  
3.3 Drug list and specialty list sent to Mats Erntell at STRAMA Group 20 February 2006  
3.4 Completion of entry of five cases per hospital to prepare for the training meeting Group 23 Dec 2005 ? 
3.5 PPS Training Workshop  Group plus STRAMA Q1 06  
3.6 PPS Training Workshop (at ECCMID) Group plus STRAMA April 2006  
3.7 Data collection  Group April-May 2006   
3.8 Data process and analysis  Dundee Team Q3 06  
3.9 Final report                 Dundee Team 01 Dec 2006   
3.10 Dissemination on ESAC website ESAC team 01 Jan 2007  
3.11 Manuscript Submission  Group 15 Feb 07  
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Key to Implementation Status 
  –   Action completed ?  –   Not known, further information required 
  –   Action on course for completion   – Change to action originally planned 
  –   Progress made but slippage on 
planned timescale  
         – Decision not to progress 
  –   Little or no progress achieved  
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Appendix A.5.1: Tables of Time Series Plots 
 
Table A.5.1.1: Plots of antibiotic use in DDD or Y over time for all hospitals 
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Table A.5.1.2- Plots of Bed-days or B over time for all hospitals 
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Table A.5.1.3: Plots of admissions or A over time for all hospitals 
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Table A.5.1.4: Plots of lengths of stay or L over time for all hospitals 
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Table A.5.1.5: Plots of discharge or R over time for all hospitals 
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TableA.5.A. 6:  Plots of DDD per occupied bed-days or YPB over time for all hospitals 
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Table A.5.1.7: Plots of DDD per admissions or YBA over time for all hospitals 
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Table A.5.1.8:  Plots of antibiotic use in DDD (vertical axis) versus Bed-days (horizontal axis) or YB for all hospitals 
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Table A.5.1.9:  Plots of antibiotic use in DDD (vertical axis) versus admissions ( horizontal axis) or YA for all  hospitals 
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Table A.5.1.10: Plots of antibiotic use in DDD (vertical axis) versus length of stay or YL for all hospitals 
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Appendix A.5.2 : RESULTS OF THE TIME SERIES 
REGRESSION ANALYSIS- LONGITUDINAL STUDY 
ESAC 
In all the tables in this appendix, S.E. and S.D. denote standard error and standard 
deviation, B_G LM Statistic is the Lagrange Multiplier test for residual autocorrelation 
proposed by Breusch and Godfrey, and Q Statistic is the Ljung-Box Statistic.  
1.1.  Regression Analysis of the Data from Hospital Number 1 
Dependent Variable: tY    
Sample: 2000M01 2005M12   
Included observations: 72   
     
     
Variable
*
 Coefficient Std. Error t-Statistic Prob.   
     
     
tB  0.454097 0.073442 6.183041 0.0000 
Intercept -17.05715 754.6053 -0.022604 0.9820 
     
     
R-squared 0.530674     Mean dependent var 4383.243 
Adjusted R-squared 0.435218     S.D. dependent var 574.4119 
S.E. of regression 431.6818     Akaike info criterion 15.13524 
Sum squared resid 10994604     Schwarz criterion 15.54630 
     
B_G LM Statistic: 0.509253;     Prob. F(6,53) 0.798626 
Q Statistic 5.0446;     Prob. Chi-Square(6) 0.538 
     
* Seasonal dummies were included but their estimated coefficients of 
are not reported. 
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1.2.  Regression Analysis of the Data from hospital number 2 
Dependent Variable: tY    
Sample: 2000M01 2005M12   
Included observations: 72   
     
     
Variable
* 
Coefficient Std. Error t-Statistic Prob.   
     
     
tB  0.900141 0.146592 6.140439 0.0000 
Intercept -5175.403 2112.162 -2.450287 0.0173 
2t  0.734558 0.043365 16.93876 0.0000 
     
     
R-squared 0.869124     Mean dependent var 8929.465 
Adjusted R-squared 0.839790     S.D. dependent var 1419.750 
S.E. of regression 568.2720     Akaike info criterion 15.69574 
Sum squared resid 18730119     Schwarz criterion 16.13843 
B_G LM Statistic: 0.431743;     Prob. F(6,52) 0.854382 
Q Statistic 3.4281;  Prob. Chi-Square(6) 0.754 
     
* Seasonal dummies were included but their estimated coefficients of 
are not reported. 
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1.3. Regression Analysis of the Data from hospital number 3 
Dependent Variable: tY    
Sample (adjusted): 2000M02 2005M12  
Included observations: 71 after adjustments  
     
     
Variable
*
 Coefficient Std. Error t-Statistic Prob.   
     
     
tB  -8.165339 3.029973 -2.694855 0.0094 
1tB   7.893086 2.977818 2.650628 0.0105 
tA  242.0226 91.19717 2.653839 0.0104 
tR  -245.2843 91.19520 -2.689662 0.0095 
Intercept 24800.99 4827.008 5.137963 0.0000 
MA(1) 0.341500 0.149825 2.279327 0.0266 
     
     
R-squared 0.232054     Mean dependent var 13590.13 
Adjusted R-squared 0.004514     S.D. dependent var 2207.099 
S.E. of regression 2202.112     Akaike info criterion 18.43740 
Sum squared resid 2.62E+08     Schwarz criterion 18.97917 
     
B_G LM Statistic: 0.531749;     Prob. F(6,48) 0.781388 
Q Statistic 2.2957;     Prob. Chi-Square(6) 0.807 
     
* Seasonal dummies were included but their estimated coefficients of 
are not reported. MA(1) captures the residual dynamics.  
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1.4. Regression Analysis of the Data from hospital number 4 
Dependent Variable: tY    
Sample (adjusted): 2000M04 2005M12  
Included observations: 69 after adjustments  
     
     
Variable Coefficient Std. Error t-Statistic Prob.   
     
     
1tY   -0.785096 0.109130 -7.194099 0.0000 
2tY   -0.482277 0.109252 -4.414371 0.0000 
Intercept 55.87122 103.8089 0.538212 0.5922 
     
     
R-squared 0.442214     Mean dependent var. 31.73176 
Adjusted R-squared 0.425311     S.D. dependent var. 1136.762 
S.E. of regression 861.7593     Akaike info criterion 16.39833 
Sum squared residuals 49013524     Schwarz criterion 16.49547 
B_G LM Statistic: 1.003410;  Prob. F(6,60) 0.431659 
Q Statistic 5.0446;  Prob. Chi-Square(6) 0.538 
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1.5. Regression Analysis of the Data from hospital number 5 
Dependent Variable: ln tY   
Sample (adjusted): 2000M03 2005M12  
Included observations: 70 after adjustments  
     
     
Variable
*
 Coefficient Std. Error t-Statistic Prob.   
     
     
ln tB  707.2610 210.6873 3.356923 0.0016 
ln tA  -341.7690 104.0279 -3.285358 0.0020 
ln tR  -369.3104 107.2161 -3.444542 0.0012 
ln tL  -710.7488 211.0320 -3.367967 0.0016 
1ln tY   -0.321629 0.126308 -2.546390 0.0144 
1ln tB   865.1927 283.0196 3.057006 0.0038 
1ln tA   -417.2828 139.8754 -2.983248 0.0046 
1ln tR   -448.2346 143.2149 -3.129804 0.0031 
1ln tL   -865.8163 283.0070 -3.059346 0.0037 
Intercept 6.238129 2.766990 2.254482 0.0291 
     
     
R-squared 0.970454     Mean dependent var 0.006987 
Adjusted R-squared 0.954697     S.D. dependent var 0.395346 
S.E. of regression 0.084148     Akaike info criterion -1.840035 
Sum squared resid 0.318637     Schwarz criterion -1.037001 
B_G LM Statistic: 1.027840;     Prob. F(6,39) 0.421995 
Q Statistic 5.4606;  Prob. Chi-Square(6) 0.486 
     
* Seasonal and shift dummies were included but their estimated 
coefficients of are not reported. 
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Given the existence of outlier, the above graph does not show the tracking power of the 
model. We therefore plot below the actual and fitted values in a graph that excludes the 
outliers hence giving a better description due to scale correction. 
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1.6. Regression Analysis of the Data from Hospital number 6 
Dependent Variable: tY    
Sample (adjusted): 2002M02 2005M12  
Included observations: 47 after adjustments  
     
     
Variable
*
 Coefficient Std. Error t-Statistic Prob.   
     
     
tB  0.435899 0.126870 3.435800 0.0017 
Intercept -1868.037 1672.381 -1.116993 0.2723 
t 13.27332 3.305054 4.016069 0.0003 
AR(1) -0.394561 0.166935 -2.363559 0.0243 
     
     
R-squared 0.600637     Mean dependent var 4945.737 
Adjusted R-squared 0.425915     S.D. dependent var 493.6625 
S.E. of regression 374.0401     Akaike info criterion 14.94049 
Sum squared resid 4476993.     Schwarz criterion 15.53096 
     
B_G LM Statistic: 0.736728;     Prob. F(6,26) 0.624746 
Q Statistic 5.8763;  Prob. Chi-Square(6) 0.318 
     
* Seasonal dummies were included but their estimated coefficients of 
are not reported. AR(1) captures the residual dynamics.  
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1.7. Regression Analysis of the Data from hospital number 7 
Dependent Variable: tY    
Sample: 2000M01 2005M12   
Included observations: 72   
     
     
Variable
*
 Coefficient Std. Error t-Statistic Prob.   
     
     Intercept 4040.993 229.5136 17.60677 0.0000 
t -14.01800 10.14780 -1.381382 0.1725 
2t  0.458597 0.134602 3.407068 0.0012 
     
     
R-squared 0.666854     Mean dependent var 4083.272 
Adjusted R-squared 0.592183     S.D. dependent var 690.4637 
S.E. of regression 440.9340     Akaike info criterion 15.18833 
Sum squared resid 11276520     Schwarz criterion 15.63102 
     
B_G LM Statistic: 1.497529;     Prob. F(6,52) 0.197434 
Q Statistic 7.6273;     Prob. Chi-Square(6) 0.267 
     
* Seasonal dummies were included but their estimated coefficients of 
are not reported. 
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1.8. Regression Analysis of the Data from hospital number 8 
Dependent Variable: ln tY   
Sample (adjusted): 2000M02 2005M12  
Included observations: 71 after adjustments  
     
     
Variable
*
 Coefficient Std. Error t-Statistic Prob.   
     
     Intercept 9.732511 0.063513 153.2362 0.0000 
t 0.002168 0.001085 1.997832 0.0506 
AR(1) 0.397041 0.124081 3.199865 0.0023 
     
     
R-squared 0.772537     Mean dependent var 9.806051 
Adjusted R-squared 0.715671     S.D. dependent var 0.183088 
S.E. of regression 0.097627     Akaike info criterion -1.630118 
Sum squared resid 0.533738     Schwarz criterion -1.152087 
     
B_G LM Statistic: 0.784650;     Prob. F(6,50) 0.586045 
Q Statistic 5.2926;     Prob. Chi-Square(6) 0.381 
     
* Seasonal and shift dummies were included but their estimated 
coefficients of are not reported. AR(1) captures the residual dynamics.  
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1.9. Regression Analysis of the Data from hospital number 9 
Dependent Variable: tY    
Sample (adjusted): 2001M03 2005M12  
Included observations: 58 after adjustments  
     
     
Variable
*
 Coefficient Std. Error t-Statistic Prob.   
     
     
1tB   0.736599 0.087365 8.431303 0.0000 
1tA   -2.850515 0.415266 -6.864316 0.0000 
Intercept 4354.114 1480.002 2.941965 0.0051 
AR(1) -0.597508 0.131400 -4.547257 0.0000 
MA(1) 0.973618 0.027295 35.66990 0.0000 
     
     
R-squared 0.822281     Mean dependent var 10592.42 
Adjusted R-squared 0.778838     S.D. dependent var 1465.603 
S.E. of regression 689.2414     Akaike info criterion 16.09372 
Sum squared resid 21377415     Schwarz criterion 16.52384 
     
B_G LM Statistic: 1.056644;     Prob. F(6,36) 0.4048 
Q Statistic 62480;     Prob. Chi-Square(6) 0.181 
     
* Seasonal dummies were included but their estimated coefficients of 
are not reported. AR(1) and MA(1) capture the residual dynamics.  
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1.10. Regression Analysis of the Data from hospital number 10 
Dependent Variable: tY    
Sample (adjusted): 2000M02 2005M12  
Included observations: 71 after adjustments  
     
     
Variable
*
 Coefficient Std. Error t-Statistic Prob.   
     
     
1tY   0.844921 0.042662 19.80500 0.0000 
tB  -4.274486 1.536348 -2.782238 0.0074 
tA  29.59793 10.23078 2.893026 0.0055 
tL  17917.15 6423.370 2.789369 0.0073 
Intercept -123283.0 42834.48 -2.878126 0.0057 
MA(1) -0.983601 0.018640 -52.76690 0.0000 
     
     
R-squared 0.523325     Mean dependent var 15672.07 
Adjusted R-squared 0.382088     S.D. dependent var 1403.604 
S.E. of regression 1103.336     Akaike info criterion 17.05524 
Sum squared resid 65736948     Schwarz criterion 17.59701 
     
B_G LM Statistic: 1.429524;     Prob. F(6,48) 0.223027 
Q Statistic 9.3034;     Prob. Chi-Square(6) 0.098 
     
* Seasonal dummies were included but their estimated coefficients of 
are not reported. MA(1) captures the residual dynamics.  
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1.11. Regression Analysis of the Data from hospital number 11 
Dependent Variable: ln tY   
Sample (adjusted): 2000M02 2005M12  
Included observations: 71 after adjustments  
     
     
Variable
*
 Coefficient Std. Error t-Statistic Prob.   
     
     
ln tR  0.980834 0.242254 4.048779 0.0001 
ln tL  1.193358 0.343932 3.469755 0.0009 
Intercept -1.152078 2.555076 -0.450898 0.6536 
t 0.008016 0.002073 3.866234 0.0003 
2t  -6.90E-05 2.57E-05 -2.689738 0.0091 
     
     
R-squared 0.922550     Mean dependent var 9.422892 
Adjusted R-squared 0.916592     S.D. dependent var 0.261721 
S.E. of regression 0.075586     Akaike info criterion -2.246367 
Sum squared resid 0.371362     Schwarz criterion -2.055154 
     
B_G LM Statistic: 1.362161;     Prob. F(6,59) 0.244914 
Q Statistic 7.2599;     Prob. Chi-Square(6) 0.297 
     
* A shit dummy was included but its estimated coefficient of is not 
reported. 
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1.12.  Regression Analysis of the Data from Hospital Number 12 
Dependent Variable: tY    
Sample (adjusted): 2000M02 2005M12  
Included observations: 71 after adjustments  
     
     
Variable
*
 Coefficient Std. Error t-Statistic Prob.   
     
     
1tY   0.340986 0.102936 3.312595 0.0017 
tB  -0.094158 0.024329 -3.870202 0.0003 
tA  1.571175 0.333532 4.710711 0.0000 
tL  168.7663 40.63591 4.153131 0.0001 
Intercept -519.3450 784.5208 -0.661990 0.5110 
t -12.80094 5.190120 -2.466405 0.0170 
     
     
R-squared 0.866824     Mean dependent var 2971.050 
Adjusted R-squared 0.817210     S.D. dependent var 741.9428 
S.E. of regression 317.2098     Akaike info criterion 14.58953 
Sum squared resid 5131724.     Schwarz criterion 15.22690 
     
B_G LM Statistic: 0.843580;     Prob. F(6,45) 0.543200 
Q Statistic 5.8840;     Prob. Chi-Square(6) 0.436 
     
* Seasonal dummies were included but their estimated coefficients of 
are not reported. 
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1.13. Regression Analysis of the Data from Number 13 
Dependent Variable: tY    
Sample (adjusted): 2000M03 2005M12  
Included observations: 70 after adjustments  
     
     
Variable
* 
Coefficient Std. Error t-Statistic Prob.   
     
     
1tY   -0.864653 0.063405 -13.63698 0.0000 
Intercept 0.537762 12.40801 0.043340 0.9656 
MA(2) -0.955491 0.029020 -32.92502 0.0000 
     
     
R-squared 0.521507     Mean dependent var 33.27455 
Adjusted R-squared 0.507224     S.D. dependent var 1364.617 
S.E. of regression 957.9340     Akaike info criterion 16.60935 
Sum squared resid 61481714     Schwarz criterion 16.70571 
     
B_G LM Statistic: 0.785024;     Prob. F(6,61) 0.585011 
Q Statistic 3.8918;  Prob. Chi-Square(6) 0.565 
     
* MA(2) capture the residual dynamics.  
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1.14. Regression Analysis of the Data from Hospital Number 14 
Dependent Variable: ln tY   
Sample: 2000M02 2005M12   
Included observations: 71   
     
     
Variable
*
 Coefficient Std. Error t-Statistic Prob.   
     
     Intercept 9.756242 0.054386 179.3880 0.0000 
t 0.020397 0.002181 9.352617 0.0000 
2t  -0.000217 2.86E-05 -7.603508 0.0000 
     
     
R-squared 0.748229     Mean dependent var 10.02630 
Adjusted R-squared 0.690808     S.D. dependent var 0.161935 
S.E. of regression 0.090044     Akaike info criterion -1.802293 
Sum squared resid 0.462154     Schwarz criterion -1.356131 
     
B_G LM Statistic: 1.240879;     Prob. F(6,51) 0.301374 
Q Statistic 10.723;     Prob. Chi-Square(6) 0.097 
     
* Seasonal dummies were included but their estimated coefficients of 
are not reported. 
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1.15.  Regression Analysis of the Data from hospital number 15 
Dependent Variable: ln tY   
Sample (adjusted): 2000M03 2005M12  
Included observations: 68 after adjustments  
     
     
Variable
*
 Coefficient Std. Error t-Statistic Prob.   
     
     
ln tB  499.6413 238.6771 2.093377 0.0422 
ln tA  -239.9044 114.7637 -2.090420 0.0425 
ln tR  -262.5544 125.4771 -2.092448 0.0423 
ln tL  -502.9137 240.1492 -2.094172 0.0422 
1ln tY   -0.969470 0.050355 -19.25274 0.0000 
1ln tB   483.4159 239.3514 2.019691 0.0497 
1ln tA   -229.6148 114.2738 -2.009339 0.0508 
1ln tR   -254.1200 125.1285 -2.030873 0.0485 
1ln tL   -483.7197 239.3273 -2.021164 0.0495 
Intercept 12.42662 2.377864 5.225958 0.0000 
t 0.007070 0.001116 6.336308 0.0000 
     
     
R-squared 0.958252     Mean dependent var 0.009821 
Adjusted R-squared 0.934950     S.D. dependent var 0.405571 
S.E. of regression 0.103441     Akaike info criterion -1.422653 
Sum squared resid 0.460098     Schwarz criterion -0.606657 
     
B_G LM Statistic: 0.134798;     Prob. F(6,37) 0.990885 
Q Statistic 1.7127;     Prob. Chi-Square(6) 0.944 
     
* Seasonal and shit dummies were included but their estimated 
coefficients of are not reported. 
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Given the existence of outlier, the above graph does not show the tracking power of the 
model. We therefore plot below the actual and fitted values in a graph that excludes the 
outliers hence giving a better description due to scale correction. 
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1.16.  Regression Analysis of the Data from Hospital Number 16 
Dependent Variable: tY    
Sample (adjusted): 2002M01 2005M12  
Included observations: 48 after adjustments  
     
     
Variable
*
 Coefficient Std. Error t-Statistic Prob.   
     
     
tA  0.767332 0.346870 2.212162 0.0336 
Intercept 4130.653 515.2639 8.016577 0.0000 
     
     
R-squared 0.540628     Mean dependent var 4953.610 
Adjusted R-squared 0.383129     S.D. dependent var 559.3012 
S.E. of regression 439.2815     Akaike info criterion 15.23397 
Sum squared resid 6753888.     Schwarz criterion 15.74076 
     
B_G LM Statistic: 0.563875;     Prob. F(6,29) 0.755384 
Q Statistic 5.2975;     Prob. Chi-Square(6) 0.506 
     
* Seasonal dummies were included but their estimated coefficients of 
are not reported. 
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1.17  Regression Analysis of the Data from hospital number 17 
Dependent Variable: tY    
Sample (adjusted): 2000M02 2005M12  
Included observations: 71 after adjustments  
     
     
Variable
*
 Coefficient Std. Error t-Statistic Prob.   
     
     Intercept 42197.82 3120.978 13.52070 0.0000 
AR(1) 0.529408 0.114203 4.635687 0.0000 
     
     
R-squared 0.842814     Mean dependent var 53315.55 
Adjusted R-squared 0.806964     S.D. dependent var 13776.55 
S.E. of regression 6052.843     Akaike info criterion 20.42918 
Sum squared resid 2.09E+09     Schwarz criterion 20.87534 
     
B_G LM Statistic: 1.743922;     Prob. F(6,51) 0.129785 
Q Statistic 8.9531;     Prob. Chi-Square(6) 0.111 
     
* Seasonal and shift dummies were included but their estimated 
coefficients of are not reported. AR(1) captures the residual dynamics.  
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1.18.  Regression Analysis of the Data from Hospital Number 18 
Dependent Variable: tY    
Sample (adjusted): 2000M03 2005M12  
Included observations: 70 after adjustments  
     
     
Variable
*
 Coefficient Std. Error t-Statistic Prob.   
     
     
tA  -15.15090 8.088878 -1.873053 0.0667 
1tA   -4.288404 1.891701 -2.266957 0.0276 
tR  21.03824 9.909456 2.123047 0.0385 
tL  5660.750 1959.943 2.888222 0.0056 
1tL   -3961.802 1887.002 -2.099522 0.0406 
Intercept 5376.520 8059.662 0.667090 0.5077 
t 47.11114 12.38936 3.802549 0.0004 
     
     
R-squared 0.734381     Mean dependent var 31425.59 
Adjusted R-squared 0.647544     S.D. dependent var 2959.521 
S.E. of regression 1757.010     Akaike info criterion 17.99765 
Sum squared resid 1.61E+08     Schwarz criterion 18.57583 
     
B_G LM Statistic: 0.605585;     Prob. F(6,46) 0.724439 
Q Statistic 5.7784;     Prob. Chi-Square(6) 0.448 
     
* Seasonal dummies were included but their estimated coefficients of 
are not reported. 
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Appendix: A.7.3:  Further analysis of ESAC Point Prevalence Survey 
7.3.1 Prevalence of antibacterial treatment by patients 
Of the total 3,483 treated patients, 1,653 (47.5%) were female, with 226 (6.5%) aged 5-
16 years, and 145 (4.2%) aged <5 years (Figure A.7.3.1).  Mean ages of treated patients 
were: 55.9 (SD 25 years), 57.4 (SD 24.9 years) in females and 54.6 (SD 25 years) in 
male patients. On average, each of the treated patients received 1.36 antibacterials.  
Female and male patients received 1.32 (2,182/1,653), and 1.40 (2,566/1,830) 
antibacterials, respectively.  In twenty age groups the number of antibacterials per 
patient did not significantly different between men and women (P=0.55).  Exposure to 
multiple antibacterial therapies was more likely in younger and older patients.  The 
number of antibacterial therapies per patient for specific age groups was: 1.40 for age < 
5 years old, 1.33 for age<17, 1.36 for age≥65, and 0.73 for all other ages.   
Figure A.7.3.1:   Distribution of Patients Received Antibacterials by Age Group 
and Sex  
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7.3.2 Prevalence of documentation of indication in case notes in 
hospitals 
Indication Not Documented (IND) in case notes for all oral antibacterials ranged from 
0% in hospital number 22 to 52% in hospital number 6 (mean 13.8%, SD 15.2).  
Prevalence of IND for all parenteral therapies was as low as 0.9% in hospital number 1 
up to 100% in hospital number 22 (mean 27.4%, SD 27.5%). For all administration 
routes, prevalence of IND varied from 2% in hospital number 7 to 100% in hospital 
number 16 and 22 (mean 36.3%, SD 34.1).  Only in three (15%) of the hospitals 
(numbers 2, 7, and 22) was IND for all drugs and all administration routes less than 
10%, while in nine (45%) hospitals (numbers 4, 5, 6, 9, 11, 16, 17, 19 and 20) 
prevalence of IND was more than 25% for all drugs and all administration routes. 
(Table A.7.3.1) 
Table A.7.3.1:  Indication Not Documented (IND) in case notes in each of the 
hospitals 
 
IND by route for all drugs (%) IND for all drugs (%) 
Hospital number Oral Parenteral Total 
1 10.2 0.9 11.1 
2 0.6 2.9 3.5 
3 16.0 2.0 18.0 
4 9.8 39.3 49.1 
5 7.8 17.8 25.6 
6 52.5 37.6 90.1 
7 1.0 1.0 2.0 
8 5.6 2.0 7.6 
9 7.0 43.7 50.7 
10 8.9 12.2 21.0 
11 46.2 52.3 98.6 
14 10.2 6.3 16.5 
15 3.6 21.1 24.7 
16 29.6 70.4 100.0 
17 7.4 46.2 53.5 
18 3.6 8.9 12.6 
19 9.4 18.0 27.3 
20 38.0 57.3 95.3 
21 9.5 7.6 17.1 
22 0.0 100.0 100 
Mean (SD) 13.8 (15.2) 27.4 (27.5) 36.3 (34.1) 
Total 13.4 22.3 35.7 
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7.3.3 Prevalence of taking relevant cultures before antibacterial 
therapy 
Adult patients received 1,544 oral antibacterials.  Relevant cultures had not been taken 
before starting oral therapy in 55% of patients.  For 2,696 parenteral therapies in adult 
patients, relevant cultures had not been taken before starting therapy in 53% of patients. 
For children, relevant cultures had not been taken in 45% (unknown in 1%).  Children 
received 142 oral antibacterials, with cultures not taken in 56%, compared to 40% of 
364 parenteral antibiotics (Table A.7.3.2).  Children were somewhat more likely to have 
cultures taken before commencing therapy, and case note documentation was more 
complete than in adults.   
Table A.7.3.2:  Prevalence of taking cultures before starting antibacterial therapy 
in adult and children given as percentage for total antibacterial therapies for two 
patient groups.  
Adults (aged17 & over) Yes No Unknown 
Oral 40.6% 55.1% 4.3% 
Parenteral 44.3% 53.0% 2.7% 
Children (aged <17) 
 
Oral 42.3% 55.6% 2.1% 
Parenteral 59.1% 40.1% 0.8% 
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Table A.7.3.3 shows the prevalence of taking cultures before antibacterial therapy for 
Community Acquired Infection (CAI) and Hospital Acquired Infection (HAI) by the 
number of antibacterial therapies. Taking relevant microbiological tests was more 
common in HAI (58.1%) than in CAI (52.8%).    
Table A.7.3.3:  Prevalence of taking cultures before treatment by percentage for 
total number of antibacterial therapies for CAI (community acquired infection) 
and HAI (hospital acquired infection) 
  CAI HAI 
Yes (%) 52.8 58.1 
No (%) 44.1 37.8 
Unknown (%) 3.1 4.1 
 
7.3.4 Analysis by clinical groups 
On the day of the survey, distribution of the total of 3,483 treated patients in 6 main 
departments including Departments of Medicine, Surgery, ICU, Paediatrics, Obstetrics 
& Gynaecology, and Geriatric medicines was 41.1% (1,432), 35.5% (1,237), 7.2% 
(250), 10.7% (371), 4.7%(182) and 0.32% (11), respectively.  The proportion of all 
antibacterial therapies (4,748) in the departments of Medicine, Surgery, ICU, 
Paediatrics, Obstetrics & Gynaecology, and Geriatric Medicine was 41% (1,964),  
34.6% (1,657), 8.1% (386), 10.6% (506), 4.7% (224) and 0.2%, respectively.  The total 
use of antibacterials was 5,916 DDD.  In Table A.7.3.4, more measures are provided for 
each clinical group.  The percentage of prescribed daily doses (PDD) has the same 
ranking as the use in DDD.  The ratio of PDD to DDD in different departments is more 
than 1.8 (other departments including Geriatric Medicine and Genecology & Obstetrics) 
suggesting that the total use in DDD for hospitals overestimates the number of patients 
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exposed to antibacterial therapy.  The noteworthy finding is the higher ratio PDD/DDD 
in Paediatrics (2.1) than in Medical Departments (1.9) (Table A.7.3.4).    
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Table A.7.3.4: Prevalence of antibacterials prescribed in main clinical groups. 
Other includes Geriatrics Medicine and Genecology & Obstetrics. PDD: 
Prescribed Daily Dose, AB: Antibacterial 
Clinical group Medicine Surgery ICU Paediatrics Other 
Number of patients 1432 1237 250 371 193 
% of total 41.1 35.5 7.2 10.7 5.5 
Number of therapies 1964 1657 386 506 235 
%  of total 41.0 34.6 8.1 10.6 4.9 
Number of DDDs 2689 2083 537 371 236 
% of total 45.5 35.2 9.1 6.3 4.0 
Number of PDDs 5,201 4,480 1,371 773 420 
% of total 42.5 36.6 11.2 6.3 3.4 
PDD/DDD 1.9 2.2 2.6 2.1 1.8 
DDD/AB 1.4 1.3 1.4 0.7 1.0 
DDD/Patient 1.9 1.7 2.1 1.0 1.2 
PDD/ Patient 3.6 3.6 5.5 2.1 2.2 
Number of AB/patients 1.4 1.3 1.5 1.4 1.2 
 
7.3.5 Analysis by anatomic site of therapy 
The greatest proportion of antibiotics were used in treating infections in the respiratory 
tract (24.1%), followed by Skin, Soft Tissue, Bone & Joint (SSTBJ) (18.1%), undefined 
site (15.8%), intra-abdominal (15%) and urinary tract (13.3%).  The undefined site 
included bacteraemia, Systemic Inflammatory Response Syndrome (SIRS) with no clear 
anatomic site, and undefined site with no systemic inflammation.  The prevalence of 
patients who received antibacterials for five other anatomic sites was less than 5%.  The 
commonest anatomical systems were the respiratory tract (28.9%) for treatment and 
intra-abdominal (22.9%) for prophylaxis (Table A.7.3.5).  The anatomical system was 
undefined for 569 (15.8%) patients: 275 of these patients had sepsis, 168 of these had 
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bacteraemia with no defined site of origin. One hundred and twenty-six antibacterials 
were prescribed to patients with an undefined site of infection and with no systemic 
inflammation.  The proportion of patients who received antibacterials for prophylaxis 
after intra-abdominal surgery were higher for SSTBJ, Otorhinolaryngology, and 
undefined with 15.6%, 13.5% and 12.3% respectively for these anatomic sites.  In the 
treatment group following the respiratory tract, the other main anatomic sites more 
prevalent among treated patients were SSTBJ (18.8%), Undefined (16.9%) and urinary 
tract (13.5%) were the other anatomic sites more prevalent among treated patients.   
Table A.7.3.5  Anatomical sites recorded for treatment and prophylaxis. The 
total (3,599) is greater than the number of patients treated (3, 483) because some 
patients had antibacterials prescribed for more than one anatomic site. 
System 
Diagnosis 
site  
% Prophylaxis 
% total 
prophylaxis 
Treatment 
% total 
treatment 
Respiratory 867 24.1% 69 8.2% 798 28.9% 
Skin, Bone & Joint 650 18.1% 131 15.6% 519 18.8% 
Undefined 569 15.8% 103 12.3% 466 16.9% 
Intra-abdominal 540 15.0% 192 22.9% 348 12.6% 
Urinary tract 471 13.1% 99 11.8% 372 13.5% 
Otorhinolaryngology 163 4.5% 113 13.5% 50 1.8% 
Genital 133 3.7% 78 9.3% 55 2.0% 
Cardiovascular 108 3.0% 29 3.5% 79 2.9% 
CNS 86 2.4% 21 2.5% 65 2.4% 
Eye 12 0.3% 4 0.5% 8 0.3% 
Total 3599  839  2760  
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7.3.6 Analysis by indication  
In total, 3,587, indications were recorded for 3,483 patients, of which 104 applied to 
patients with more than one indication.  CAI was the indication in 47.5% (1703/3,587), 
compared to HAI 28.9% (n=1038), surgical prophylaxis for 16.8% (n=602), and 
medical prophylaxis for 6.8%.  More patients therefore received antibacterials for 
treatment (76.4%) than for prophylaxis (23.6%) (Table A.7.3.6).  
Table A.7. 3,6:  Indication for therapy 
Indication for therapy  
Number of  
patients 
Percentage of  
total patients 
A. Community acquired infection 1,703 47.5% 
B1. Postoperative infection 307 8.6% 
B2. Other intervention related infections 145 4.0% 
B3. C. difficile enterocolitis 33 0.9% 
B4. Other hospital acquired infections 492 13.7% 
B5. Infection is present at admission from 
another hospital 
61 1.7% 
B. Hospital acquired infection total 1,038 28.9% 
C1. prophylaxis one dose 155 4.3% 
C2. prophylaxis one day 99 2.8% 
C3. prophylaxis >1 day 348 9.7% 
C. Surgical prophylaxis total 602 16.8% 
D. Medical prophylaxis 244 6.8% 
Grand Total 3,587 
 
 
 
Analysis by indication in each of the hospitals 
Analysis of indication by hospital shows that in 16 out of 20 (80%) of hospitals, CAI 
was the commonest indication. In three hospitals (numbers 11, 17, and 19) hospital 
acquired infections was the commonest indication for treatment and in one hospital 
(number 21) a roughly equal number of patients were treated for CAI or HAI.   The 
percentage of antibacterial therapies for CAI ranged from 23.5% in hospital number 19 
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to 83% in hospital number 5 (mean 53.1%, SD 16%). The prevalence of HAI varied 
from 28% in hospital number 5 to 42.3% in hospital number 2 (mean 28%, SD11.6%).  
For surgical prophylaxis, the percentage of prescribed antibacterials varied from 0% in 
hospital number 5 to 25.3% in hospital number 9 (mean 13.3%, SD 6.8%).  The 
proportion of antibacterials used for medical prophylaxis ranged from 0% in hospital 
number 9 to 18.2% in hospital number 11 (mean 5.6%, SD 4.5%) (Figure A.7.3.2).  
Regarding the mean and standard deviations, the variations between the hospitals by 
antibacterial therapy was highest for CAI followed by HAI, surgical prophylaxis, and 
medical prophylaxis. For this and other analyses by hospital, it is noteworthy to 
remember that hospitals 5 and 17 were infectious diseases hospitals.  
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Figure A.7.3.2: Indication for antibacterial therapy presented as percentage from total therapies in each hospital. A: Community 
acquired infection, B: Hospital acquired infection, C: Surgical prophylaxis, D: Medical prophylaxis 
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7.3.7 Antibacterial use for surgical prophylaxis 
Duration of surgical prophylaxis antibacterial therapy in each of the hospitals 
The number of patients in each hospital who received antibacterials for surgical 
prophylaxis ranged from 2 in hospital number 16 to 86 in hospital number 18 (mean 
31.2, median 24, SD 24.6).  The proportion of patients given surgical prophylaxis who 
received one dose ranged from 0% in hospitals number 3, 7, and 20, to 54% in hospital 
number 19 (mean 29.1%, SD 25.6%).  One-day prophylaxis ranged from 0% in 
hospitals 4, 16, and 20, to 44.5% in hospital number 22 (mean 20.6%, SD 20.1%).  
Prevalence of receiving more than one day pre-operative prophylaxis ranged from 0% in 
hospitals 2 and 16, to 100% in hospital number 20 (mean 50.3%, SD 30.9%) (Figure 
A.7.3.3).  The mean number of patients was higher in more than one-day duration and 
the convergence of hospitals was less in number of patients of more than one-day 
surgical prophylaxis than 2 other durations (comparing standard deviations of mean for 
three durations). The number of antibacterials for each of the patients receiving pre-
operative prophylaxis varied from 1 antibacterial to 2 for all three durations of treatment 
but was different across the hospitals. 
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Figure A.7.3.3:  Duration of surgical prophylaxis presented as percentage from total number patients received antibacterials for 
this indication in each hospital.  
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Most commonly prescribed antibacterials for surgical prophylaxis  
Prescribed doses for the most commonly prescribed antibacterials for each of the 
differing surgical prophylaxis durations are shown in table A.7.3.7, although these only 
account for a relatively small proportion of all antibiotics used.  The ratio of PDD/DDD 
for the three most commonly prescribed antibacterials is less than 0.5, while it is close 
to one for one-day prophylaxis and close to more than 1 for four top antibacterials used 
for >one-day duration. Antibacterials for one dose and one-day prophylaxis are most 
commonly parenteral while for > one-day, one of them is oral (Amoxicillin and enzyme 
inhibitor (EI) or Co-amoxiclav).  Two common antibacterials in three categories are 
Cefazoline and Parenteral Cefuroxime.  For Cefazoline the PDD/DDD increases with 
duration of prophylaxis for 0.4 to 1.3.  For Cefuroxime the ratio is lower in one dose 
than 2 other durations.  It suggests that in surgical prophylaxis the prescribed dose can 
increase with the duration of prophylaxis and lead to more antibacterial consumption. 
This was investigated for some other antibacterials and the finding was the same (data 
not shown).  
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Table A.7.3.7:  Most commonly prescribed antibiotics in each group of surgical 
prophylaxis and the ratio of Prescribed Daily Dose (PDD) to DDD. 
  
One dose One day > One day 
1 
AB Cefazoline P Cefazoline P Cefuroxime P 
Percentage 35.9% 31.3% 17.2% 
PDD/DDD 0.4 1.0 0.8 
2 
AB Cefuroxime P Cefuroxime P 
Amoxicillin & EI, 
O 
Percentage 17.6% 25.0% 12.7% 
PDD/DDD 0.5 0.9 1.7 
3 
AB 
Amoxicillin & 
EI, P  
Metronidazole P 
Percentage 11.8% 
 
12.7% 
PDD/DDD 0.4 
 
1.0 
4 
AB 
  
Cefazoline P 
Percentage 
  
10.8% 
PDD/DDD 
  
1.3 
Number 
of 
therapies 
 
170 112 425 
 
7.3.8 Antibacterial use for community acquired infection (CAI) 
Analysis of CAI by 1,729 anatomical sites of infection found 1,703 patients who were 
treated for infections and received 2,299 antibacterials in 3,157 DDD, equivalent to 1.33 
antibacterials per patient and 1.83 DDDs per patient on the day of survey.  There were 
substantial variations in the number of prescribed antibacterials with the number of 
DDDs by anatomic sites of infection.  Therefore, data were examined for the three most 
commonly prescribed antibacterials (providing that each was used at least 10 times) by 
anatomic site of infection and their relevant ratios of PDD to DDD (Table A.7.3.8).  The 
top three antibacterials varied with site of infection.  Of the 16 antibacterials listed in the 
table, the ratio of PDD/DDD was <1 in 3, equal to 1 in 5, and >1 in 7 antibacterials.  
Cefuroxime was among the top antibacterials for 4 sites of infection, but with different 
ratios of PDD/DDD for different sites of infection: intra-abdominal (1.1), respiratory 
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(0.9), undefined (1.2), and urinary tract (1.2).  Alert Antibacterials feature in four of the 
16 cells:  Gentamicin (2 times), Ceftriaxone, and parenteral Ciprofloxacin.  Oral 
Amoxicillin & EI used in respiratory and urinary tract infections had different 
PDD/DDD ratios of 1.7 and 1.8.  There were large differences in Gentamicin dosing for 
cardiovascular versus undefined infections with the ratios being 1.6 versus 0.7.  
Benzylpenicillin used in SSTBJ with a PDD/DDD ratio of 2.2 was the highest in the 
table. Average prescribed doses to the DDDs was higher in SSTBJ followed by 
respiratory, urinary tract, intra-abdominal and undefined infections.  
Table A.7.3.8 Three most commonly antibacterials prescribed at least 10 times 
for treatment of community acquired infection by anatomic site of infection, and 
the relevant ratio of PDD to DDD 
Diagnosis site 1
st
 AB, PDD/DDD 2
nd
  AB , PDD/DDD 3
rd
  AB, PDD/DDD 
Cardiovascular Gentamicin P 1.6         
Intra-
abdominal 
Metronidazole P 1 Ciprofloxacin O 1 Cefuroxime P 1.1 
Respiratory 
Amoxicillin & EI, 
P 
1 
Amoxicillin & EI, 
O 
1.7 Cefuroxime P 0.9 
SSTBJ Ciprofloxacin O 1 Clindamycin P 1.1 
Benzylpenicillin  
P 
2.2 
Undefined Ceftriaxone P 0.9 Cefuroxime P 1.2 Gentamicin P 0.7 
Urinary tract Ciprofloxacin P 0.9 
Amoxicillin & EI, 
O 
1.8 Cefuroxime P 1.2 
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Antibacterial use for Community Acquired Infection by anatomic site of infection  
Figure A.7.3.5 shows antibacterial use by anatomic sites of infection for CAI.  Patients 
were most commonly treated for CAI infections of the respiratory tract (32.4%), SSTBJ 
(19.1%), and intra-abdominal (14.2%) followed by undefined site (12.5%) and urinary 
tract (11%).  The number of antibacterials per patient ranged from 1.1 in urinary tract 
infections to 1.63 in eye infection (mean 1.37, SD 0.17 antibacterial per patient).   Mean 
DDDs per patient varied from 1.31 for urinary tract to 3.95 for cardiovascular infections 
(mean: 2.04, SD 0.84 DDDs per patient).  There is large variation in the number of 
DDDs per patient by anatomic site of infections with no significant association between 
DDD/Patient and AB/Patient for different anatomic sites of infection (correlation 
coefficient 0.49, P=0.15).     
Figure A.7.3.5:  Antibacterial use by site of infection for Community Acquired 
Infection. 
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Antibacterial use for Community Acquired Infection in hospitals 
Table A.7.3.9 shows details of antibacterial use for CAI by hospital.  The proportion of 
treated patients receiving antibacterials for CAI ranged from 24% in hospital 19 to 85% 
in hospital number 5 (mean 52.2%, SD 15.7%).  In 10 hospitals the prevalence was 
more than 50% and in 2 hospitals it was less than 30%.  For all antibacterial use, the 
mean percentage of antibacterials used for CAI was 53% (SD 16%) and it ranged from 
23.4% in hospital number 19 to 83% in hospital number 5.  The percentage of DDD for 
CAI varied from 31% in hospital number 19 to 88% in hospital number 5 (mean 57.5%, 
SD 14.4%). The number of antibacterials per patient was higher than 1 in all hospitals, 
varying from 1.01 in hospital number 6 to 1.63 in hospital number 14 (mean 1.32, SD 
0.16). The number of DDD/Patient ranged from 1.11 in hospital number 22 to 2.80 in 
hospital number 4 (mean 1.84, SD 0.44).  The ratio of PDD/DDD for CAI ranged from 
1.32 in hospital number 8 to 2.37 in hospital number 2 (mean 1.89, SD 0.32).  Ranking 
the hospitals by each of the 5 measures presented in Table A.7.3.9. and comparing them 
with each other gives 5 different sorted tables with some similarities. Hospitals have 
similar rankings for the first 3 measures (% patients, % antibacterial therapies and 
%DDD, all from the total).  One hospital has the same position for 3 measures above 
the mean and 6 hospitals have the same positions below the mean. With regards to two 
other measures, AB/patient and PDD/DDD, apart from one hospital, all other hospitals 
had different positions either in their position from the mean or in general.  It suggests 
that in most of the hospitals, CAI, none of the measures by themselves can fully 
describe antibacterial use. The first three measures are mostly about casemix and the 
second set of two measures are about antibiotic choice.   With regards to means and 
standard deviations there is large variation across hospitals for all measures, especially 
for prevalence of CAI from total patients, percentage of antibacterials from the total, 
and percentage of use in DDD from the total use.  Analysis of the data for prescribed 
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daily doses by anatomic site for each hospital could explain the variations between 
hospitals but this was beyond this chapter.  
Table A.7.3.9:  Antibacterial use by hospital for Community acquired Infection 
(CAI)  
Hospital 
% treated 
patients 
with CAI 
% all AB 
therapies used 
for CAI 
% of total 
DDDs 
used for 
CAI 
AB/patient 
treated for 
CAI 
PDD/DDD 
for 
patients 
treated 
for CAI 
1 58.1 62 64.9 1.24 2.17 
2 43.4 42.9 48.1 1.38 2.37 
3 61.4 57 52.6 1.33 1.94 
4 54 56.1 59.3 1.29 2.02 
5 84.5 82.9 88.2 1.15 1.80 
6 68.4 67.3 75.8 1.01 1.69 
7 63 63.3 61.6 1.35 1.94 
8 54.8 57.4 62.7 1.48 1.32 
9 58.3 61 72.2 1.19 2.14 
10 41.9 44.8 47.3 1.62 1.90 
11 28.8 27.2 37.4 1.22 1.59 
14 48.9 55.8 64.6 1.63 1.59 
15 48.4 49.7 52.4 1.38 1.40 
16 76.2 75.9 74.7 1.28 2.29 
17 31 31.4 41.3 1.49 2.14 
18 41.5 41.8 47 1.28 2.06 
19 24.1 23.4 30.7 1.11 1.53 
20 49.4 51.5 53.9 1.48 1.77 
21 40 41.3 46.1 1.38 1.84 
22 67.3 68.7 68.2 1.20 2.43 
Mean 52.2 53.1 57.5 1.32 1.89 
SD 15.7 15.6 14.4 0.16 0.32 
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7.3.9 Antibacterial use for hospital acquired infection (HAI) 
The total number of patients treated for HAI was 1,015.  Types of infections that were 
categorised under Hospital Acquired Infections were: post operative infection (n=307 
patients), intervention related infection (n=145), C. Difficile enterocolitis (n=33), other 
hospital acquired infections (n=492), and infections present on admission from another 
hospital (n=61).  For a small number of patients, there was more than one source of the 
HAI, with the 1,015 patients having 1,038 sources of HAI. The total number of 
antibacterials prescribed for HAI was 1,425.  Four hundred and ten patients received 
more than one antibacterial for an HAI, of which 53 received 3 to 5 antibacterials.  To 
allow more in-depth analysis by type of antibacterials used in each of the anatomic sites 
of infection, data were analysed for the top three antibacterials (providing that they were 
prescribed at least 10 times) and their ratio of PDD/DDD (Table A.7.3.9). Seven out of 
sixteen of the most commonly prescribed antibacterials by anatomic site of infection 
were Alert Antibiotics including: parenteral Vancomycin (3 times), Piperacillin & EI (2 
times), Meropenem, and parenteral Ciprofloxacin.  Most of the other antibacterials were 
broad-spectrum.  Seven out of sixteen were oral antibacterials.  Parenteral Vancomycin 
was the most commonly used antibacterial for CNS, SSTBJ, and undefined infections 
with a PDD/DDD ratio of less than 1 (from 0.7 to 0.8).  Oral Ciprofloxacin, with 4 
times the frequency in the table of top three antibacterials, had a PDD/DDD of 0.9 to 
1.1.  The average PDD/DDD of three top antibacterials was higher in SSTBJ, followed 
by respiratory, undefined, intra-abdominal and urinary tract infections.  Overall, six out 
of the antibacterials in the table of top three had a PDD/DD ratio more than 1 (range 1.2 
to 1.9); for seven the ratio was less than 1 (0.6 to 0.9) and in three remaining 
antibacterials it was equal to 1 (Table A.7.3.10). 
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Table A.7.3.10: Three most commonly antibacterials prescribed at least 10 times 
for treatment of hospital acquired infection by anatomic site of infection, and the 
relevant ratio of PDD to DDD 
Diagnosis site 1st AB, PDD/DDD 2nd  AB, PDD/DDD 3rd  AB, PDD/DDD 
CNS Vancomycin P 0.7 
   
  
Intra-abdominal Metronidazole O 0.6 Metronidazole P 1 Ciprofloxacin P 1.3 
Respiratory Piperacillin & EI, P 1 Ciprofloxacin O 1.2 Amoxicillin &EI, P 1.2 
SSTBJ Vancomycin P 0.8 Ciprofloxacin O 1.2 Amoxicillin &EI, O 1.9 
Undefined Vancomycin P 0.7 Piperacillin & EI, P 1 Meropenem P 1.6 
Urinary tract Ciprofloxacin O 0.9 Cotrimoxazole O 0.8 Norfloxacin O 0.9 
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Antibacterial use for Hospital Acquired Infection by anatomic site of infection 
Analysis of HAIs infection by anatomic site of infection showed that 1,038 sources of 
HAI were associated with 1,043 anatomic sites of infection, with patients receiving 
1,425 antibacterials in 1,738 DDD.  The mean number of DDDs per patient was 1.2 and 
antibacterials per patient was 1.3.  The commonest sites of infections were:  undefined 
site of infection (24.5% of total HAIs) followed by respiratory infection (23%), SSTBJ 
(19(2%), urinary tract (14%), and intra-abdominal (12.3%).  The percentage of total 
antibacterial therapies used for each site was undefined sites of infection (26.9% from 
total) followed by respiratory (23.3%), SSTBJ (19.7%) intra-abdominal (12.5%), and 
urinary tract infection (11.6%).  The number of antibacterials per patients ranged from 
1.1 for urinary tract infections to 1.5 for undefined infections (mean 1.35, SD 0.12). The 
number of DDDs per patient ranged from 1.1 in genital infection to 1.5 in CNS 
infection (mean 1.23, SD 0.15) (Figure A.7.3.6). 
Figure A.7.3.6: Antibacterial use for hospital acquired infection (HAI) for 
different diagnosis sites measured by number of antibacterials number of patients, 
number of antibacterials per patient and number DDD per patient. 
 
0
1
2
3
4
0
200
400
600
800
Anatomic Site of Infection
Number of antibiotics Number of patients AB/ Patient DDD/Patient
Appendix A.7.3 312 
 
Antibacterial use for HAI by hospital 
Antibacterial use for HAI by hospital is shown in Table A.7.3.11. The percentage of 
treated patients with an HAI ranged from 9.1% in hospital number 5 to 51.8% in 
hospital number 19 (mean 27.2%, SD 10.8%).  The percentage of antibacterials used to 
treat HAIs ranged from 10.1% in hospital number 5 to 55.5% in hospital number 19 
(mean 28%, SD 11.6%). The percentage of all antibacterial DDDs  used to treat HAIs 
varied from 10.3% in hospital number 5 to 56% in hospital number 19 (mean 26.9%, 
SD 11.9%). The number of antibacterials prescribed for the treatment of HAIs per 
patient was higher than 1 in all hospitals, and varied from 1.09 in hospital number 6 to 
1.67 in hospital number 17 (mean 1.4, SD 0.2).  The average ratio of PDD to DDD for 
antibacterials in HAI indications was considerably more than one in all hospitals.  The 
minimum was 1.62 in hospital number 15 and the maximum was as high as 4.55 in 
hospital number 9 (mean 2.3, SD 0.8).  The ranking of the hospitals by the first 3 
measures (% patients, % AB therapies, % of DDD of the total),  and the other 2 
measures (AB/patients and PDD/DDD) for both CAI (Table 7.13) and HAI (Table 
A.7.3.11) allowed a comparison between these two types of Acquired Infection.  The 
hospitals above and below the mean are similar however, for 2 hospitals the positions 
above the mean are similar and for another 2 hospitals with positions below the mean 
the ranks are the same for the first 3 measures. For the other 2 measures, the ranking 
positions are quite similar for all hospitals.  The standard deviations of AB/Patient and 
DDD/Patients are relatively low, indicating less variability of these two measures based 
on anatomic sites of infection. There is a significant and positive association between 
DDD/patients and AB/patients (correlation coefficient= 0.65, P=0.05).   
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Standard deviations from mean for each of the 5 measurements show large variations 
across the hospitals for nearly all measures, however, the number of antibacterials per 
patient had less variation than the others. Nonetheless, the variations are less than the 
same measures for CAI.  
Table A.7.3.11:  Antibacterial use for hospital acquired infection (HAI) by means 
of number of treated patients, Antibacterial (AB) therapies, DDD from total in the 
survey, number of antibacterials per patient and PDD to DDD ratios. 
Hospital % Patients 
% AB 
therapies 
% DDD AB/patient PDD/DDD 
1 21.5 19.4 18.6 1.05 1.79 
2 38.5 42.4 39.4 1.53 3.23 
3 24.3 27.0 23.6 1.59 1.84 
4 18.0 19.7 17.4 1.36 2.38 
5 9.1 10.1 10.3 1.44 1.52 
6 22.4 23.8 18.2 1.09 2.13 
7 20.5 21.4 20.7 1.40 1.65 
8 37.9 36.3 34.5 1.42 1.77 
9 12.8 13.6 11.3 1.21 4.55 
10 34.6 34.9 34.3 1.59 2.15 
11 36.3 37.6 36.3 1.34 2.69 
14 23.1 22.0 22.0 1.38 2.09 
15 23.4 24.7 25.7 1.41 1.62 
16 19.0 16.7 14.3 1.13 2.58 
17 36.5 40.8 39.0 1.67 4.06 
18 32.6 33.2 32.0 1.34 2.40 
19 51.8 55.5 56.0 1.25 2.31 
20 23.6 23.7 23.8 1.48 1.63 
21 40.4 40.6 42.1 1.44 2.39 
22 17.3 17.4 17.6 1.18 1.98 
Mean 27.2 28.0 26.9 1.4 2.3 
SD 10.8 11.6 11.9 0.2 0.8 
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7.3.10 Combination therapy 
To assess the number of prescribed antibacterials for each patient, data were analysed 
for patients receiving one, two, three, and >3 antibacterials (Table A.7.3.12). The total 
(3,599) is greater than the number of patients treated (3, 483) because some patients had 
antibacterial prescribed for  more than one anatomic site.  In total 65.3% (n=2,381) of 
patients received only one antibacterial while 30.2% (n=1,102) of them were treated 
with two drugs.  Up to three antibacterials were prescribed for 4% (n= 147) and four or 
five antibacterials for 0.4% (n=16) of patients.  Mono-therapy ranged from 97% 
(hospital number 6) to 47% (hospital number 10) with a median of 67% and SD of 13%.  
Incidence of receiving up to two antibacterials ranged from 45% (hospital number 10) 
to 3% (hospital number 6). The mean, median and SD were 28%, 30% and 11%.  
Treatment with up to three antibacterials ranged from 0% (in hospitals 6 and 19) to 
8.1% (hospital number 17).  In this group mean, median and SD were 3.5%, 3 % and 
2%.  Treatment with up to 4 and 5 antibacterials ranged from 4% (hospital number 3) to 
0% in 12 hospitals. Mean median and SD were 0.5%, 0% and 1%.  Overall, each patient 
in the PPS received a mean of 1.4 antibacterials, which varied from 1.03 (hospital 
number 6) to 1.6 (hospital number 10), with a median and SD of 1.3 and 0.15 (Table 
A.7.3.12).    
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Table A.7.3.12:  Number of patients received one or more antibacterials and average number antibacterial per treated patients in 
each hospital and in total 
 
Hospital 
number 
Incidence of multiple antibacterial prescribing per patient % (no.) Average  antibacterials per patient  
1 2 3 4&5 Patients Antibacterials Patients Ratio 
1 81.5 (75) 17.4 (16) 1.1 (1) 0.0 (0) 92 108 91 1.2 
2 61.1  (77) 34.9 (44) 2.4 (3) 1.6 (2) 126 170 121 1.4 
3 57.3 (43) 33.3 (25) 5.3 (4) 4.0 (3) 75 100 68 1.5 
4 76.1 (108) 21.8 (31) 2.1 (3) 0.0 (0) 142 173 139 1.2 
5 80.7 (88) 18.3 (20) 0.9 (1) 0.0 (0) 109 129 108 1.2 
6 96.9 (95) 3.1 (3) 0.0 (0) 0.0 (0) 98 101 98 1.0 
7 63.5 (47) 32.4 (24) 4.1 (3) 0.0 (0) 74 98 71 1.4 
8 58.1 (108) 34.9 (65) 7.0 (13) 0.0 (0) 186 251 173 1.5 
9 80.0 (144) 18.3 (33) 1.7 (3) 0.0 (0) 180 213 177 1.2 
10 47.1 (128) 45.2 (123) 7.4 (20) 0.4 (1) 272 395 251 1.6 
11 66.8 (181) 27.7 (75) 4.4 (12) 1.1 (3) 271 346 256 1.4 
14 57.0 (159) 36.9 (103) 6.1 (17) 0.0 (0) 279 382 262 1.5 
15 66.8 (169) 31.2 (79) 2.0 (5) 0.0 (0) 253 332 248 1.3 
16 72.1 (31) 25.6 (11) 2.3 (1) 0.0 (0 ) 43 54 42 1.3 
17 49.0 (103) 42.4  (89) 8.1 (17) 0.5 (1) 210 299 192 1.6 
18 67.3 (345) 28.7 (147) 3.7 (19) 0.4 (2) 513 660 492 1.3 
19 84.7 (94) 15.3 (17) 0.0 (0) 0.0 (0) 111 128 111 1.2 
20 57.3 (157) 38.3 (105) 4.0 (11) 0.4 (1) 274 379 262 1.4 
21 61.5 (147) 31.8 (76) 5.4 (13) 1.3 (3) 239 315 223 1.4 
22 82.8 (82) 16.2 (16) 1.0 (1) 0.0 (0) 99 115 98 1.2 
Total 65.3% (2,381) 30.2% (1,102) 4.0% (147) 0.4% (16) 3646 4,748 3483 1.4 
Mean 64.8% 27.7% 3.4% 0.5% 
   
1.33 
SD 13.1% 11% 2% 1% 
   
0.15 
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7.3.11 Use of selected antibacterial groups 
The prescription of parenteral antibacterials and the sum of Fluoroquinolones and third 
generation Cephalosporins were analysed for each of the hospitals (Figures A.7.3.7 and 
A.7.3.8).  Fluoroquinolones and third generation Cephalosporins were selected for 
examination as they are broad-spectrum antibacterials and available in all of the study 
hospitals.  From a total of 4,748 antibacterial therapies, 1,015 (21.4%) were either 
Fluoroquinolones or third generation Cephalosporins.  The percentage of antibacterial 
prescribing due to these 2 groups of antibacterials ranged from 9.3% in hospital number 
9 to 36.4% in hospital number 5 (mean 20.5%, SD 6.9%).  The standard deviation of the 
mean indicates that there is considerable variation among the hospitals. In 10 hospitals 
the prevalence was >20% and in 2 hospitals it was just below 10%. The most striking 
finding is the difference between two infectious diseases hospitals (5 and 17).  In 
hospital 5 CAI and In hospital 17 HAI were more prevalent. On the survey day, hospital 
5 was the highest user of Fluoroquinolones and third generation Cephalosporins while 
hospital 17 was the lowest one.  In total, parenteral antibacterials accounted for 64.5% 
(3,60/4,748) of all antibacterial use, ranging from 39% in hospital number 8 to 91% in 
hospital number 22 (mean 64.4%, SD= 16%).  In 15 out of 20 hospitals, parenteral 
therapy accounted for ≥50% of total antibacterial therapy.  
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Figure A.7.3.7: Use of Fluoroquinolones and third generation Cephalosporins in 
each hospital, presented as a percentage of total antibacterial therapy  
 
 
Figure A.7.3.8: Use of parenteral antibacterials in each hospital as a percentage of 
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7.3.12  Discussion 
Presented results for determinants of antibacterial use by clinical groups showed the 
greatest proportion of antibacterial exposure and use was in medical departments.  
Across all departments, the PDD/DDD was higher than 1.8.  Variation at patient level 
was most strongly associated with indication and anatomic site.  An average PDD/DDD 
of 2.1 in Paediatric Departments is alarming because the WHO DDD are assigned for 
adults and the presided daily doses for children are lower. This will need further studies 
to investigate, especially with regards to absolute number of paediatric ICU beds which 
was impossible to gauge in this study.   
Also analysis of data should be undertaken by breaking children data down into ICU 
and non-ICU, and into indication and anatomic site as these were beyond this thesis.    
Nonetheless, in future studies the software should have a warning to avoid entering the 
survey year as the year of birth. For this study we tried to identify and validate 
children’s data from other inputs which was not impossible for all records.  
The most common indication was CAI (47.5%) followed by HAI (28.9%), Surgical 
prophylaxis (16.8%) and medical prophylaxis. There were differences between CAI and 
HAI when data were analysed within the hospitals and within anatomic sites of 
infection.  Prevalence of HAI from total admitted patients was 9%.   
The prevalence of infection by the number of patients and number of antibiotic 
therapies for sites of infection revealed that except for the most common sites of 
infection in HAI (undefined) the other common sites of infection (respiratory, SSTBJ, 
intra-abdominal, and urinary tract) ranked the same in HAI and CAI, all with higher 
prevalence in CAI.  For different sites of infection, the ranges for DDD/patient and 
AB/patient in CAI were generally higher in general and the difference was bigger for 
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each of the anatomic sites.  In HAI these two measures have significant positive 
association therefore in CAI, the use in DDD was higher and it was not dependant on 
the number of antibacterials used in treatment. The Top antibacterials in CAI and HAI 
are mainly different for similar sites of infection.  The use of Alert Antibiotics was more 
common in HAI. Only parenteral Metronidazole used both for CA and HA intra-
abdominal infections with a PDD/DDD equal to one.  Parenteral Amoxicillin & EI was 
used both in HA and CA respiratory infections but the PDD/DDD was higher in CA and 
it was the same for oral Ciprofloxacin for SSTBJ in HA and CA.  Within the top 
antibacterials only 4 out of 16 in CAI and 3 out of 16 in HAI have PDD equal to DDD, 
yet the distribution by anatomic sites are different. Analysis by hospital showed the 
higher prevalence of CAI (mean 52.2%) and subsequently more use by means of the 
number of antibacterial treatments and DDD, than HAI. Nonetheless the use by means 
of AB/patient was higher in HAI (mean of 1.4 versus 1.32 for CAI). Mean PDD/DDD 
was also higher in HAI (2.2 versus 1.89 in CAI). Without further analysis, which can be 
necessary, it can be concluded that because CAI is around two times more prevalent 
although the PDD/DDD is slightly more in HAI the total antibacterial use in hospitals 
can be better explained by the prevalence of CAI.  A preliminary ranking that was 
performed for 5 measures of antibacterial use (% patients, % AB therapies, % DDD, 
AB/patient, and PDD/DDD for CAI and HAI suggests applying true ranking.  However, 
it can be assumed that all of these measures are needed to better explain prevalence of 
antibacterial use.  In this study we had two infectious diseases hospital (hospitals 5 and 
17).  Except for the number of patients receiving antimicrobials from the total number 
of admitted patients that was high in both of the hospitals (could be expected), they 
were different in all other measures.  Therefore regardless of type of treatment or 
prophylaxis by anatomic site, it is hard to judge hospitals based on their general 
characteristics.   
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The prevalence of taking culture before initiating antibacterial therapy for HAI.  In 
general, most of antibacterials prescribed before taking relevant culture (51%). There 
were differences based on route of administration and to age groups but the focus was 
mainly on treatment rather than prophylaxis which showed the start of antibacterials 
before taking a culture was as high as 44.1% in CAI and 37.5% in HAI. The only 
anatomic site of infection was urinary tract both for CAI and HAI with a high 
prevalence of taking culture before treatment (71% and 72%). For other sites of 
infection, the start of antibiotic treatment without taking a culture was high from 38% to 
46% with differences between HAI and CAI. Taking a culture before antibiotic therapy 
makes it possible to shift to an appropriate choice of antibiotic and it leads to 
improvement in the antibacterial therapy and a cost saving. Some patients with CAI 
might have had their culture taken before hospitalisation or they might be on antibiotic 
treatment on admission.  Nonetheless, for two site of infection in hospital acquired, 
namely, pneumonia   and SSTBJ (47.3% and 37.9%) of antibacterials initiated before 
taking a culture.  In daily clinical practice we cannot expect that before all antibacterial 
therapy a culture test could be taken.  On the other hand, in this study prevalence of 
taking culture before therapy was much higher in UTI than for other sites of infection.  
It suggests that easy and cheap microbiology tests are more common and traditional.  
Production of clinically relevant microbiology reports can be an indicator of hospital 
infection management performance 
1, 2
  specially for severally ill patients. 
3
  Patient-
specific culture and susceptibility data optimises individual antimicrobial management 
4
 
and improves guidelines for empirical treatment.  
The use of third generation Cephalosporins and Fluoroquinolones was as high as  21.4% 
of the total therapies.  This selected group of antibacterials and parenteral antibacterials 
(which accounted for 64.5% of therapies) are associated with antibacterial resistance 
and increased cost.    
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Appendix A.8: ESAC Hospital Questionnaire 
ESAC II, Hospital Subproject 
 
 
Hospital Questionnaire 
   
Dear colleagues 
Within the HC project we wish to identify time trends in antibiotic use in hospitals in an 
individual basis. This questionnaire is designed to identify any variable that could have 
an impact on hospital antibiotic.  
It is confirmed that in all steps of the project the hospitals’ names will be anonymous. 
Some questions can be answered simply by a Yes/No and some of them require a brief 
explanation. Add additional space if required.  Please return completed questionnaire no 
later than 15 April 2006. 
 
A) Population and hospital demographic factors: 
Is your hospital a: 
1) teaching hospital ? Y/N.............................. 
 
 
2) secondary or tertiary? ............................... 
 
 
3) Total number of inpatient beds: 
2000  2003  
2001  2004  
2002  2005  
 
 
4) Number of inpatient deaths: 
2000  2003  
2001  2004  
2002  2005  
 
 
In your hospital is there 
5) an adult  ICU? 
 Y N Number of 
beds 
 Y N Number of beds 
2000    2003    
2001    2004    
2002    2005    
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6) a paediatric ICU? 
 Y N Number of beds  Y N Number of beds 
2000    2003    
2001    2004    
2002    2005    
7) paediatrics ward( including ICU)? 
 Y N Number of beds  Y N Number of beds 
2000    2003    
2001    2004    
2002    2005    
 
8) haematology speciality? 
 Y N Number of beds  Y N Number of beds 
2000    2003    
2001    2004    
2002    2005    
 
9) an infectious diseases specialty? 
 Y N Number of beds  Y N Number of beds 
2000    2003    
2001    2004    
2002    2005    
 
10) a renal dialysis speciality? 
 Y N Number of beds  Y N Number of beds 
2000    2003    
2001    2004    
2002    2005    
 
11) organ transplant speciality? 
 Y N Number of beds  Y N Number of beds 
2000    2003    
2001    2004    
2002    2005    
 
12) acute beds used for long term care like psychology? 
 Y N Number of beds  Y N Number of beds 
2000    2003    
2001    2004    
2002    2005    
 
 
13) Number of pharmacists (FTE)? 
2000  2003  
2001  2004  
2002  2005  
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14) Number of infectious diseases specialists (FTE)? 
2000  2003  
2001  2004  
2002  2005  
 
 
15) Number of Infection control nurses (FTE)? 
2000  2003  
2001  2004  
2002  2005  
 
 
16)Number of clinical microbiologists(FTE)? 
2000  2003  
2001  2004  
2002  2005  
 
 
 
B- Economic factors: 
17) Is drug expenditure in the hospital covered by national health care system? 
 Y N  Y N 
2000   2003   
2001   2004   
2002   2005   
 
 
18) Do inpatients pay for a proportion of their drug expenses? 
 Y N  Y N 
2000   2003   
2001   2004   
2002   2005   
 
 
19) Are there financial incentives for the physicians based on their prescribing? 
 Y N  Y N 
2000   2003   
2001   2004   
2002   2005   
 
 
Within your hospital 
20) is the drug  budget accounted to clinical speciality? 
 Y N  Y N 
2000   2003   
2001   2004   
2002   2005   
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21) is the drug budget accounted to hospital pharmacy? 
 Y N  Y N 
2000   2003   
2001   2004   
2002   2005   
 
 
C- Database factors: 
 
22) Are all antibiotics needed for inpatients supplied only by the hospital pharmacy? 
 Y N  Y N 
2000   2003   
2001   2004   
2002   2005   
 
 
23) Are antibiotics prescribed at discharge excluded from database? 
 Y N  Y N 
2000   2003   
2001   2004   
2002   2005   
 
 
24) Are antibiotics supplied to outpatient clinics excluded from database? 
 Y N  Y N 
2000   2003   
2001   2004   
2002   2005   
 
 
25) Are wasted drugs ( e.g. expired in ward stock, damaged, missed, unused liquid 
preparations) excluded from database? 
 Y N  Y N 
2000   2003   
2001   2004   
2002   2005   
 
 
26) Are returned drugs to the pharmacy subtracted from pharmacy dispensing data? 
 Y N  Y N 
2000   2003   
2001   2004   
2002   2005   
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27) Is there occasional drug shortage? Please specify which drugs and in which month 
or quarter? (This is only relevant to shortage in those antibiotics need to be replaced 
with antibiotics from a different class or with no substitute at all).  
 Y N  Y N 
2000   2003   
2001   2004   
2002   2005   
 
 
 
28) Which antibiotics were introduced in your hospital during this period? Please 
specify in which month or quarter. 
2000  
2001  
2002  
2003  
2004  
2005  
 
 
30) Which antibiotics are no longer available from your hospital pharmacy?  
2000  
2001  
2002  
2003  
2004  
2005  
 
 
30) If any drug donations are made to/from your hospital, are they considered in 
pharmacy stock data? Please specify. 
 Y N  Y N 
2000   2003   
2001   2004   
2002   2005   
 
 
31) Is there any change in dispensing strategies in your hospital? Please specify. 
 Y N  Y N 
2000   2003   
2001   2004   
2002   2005   
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D- Microbiology related factors: 
 
32) Change in policy or facilities in quantity and selection criteria of patients’ 
specimens? 
 Y N  Y N 
2000   2003   
2001   2004   
2002   2005   
 
 
 
E- Managerial system factors: 
 
Is there  
33) an Infection Control Committee? 
 Y N  Y N 
2000   2003   
2001   2004   
2002   2005   
 
 
 
34) an established antibiotic prescribing management group? 
 Y N  Y N 
2000   2003   
2001   2004   
2002   2005   
 
 
35) local prescription formulary/guidelines on use of antibiotics against diagnosis? 
 Y N  Y N 
2000   2003   
2001   2004   
2002   2005   
 
 
36) training for medical students/doctors targeted at antibiotic prescribing as a part of 
their education and/or regular basis? 
 Y N  Y N 
2000   2003   
2001   2004   
2002   2005   
 
 
37) Are antibiotic policy/guidelines available in printed format? 
 Y N  Y N 
2000   2003   
2001   2004   
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2002   2005   
 
 
38) Are antibiotic policy/guidelines available electronically? 
 Y N  Y N 
2000   2003   
2001   2004   
2002   2005   
 
 
39) Is there online decision support system for antibiotic prescribing based on patient 
specific clinical findings which is used in a routine basis in your hospital? 
 Y N  Y N 
2000   2003   
2001   2004   
2002   2005   
 
 
 
 40) Are there any restrictions in supply of medicine e.g. a restricted drug procurement 
list against an approved formulary, stop orders? 
 Y N  Y N 
2000   2003   
2001   2004   
2002   2005   
 
 
 
41) Is there regular feedback to physicians on infection control and antibiotic 
resistance? How often? 
 Y N  Y N 
2000   2003   
2001   2004   
2002   2005   
 
 
42) Is there regular feedback to physicians on antibiotic use? How often? 
 Y N  Y N 
2000   2003   
2001   2004   
2002   2005   
 
 
43) Are patients’ records, lab results and prescriptions  kept in paper or electronic 
format? ( Please provide details)? 
 Paper Electronic  Paper Electronic 
2000   2003   
2001   2004   
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2002   2005   
 
 
44) Is there any intervention to improve antibiotic prescribing in your hospital? Give 
details in 1-2 sentences about duration of the intervention and antibiotics included in the 
intervention.  
 Y N  Y N 
2000   2003  
 
 
2001  
 
 2004   
2002  
 
 2005   
 
 
45) Are there other activities to improve antibiotic prescribing/infection control/hospital 
cleanness which are regulated by public/NGOs/media rather than by hospital 
authorities? 
 Y N  Y N 
2000   2003   
2001   2004   
2002   2005   
 
 
